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Abstract 	  To	   live	   a	  healthy	   life,	  humans	  need	   to	   co-­‐exist	  with	   foreign	  organisms.	  These	  consist	  of	  the	  thousands	  of	  different	  types	  of	  microbes	   that	   colonize	   the	   human	   body.	   But	   also,	   in	   the	  case	   of	   a	   pregnant	   woman,	   the	   fetus	   can	   be	   viewed	   as	   a	  foreign	   organism.	   To	   avoid	   disease,	   the	   barriers	   of	   the	  human	  body,	  e.g.	  the	  mucosal	  surfaces,	  must	  be	  maintained.	  Here	  the	  innate	  immune	  defense	  system	  plays	  an	  important	  role.	  	  The	   salivary	   scavenger	  and	  agglutinin	   (SALSA),	   also	  known	  as	   gp340,	   DMBT1	   and	   SAG,	   is	   a	   molecule	   found	   at	   most	  mucosal	  surfaces.	  SALSA	  is	  associated	  with	  the	  epithelium	  or	  secreted	   into	   the	   lining	   fluids,	   such	   as	   tears,	   saliva	   and	  mucus	  in	  the	  respiratory	  tract.	  SALSA	  is	  known	  to	  bind	  and	  agglutinate	  a	  broad	  spectrum	  of	  bacteria,	  as	  well	  as	  viruses,	  and	   thus	   play	   a	   role	   in	   the	   innate	   immune	   defense	   against	  invading	   microbes.	   The	   effect	   of	   SALSA	   is	   mediated	   in	  concert	   with	   several	   other	   defense	   molecules	   such	   as	   IgA,	  surfactant	  proteins	  A	  and	  D,	  and	  the	  complement	  component	  C1q.	   These	   have	   all	   been	   shown	   to	   be	   ligands	   of	   SALSA.	  Alongside	  the	  role	  of	  SALSA	  in	  innate	  immunity,	  evidence	  for	  a	   function	   in	   epithelial	   and	   stem	   cell	   differentiation	   has	  emerged.	  	  	  This	   thesis	   work	   has	   addressed	   the	   function	   of	   SALSA	   in	  innate	  immunity,	  especially	  in	  early	  life.	  SALSA	  was	  found	  in	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the	  amniotic	   fluid	  and	   in	  meconium	  and	   feces	  of	  newborns.	  In	  fact,	  SALSA	  was	  among	  the	  most	  abundant	  proteins	  in	  the	  intestines	   of	   newborn	   children.	   By	   comparing	   the	   SALSA	  protein	   in	   the	   different	   samples	   we	   found	   size	  polymorphisms,	  varying	  from	  one	  individual	  to	  another,	  but	  also	   from	   compartment	   to	   compartment	   within	   the	   same	  individual.	   Specifically,	   we	   found	   structural	   variations	   in	  SALSA	   correlating	   to	   the	   known	   bacterial	   binding	   peptide	  sequence,	  SRCRP2,	  and	  the	  putative	  polymerization	  domain,	  the	  zona	  pellucida	  domain.	  These	  differences	  were	  found	  to	  alter	   the	   ability	   of	   SALSA	   to	   bind	   known	   endogenous	   and	  bacterial	  ligands.	  	  SALSA	   was	   also	   found	   to	   be	   expressed	   in	   the	   human	  placental	   and	   decidual	   tissues.	   In	   the	   1st	   trimester	   of	  pregnancy,	   SALSA	   was	   detected	   sporadically	   in	   maternal	  decidual	   capillaries.	   Closer	   to	   term	   SALSA	  was	   found	   to	   be	  expressed	  by	   the	   syncytiotrophoblast	   layer	  of	   the	  placental	  villous	  trees.	   In	  certain	  sites,	  e.g.	  at	  disrupted	  and	  damaged	  areas	   of	   the	   syncytium,	   SALSA	   was	   found	   deposited	   into	  fibrinoid	   formations.	   It	   partially	   co-­‐localized	   with	   the	  fibrinoid	   component	   fibronectin.	   Damage	   of	   the	  syncytiotrophoblast	  layer	  is	  a	  common	  histological	  finding	  of	  several	   pregnancy	   complications.	  We	   thus	   investigated	   the	  presence	  of	  SALSA	  in	  amniotic	  fluids	  and/or	  placentas	  from	  patients	   with	   pre-­‐eclampsia,	   intra-­‐uterine	   growth	  restriction,	  diabetes	  mellitus	  type	  1	  and	  gestational	  diabetes.	  SALSA	   levels	   were	   increased	   in	   amniotic	   fluid	   samples	  collected	  before	  the	  20th	  week	  of	  gestation	  from	  women	  who	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later	   developed	   pre-­‐eclampsia,	   but	   no	   other	   differences	  between	  the	  groups	  were	  observed.	  	  Complement	   activation	   has	   been	   observed	   at	   the	   feto-­‐maternal	   interface	   of	   both	   healthy	   and	   complicated	  pregnancies.	  SALSA	  had	  previously	  been	  found	  to	  bind	  C1q.	  Thus,	  it	  was	  of	  interest	  to	  investigate	  the	  ability	  of	  SALSA	  to	  interact	  directly	  with	  the	  complement	  system.	  We	  found	  that	  SALSA	   bound	   to	   both	   mannan-­‐binding	   lectin	   and	   to	   some	  extent	   to	   all	   three	   ficolins	   (H,	   L	   and	   M).	   SALSA	   activated	  complement,	   when	   it	   was	   bound	   to	   a	   surface.	   In	   contrast,	  fluid-­‐phase	   SALSA	   was	   able	   to	   inhibit	   the	   deposition	   of	  complement	   on	   SALSA	   non-­‐binding	   microbial	   surfaces.	   It	  thus	  acted	  in	  dual	  fashion	  to	  target	  complement	  attack.	  	  	  In	   the	   human	   placenta	   we	   observed	   C1q-­‐targeting	   of	   the	  SALSA-­‐positive	   fibrinoid	   formations.	   C1q	   and	   complement	  are	  known	  to	  function	  in	  the	  clearance	  of	  apoptotic	  cells	  and	  debris.	   Thereby	   SALSA	   and	   complement	   probably	   have	   a	  cooperative	  function	  in	  the	  containment	  and	  clearance	  of	  the	  injured	   structures,	   thus	   linking	   its	   innate	   immune	   activity	  with	  the	  maintenance	  of	  tissue	  homeostasis.	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Abbreviations 	  AF	   	   	   Amniotic	  fluid	  AP	   	   	   Alkaline	  phosphatase	   	  APC	  	   	   	   Antigen-­‐presenting	  cell	  BSA	   	   	   Bovine	  serum	  albumin	  C	  	   	   	   Complement	  CR	   	   	   Complement	  receptor	  CRD	   	   	   Carbohydrate	  recognition	  domain	  CRIg	   Complement	  receptor	  of	  the	  immunoglobulin	  family	  CRP	   	   	   C-­‐reactive	  protein	  CUB	  	   C1r/C1s,	  urchin	  embryonic	  growth	  factor	  and	  bone	  morphogenetic	  protein-­‐1	  	  C3aR	   C3a	  receptor	  C5aR	   C5a	  receptor	  DM	   Diabetes	  mellitus	  type	  1	  DMBT1	   Deleted	  in	  malignant	  brain	  tumors	  1	  	  DSS	   	   	   Dextran	  sulfate	  sodium	  EDTA	   	   	   Ethylene	  diamine	  tetraacetic	  acid	  EGTA	   	   	   Ethylene	  glycol	  tetraacetic	  acid	  ELISA	   	   	   Enzyme	  linked	  immuno-­‐sorbent	  assay	  Fv	   	   	   Fetal	  vessels	  GAS	   	   	   Group	  A	  streptococcus,	  S.	  pyogenes	  GBS	   	   	   Group	  B	  streptococcus,	  S.	  agalactiae	  GDM	   	   	   Gestational	  diabetes	  	  GlcNAc	   	   N-­‐acetylglucosamine	  gp340	  	   	   Glycoprotein	  of	  340	  kDa	  HIS	   	   	   Heat-­‐inactivated	  serum	  HIV-­‐I	   	   	   Human	  immunodeficiency	  virus	  type	  1	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HRP	   	   	   Horseradish	  peroxidase	  IAV	   	   	   Influenza	  A	  virus	  	  IHC	  	   	   	   Immunohistochemistry	  IL	   	   	   Interleukin	  	  IUGR	   	   	   Intra-­‐uterine	  growth	  restriction	  IVS	   	   	   Intervillous	  space	  Kb	   	   	   Kilobase	  Lea	   	   	   Lewis	  antigen	  a	  Leb	   	   	   Lewis	  antigen	  b	  Lex	   	   	   Lewis	  antigen	  x	  Ley	   	   	   Lewis	  antigen	  y	  LPS	   	   	   Lipopolysaccharide	  mAb	   	   	   Monoclonal	  antibody	  MAC	   	   	   Membrane	  attack	  complex	  MASP	   	   	   MBL-­‐associated	  serine	  protease	  MBL	   	   	   Mannose	  binding	  lectin	  MFI	   	   	   Mean	  fluorescence	  intensity	  MHC	   	   	   Major	  histocompatibility	  complex	  MS	  	   	   	   Mass	  spectrometry	  NB	  	   	   	   Northern	  blotting	  	  NLR	   	   	   NOD-­‐like	  receptor	  NOD2	   Nucleotide-­‐binding	  oligomerization	  domain	  2	  NHS	   	   	   Normal	  human	  serum	  OD	   	   	   Optical	  density	  O/N	   	   	   Over	  night	  OPD	   	   	   1,2-­‐phenylenediamine	  pAb	   	   	   Polyclonal	  antibody	  PBS	   	   	   Phosphate-­‐buffered	  saline	  PE	   	   	   Pre-­‐eclampsia	  PRM	  	   	   	   Pattern	  recognition	  molecule	  PMA	   	   	   Phorbol	  12-­‐myristate	  13-­‐acetate	  PVDF	   	   	   Polyvinylidene	  fluoride	  rMASP-­‐2	   	   Recombinant	  MASP-­‐2	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rMBL	   	   	   Recombinant	  MBL	  rM-­‐ficolin	   	   Recombinant	  M-­‐ficolin	  rRNA	   	   	   Ribosomal	  ribonucleic	  acid	  	  rSALSA	   	   Recombinant	  SALSA	  RT-­‐PCR	   Reverse	  transcriptase	  polymerase	  chain	  reaction	  	  SA	   Spiral	  arteries	  SAG	  	   	   	   Salivary	  agglutinin	  	  	  SALSA	  	   	   Salivary	  scavenger	  and	  agglutinin	  SD	   	   	   Standard	  deviation	  SDS-­‐PAGE	   Sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  Se(+)	   Secretor	  Se(-­‐)	   Non-­‐secretor	  SID	  	   	   	   SRCR	  interspersed	  domain	  SpA	   	   	   Surfactant	  protein	  A	  	  SpD	  	   	   	   Surfactant	  protein	  D	  	  SRCR	  	   	   	   Scavenger	  receptor	  cysteine-­‐rich	  	  SRCR-­‐SF	   Scavenger	  receptor	  cysteine-­‐rich	  superfamily	  SRCRP2	   Scavenger	  receptor	  cysteine-­‐rich	  peptide	  2	  STP	   	   	   Serine	  threonine	  proline	  TBS	   	   	   Tris-­‐buffered	  saline	  TTSB	   	   	   Tris	  saline	  buffer	  containing	  tween	  TNF-­‐	  α	  	   	   Tumor	  necrosis	  factor	  α	  TLR	  	   	   	   Toll-­‐like	  receptor	  ZP	  	   	   	   Zona	  pellucida	  	  VBS	   	   	   Veronal-­‐buffered	  saline	  WB	  	   	   	   Western	  blotting	  	  w/w	   	   	   weight	  versus	  weight	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Introduction 	  An	   individual	   human	   being	   is	   a	   unique	   organism	   distinct	  from	  all	   other	   living	  organisms.	   In	  pregnancy,	  however,	  we	  may	   think,	   that	   a	   fetus	   inside	   a	   pregnant	  woman	   is	   part	   of	  her.	   But	   in	   reality,	   within	   the	   mother	   there	   is	   a	   separate	  compartment	   for	   the	   child,	   and	   a	   barrier	   between	   the	  mother’s	  and	  the	  child’s	  tissues.	  In	  a	  smaller	  scale	  we	  know	  that	  the	  human	  body	  harbors	  thousands	  of	  different	  species	  of	  bacteria.	  In	  fact,	  on	  the	  average	  there	  are	  roughly	  10	  times	  as	  many	  bacterial	  cells	  living	  in	  the	  human	  body,	  as	  there	  are	  human	   cells.	   However,	   there	   is	   still	   a	   clear	   barrier	   keeping	  the	  bacteria	  separated	  from	  the	  parenteral	  human	  tissues.	  As	  such,	  we	  need	  to	  think	  of	  the	  surface	  of	  the	  human	  body	  not	  only	  as	  the	  skin	  and	  other	  visible	  parts,	  but	  also	  the	  surfaces	  within	   the	   human	   body,	   the	   mucosal	   surfaces,	   such	   as	   the	  gastro-­‐intestinal,	   respiratory,	   urinary	   and	   the	   genital	   tracts	  and	  during	  pregnancy	  even	  the	  placenta.	  	  	  Maintaining	   these	   barriers	   is	   essential	   for	   a	   healthy	   life.	  When	   the	   barriers	   are	   breached	  we	   become	   susceptible	   to	  diseases	   such	   as	   infections	   and,	   for	   pregnant	   women,	   to	  certain	   pregnancy	   complications.	   To	   prevent	   barrier	  damage,	  mechanical	   defenses	   exist,	   for	   example	   the	   gastric	  acid,	   the	   impenetrable	   skin,	   and	   the	   activity	   of	   cilia	   to	  constantly	   remove	   bacteria	   and	   waste	   products	   out	   of	   the	  lungs.	   However,	   for	   an	   efficient	   and	   more	   sophisticated	  protection	   the	   immune	   system	   is	   needed.	   It	   plays	   an	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indispensable	   role	   in	   constantly	  monitoring	   the	   surfaces	   of	  the	  human	  body.	  	  The	   immune	   defense	   system	   consists	   of	   an	   innate	   and	   an	  adaptive	  part.	  The	  innate	  immune	  system	  utilizes	  a	  number	  of	  evolutionarily	  conserved	  anti-­‐microbial	  molecules	  as	  well	  as	  cells	  with	  receptors	  specialized	  in	  recognizing	  a	  vast	  array	  of	   microbial	   structures.	   In	   contrast,	   the	   adaptive	   immune	  system	   is	   only	   engaged	   upon	   specific	   challenge	   and	  presentation	  of	   an	   antigen.	  Activation	  of	  T-­‐cells	   and	  B-­‐cells	  of	   adaptive	   immunity	   leads	   to	   a	   more	   precise	   and	   long-­‐lasting	  defense.	  T-­‐cells	  direct	  cell-­‐mediated	  immunity	  and	  B-­‐cells	  develop	  into	  antibody-­‐producing	  plasma	  cells.	  Because	  a	  newborn	  child	  has	  not	  yet	  encountered	  a	  broad	  spectrum	  of	  microbes,	   its	   adaptive	   immune	   system	   is	   still	   immature.	  Although	   some	   antibodies	   are	   transferred	   directly	   from	  mother	   to	   child	   via	   the	   placenta	   and	   breast	  milk,	   the	   child	  still	  relies	  mostly	  on	  the	  innate	  immune	  system	  in	  early	  life.	  	  	  It	   is	   obvious	   that	   maternal	   immune	   activation	   against	   the	  “foreign”	   fetus	   would	   be	   catastrophic.	   In	   addition,	   human	  health	   relies	   on	   peaceful	   and	   synergistic	   interactions	   with	  the	   colonizing	   microbiota.	   Therefore,	   a	   strict	   regulation	  targeting	   the	   immune	   system	   towards	   some,	   but	   not	   all	  foreign	   organisms	   exists.	  When	   the	  monitoring	   cells	   of	   the	  innate	   immune	   system,	   such	   as	   dendritic	   cells	   and	  macrophages,	   meet	   a	   foreign	   organism	   their	   response	   and	  interaction	  with	  T-­‐cells	  and	  adaptive	   immunity	  depends	  on	  the	   local	   environment	   of	   danger	   signals.	   Binding	   and	  activation	  of	  anti-­‐microbial	  proteins	  and	  enzymatic	  cascades,	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such	  as	   the	  complement	   (C)	  system,	  are	   important	   features	  when	   the	   immune	   system	   decides	  whether	   to	  mount	   a	   full	  attack	  or	  simply	  tolerate	  the	  target.	  Therefore	  a	  malfunction	  of	   these	   systems	   may	   lead	   to	   unwanted	   immunological	  responses	   and	   subsequent	   diseases.	   Elucidating	   the	   role	   of	  these	  molecules	   is	  of	  utmost	   importance,	   and	   therefore	   the	  overall	   scope	   of	   this	   study.	   By	   understanding	   the	   basic	  physiological	   mechanisms	   we	   may	   also	   realize	   what	   goes	  wrong	  in	  the	  case	  of	  illness.	  Finally,	  understanding	  the	  basic	  pathophysiological	   mechanisms	   will	   help	   us	   finding	   new	  ways	  to	  cure	  the	  respective	  diseases	  –	  maybe,	  one	  day,	  with	  a	  pill	  of	  SALSA!	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Physical structure The	  barrier	   between	   the	   human	  body	   and	   the	   surrounding	  environment	   consists	  of	   the	   skin	   and	   the	  mucosal	   surfaces.	  The	  main	  mucosal	   surfaces	   are	   the	  mouth,	   the	   respiratory	  tract,	   the	   gastric	   sac	   and	   the	   intestines	   with	   variation	  observed	   between	   duodenum,	   jejunum,	   ileum	   and	   colon.	  While	   the	   skin	  makes	   up	   approximately	   2	  m2,	   the	  mucosal	  surfaces	  cover	  up	  to	  300	  m2,	  making	  them,	  by	  far,	  the	  largest	  interface	   between	   the	   human	   host	   and	   foreign	   organisms	  [197].	  The	  skin	  is	  covered	  by	  several	  layers	  of	  dead	  and	  living	  epithelial	   cells	   providing	   an	   extensive	   mechanical	   barrier.	  However,	  the	  mucosal	  surfaces	  are	  only	  covered	  by	  a	  single	  layer	   of	   epithelial	   cells	   making	   the	   requirement	   for	   strong	  immunological	  regulation	  evident	  [23].	  	  	  
Cells of the mucosal surfaces The	   key	   players	   at	   the	   mucosal	   surfaces	   are	   the	   single-­‐layered	   epithelial	   cells.	   Seeded	   on	   a	   basement	   membrane	  these	   cells	   make	   up	   the	   main	   barrier	   to	   the	   environment.	  The	  polarized	  epithelial	  cells	  are	  covered	  with	  a	   thick	   layer	  of	  mucus	   on	   the	   luminal	   side	   designed	   to	   help	   them	   in	   the	  interactions	  with	   the	   colonizing	   bacteria	   [32].	   The	   epithelial	  cells	   are	   mainly	   involved	   in	   absorption	   and	   digestion	   of	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nutrients,	   however,	   they	   have	   also	   been	   shown	   have	   very	  important	   immunological	   functions,	   e.g.	   the	   expression	   of	  specific	  microbial	  receptors	   [23].	   In	  addition	  to	  the	  epithelial	  cells,	  other	  cell	  types	  play	  important	  roles	  in	  maintaining	  the	  mucosal	   barrier	   such	   as	   goblet	   cells,	   endocrine	   cells	   and	  Paneth	   cells.	   These	   cells	   secrete	   a	   large	   number	   of	  substances	  involved	  in	  the	  interactions	  with	  the	  microbiota,	  e.g.	   mucus	   components,	   acid	   in	   the	   stomach,	   epithelial	  growth	  factors	  and	  antibacterial	  peptides	  [197].	  	  A	  great	  number	  of	  immunological	  cells	  are	  found	  both	  below	  the	  single	   layered	  epithelium	  and	  interspersed	  between	  the	  epithelial	   cells.	   Antigen-­‐presenting	   cells	   (APCs)	   such	   as	  dendritic	  cells	  and	  specialized	  M-­‐cells	  are	  found	  with	  direct	  contact	   to	   the	   gut	   lumen.	   In	   the	   underlying	   lamina	   propria	  both	  B-­‐cells	  and	  T-­‐cells	  gather	   in	  specialized	  compartments	  known	  as	  Peyer’s	  patches.	  In	  addition,	  isolated	  lymphocytes	  and	   innate	   immune	   effector	   cells	   such	   as	   macrophages,	  natural	  killer	  cells	  and	  mast	  cells	  are	  found	  spread	  out	  in	  the	  entire	   subepithelial	   compartment	   [22].	   An	   overview	   is	   given	  in	  Figure	  1.	  	  
Bacterial colonization of the mucosa Humans	   are	   born	   virtually	   sterile,	   but	   immediately	   after	  birth	  the	  body	  is	  colonized	  by	  a	  multitude	  of	  microorganisms	  [96].	  Some	  studies	  have	  shown	  bacterial	  colonization	  of	  both	  amniotic	   fluid	   and	   infant	   meconium	   from	   healthy	  individuals,	   suggesting	   that	   bacteria	  may	   be	   present	   in	   the	  amniotic	  cavity	  already	  during	  pregnancy	  [9,	  77].	  However,	  the	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Figure	   1:	   Immunology	   of	   the	  mucosal	   surfaces	   exemplified	   by	   the	  
gut.	  	  
Epithelial	   cells	   line	   the	   surface	   of	   the	   gut,	   with	   dendritic	   cells	  
protruding	  through	  the	  cell	  layer	  to	  monitor	  the	  lumen.	  M-­‐cells	  are	  
responsible	   for	   transporting	   luminal	   antigens	   to	   the	   structured	  
lymphoid	  organs,	  Peyer’s	  patches,	  with	  distinct	  T-­‐cell	   areas	   (blue)	  
and	  B-­‐cell	   follicles	  (yellow).	   In	  addition,	   intra-­‐epithelial	  T-­‐cells	  are	  
found	   scattered	   throughout	   the	   mucosal	   surface.	   When	   the	  
epithelium	  is	  damaged,	  lumen	  defense	  molecules	  meet	  and	  interact	  
with	   the	   cells	   and	   molecules	   from	   the	   tissue	   to	   protect	   against	  
infection	  and	  to	  initiate	  healing.	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main	   colonizing	   microbes	   appear	   from	   the	   surrounding	  environment,	  and	  in	  particular	   from	  the	  vaginal	   flora	  of	   the	  mother.	  Eventually	  the	  commensal	   flora	  of	   the	  human	  body	  displays	  a	  profound	  diversity	  with	  more	  than	  1000	  different	  species	  co-­‐existing	  within	  the	  human	  host	  [197].	  Most	  of	  these	  bacteria	   exist	   in	   a	   symbiotic	   relationship	   with	   the	   human	  host	   (mutualism).	   However,	   disruption	   of	   this	   mutualistic	  balance	   can	   lead	   to	   disease.	   Under	   certain	   conditions	  bacteria	  may	   become	   opportunistic	   pathogens	   leading	   to	   a	  harmful	  infection	  of	  the	  host	  [36].	  In	  contrast,	  an	  over-­‐reactive	  immune	  system	  may	  cause	  chronic	   inflammation	  such	  as	   in	  Chron’s	  disease	  [67,	  140].	  	  	  The	   specific	   mucosal	   tissues	   make	   up	   specific	  microenvironments,	   and	   therefore	   also	   attract	   the	  colonization	   of	   certain	   types	   of	   microorganisms	   [116].	   An	  example	   is	   the	   acid-­‐tolerance	   of	  Helicobacter	   pylori,	   which	  enables	   it	   to	   colonize	   the	   gastric	   epithelium	   [145].	   Only	   a	  minor	  proportion	  of	  the	  microbiota	  has	  been	  cultured	  so	  far,	  thus	   we	   only	   have	   a	   fairly	   limited	   understanding	   of	   the	  bacterial	   diversity	   of	   the	   human	   body.	   However,	   modern	  techniques	  such	  as	  RT-­‐PCR	  of	  16S	  rRNA	  and	  proteomics	  are	  providing	   a	   greater	   understanding	   of	   the	   bacterial	  composition	  and	  diversity	  within	  the	  human	  body.	  	  	  	  The	  oral	  cavity	  harbors	  up	  to	  500	  different	  bacterial	  species	  located	   on	   the	   teeth,	   gingival	   crevices,	   plaques,	   buccal	  mucosa	   and	   tongue	   [144].	   The	   main	   phyla	   found	   are	  Deferribacteres,	   Spirochetes,	   Fusobacteria,	   Actinobacteria,	  Firmicutes,	   Proteobacteria,	   and	   Bacteroidetes	   	   [144].	   The	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bacteria	  attached	  to	  the	  tooth	  surfaces	  form	  biofilms	  known	  as	  dental	  plaques.	   In	   the	  gingival	   crevices	   large	  amounts	  of	  Gram-­‐negative	   anaerobes,	   especially	   Porphyromonas	  
gingivalis,	  are	  believed	  to	  be	  involved	  in	  the	  pathogenesis	  of	  periodontal	  disease	  [149].	  	  The	  environment	  of	  the	  gastric	  sac	  is	  highly	  acidic,	  and	  thus	  acts	   as	   a	   chemical	   tool	   to	   limit	   the	   local	   bacterial	   flora	   and	  entry	   of	   pathogens	   into	   the	   intestine.	   Still,	   some	  organisms	  are	  able	  to	  survive	  the	  acidic	  environment,	  and	  more	  than	  a	  hundred	  different	  species	  have	  been	  found	  here	  [11].	  H.	  pylori	  is	   a	   known	   causative	   agent	   of	   gastric	   and	   duodenal	   ulcers	  and	   also	   of	   gastric	   cancers	   [145].	   However,	   it	   is	   commonly	  found	  to	  colonize	  the	  gastric	  epithelia	  of	  healthy	  individuals	  as	  well	  [145].	  	  	  A	   great	   variation	   of	   microbial	   colonization	   is	   seen	   in	   the	  various	   sections	   of	   the	   intestine.	   Few	  bacteria	   are	   found	   in	  the	  duodenum	  and	   jejunum,	  whereas	  the	   ileum	  contains	  up	  to	   109	   bacteria	   /	  ml	   lumen	   content	   with	   a	   great	   degree	   of	  species	  variation.	  However,	  the	  richest	  and	  most	  diversified	  bacterial	  population	  is	  found	  in	  the	  human	  colon	  [197].	   	  Most	  of	  the	  bacteria	  are	  strict	  anaerobes	  with	  the	  most	  abundant	  phyla	   being	   Firmicutes	   and	   Bacteroidetes,	   followed	   by	  Proteobacteria,	   Actinobacteria,	   Fusobacteria,	   and Verrucomicrobia	  [41].	  	  	  The	   urogenital	   tract	   is	   kept	   mostly	   sterile	   by	   the	   flushing	  effect	  of	  urine.	  The	  main	  colonizers	  of	  the	  vaginal	  epithelium	  are	   Lactobacillus.	   In	   fact,	   in	   some	   individuals	   various	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Lactobacillus	   species	   were	   found	   to	   be	   the	   only	   microbes	  present.	   However,	   other	   common	   colonizers	   were	  
Gardnerella	  vaginalis	  and	  streptococcal	  species	  [70].	  	  	  	  Unlike	   the	   above-­‐described	   mucosal	   surfaces,	   the	  respiratory	  tract	  is	  equipped	  with	  efficient	  mechanical	  tools,	  such	  as	  cilia-­‐mediated	  movement	  of	  the	  mucus,	  keeping	  the	  trachea,	   bronchi	   and	   alveoli	   sterile	   under	   normal	   healthy	  conditions	  [211].	  However,	  the	  upper	  parts	  of	  the	  respiratory	  tract,	   such	   as	   the	   nose,	   nasopharynx	   and	   oropharynx	   are	  inhabited	   by	   a	   great	   variety	   of	   microbes.	   These	   include	  staphylococci,	   streptococci,	   Corynebacteria	   and	   Gram-­‐negative	  cocci.	  Some	  of	   the	  colonizing	  bacteria,	   for	  example	  
Streptococcus	   pneumoniae	   and	   Neisseria	   meningitidis,	   may	  cause	   life-­‐threatening	   infections	   such	   as	   pneumonia	   and	  meningitis	  [36,	  197].	  	  
Immunology of the mucosal surface   The	  immune	  system	  of	  the	  mucosal	  surfaces	  is	  different	  from	  the	  systemic	  immune	  system.	  Both	  harmful	  antigens,	  such	  as	  those	   of	   pathogens,	   and	   non-­‐harmful	   antigens,	   such	   as	  degraded	   food	  and	   components	  of	   commensal	  bacteria,	   are	  present	   in	   the	   mucosa.	   An	   equal	   immune	   response	   to	   all	  types	  of	  antigens	  could	  be	  harmful	  to	  the	  human	  host.	  Thus	  induction	  and	  maintenance	  of	   tolerance	  to	  many	  bacteria	   is	  essential.	   The	   polarized	   epithelium	   operates	   together	   with	  the	   underlying	  APCs	   to	  monitor	   the	  microbial	   colonization.	  These	  cells	  carry	  receptors	  on	  their	  surfaces,	  including	  those	  for	  C	  components,	   antibodies	  and	   lipopolysaccharide	   (LPS).	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A	   specific	   system	   of	   pattern	   recognition	  molecules	   (PRMs)	  such	  as	  the	  Toll-­‐like	  and	  Nod-­‐like	  receptors	  (TLRs	  and	  NLRs,	  respectively)	   can	   give	   immunosuppressive	   or	  immunoinductive	  signals	  depending	  on	  where	  and	  by	  which	  factors	   the	   receptors	   are	   engaged.	   In	   general,	   luminal	  antigens	  cause	  no	  harm,	  but	  antigens	  on	  the	  basolateral	  side	  of	  the	  epithelia	  may	  cause	  immunological	  activation	  [163].	  The	  adaptive	   branch	   of	   the	   immune	   system	   has	   very	   special	  features	   at	   the	   mucosa,	   especially	   in	   the	   intestine.	   Both	  diffuse	  and	  well-­‐structured	  lymphoid	  tissues,	  such	  as	  Peyer’s	  patches,	  exist	  in	  direct	  connection	  to	  the	  mucosal	  epithelium	  [22].	  There	  is	  a	  predominance	  of	  memory	  lymphocytes	  in	  the	  tissue	  and	  a	   constant	   secretion	  of	   IgA	  –	   the	  most	  abundant	  immunoglobulin	  of	  the	  mucosal	  surfaces	  [23,	  24].	  	  	  A	  key	  difference	   in	   the	   immunological	  decision	  of	   tolerance	  or	   activation	   is	   the	   environment	   in	   which	   the	   APCs	   meet	  their	   antigens,	   and	   present	   them	   to	   the	   T-­‐cells.	   In	   the	  absence	   of	   inflammatory	   stimulation,	   CD103-­‐positive	  dendritic	  cells	  will	  induce	  a	  regulatory	  T-­‐cell	  phenotype	  [163].	  However,	  if	  the	  mucosal	  barrier	  is	  breached,	  e.g.	  by	  infecting	  microbes,	   a	   multitude	   of	   innate	   immune	   molecules	   are	  activated	  thus	  altering	  the	  nature	  of	  the	  antigen	  presentation	  towards	  a	  protective	  adaptive	  immune	  response	  [178].	  During	  neonatal	   life,	   an	   adaptive	   immune	   response	   is	   not	   yet	   fully	  developed,	  and	  the	  function	  of	  the	  innate	  immune	  system	  at	  the	  mucosal	  surfaces	   is	   therefore	  particularly	   important	   for	  the	  health	  of	  the	  newborn	  [96].	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When the barrier is breached – encounter with 
the complement system 
Complement activation The	  complement	  system	  is	  a	  complex	  enzymatic	  cascade	  that	  has	   evolved	   to	   both	   complement	   the	   immunological	  processes	   in	   the	   body	   but	   also	   to	   orchestrate	   the	   precise	  targeting	   of	   these	  processes.	   Complement	   is	   activated	   after	  binding	   to	   specific	   surfaces.	   Recognition	  molecules	   bind	   to	  exposed	   foreign	   or	   altered-­‐self	   molecular	   structures,	  including	  bacteria,	  viruses,	  antibody-­‐antigen	  complexes	  and	  apoptotic	   cells.	   In	   principle	   C	   components	   are	   capable	   of	  targeting	   every	   surface	   in	   the	   human	   body.	   However	   strict	  regulation	  of	   the	  activation	  ensures	   that	  C	   is	  only	  activated	  when	  needed	  –	  at	  least	  in	  healthy	  individuals,	  reviewed	  in	  [40,	  117,	  162].	  	  	  The	  C	   cascade	   is	   divided	   into	   three	  different	  pathways,	   the	  classical,	   the	   alternative	   and	   the	   lectin	   pathway	   (Figure	   2).	  The	   classical	   and	   lectin	   pathways	   are	   activated	   in	   very	  similar	  ways	  by	  the	  binding	  of	  specific	  soluble	  PRMs	  to	  their	  ligands	   [202].	   The	   PRM	   of	   the	   classical	   pathway	   is	   C1q	   and	  those	  of	   the	   lectin	  pathway	  are	   the	  mannose	  binding	   lectin	  (MBL)	  and	  the	  ficolins	  H,	  L	  and	  M	  (also	  termed	  ficolins	  1,	  2	  and	   3).	   Binding	   of	   the	   PRMs	   to	   their	   respective	   targets	  induces	   conformational	   changes	   that	   affect	   the	   C1q-­‐associated	   serine	   proteases,	   C1r/s,	   and	   MBL-­‐associated	  serine	  proteases	  1	  and	  2	  (MASP1	  and	  MASP2),	   respectively	  [7,	  148].	  The	  serine	  proteases	  activate	  C4.	  Activation	  cleaves	  C4	  into	   C4a	   and	   C4b,	   revealing	   a	   hidden	   thioester	   site,	   which	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covalently	  links	  C4b	  to	  the	  target	  surface	  in	  close	  proximity	  to	   the	   activating	   complex.	   C4b	   binds	   C2,	   which	   is	  subsequently	   cleaved	   by	   C1s	   or	   MASPs.	   The	   two	   cleaved	  components	   join	   to	   form	  the	  C4b2a	  complex	  also	  known	  as	  the	  C3-­‐convertase	  of	  the	  classical	  and	  lectin	  pathways	  [29,	  170].	  This	   is	   a	   key	   step	   in	   C	   activation.	   The	   C4b2a	   complex	  activates	   C3	   leading	   to	   deposition	   of	   C3b	   on	   the	   target	  surface	   and	   release	   of	   the	   anaphylatoxin	   C3a	   into	   the	  surrounding	  microenvironment	  [202].	  	  	  C3	   is	   a	   very	   unstable	   molecule	   in	   solution	   and	   auto-­‐hydrolyzes	  readily	  into	  C3(H2O).	  This	  marks	  the	  initiation	  of	  the	   alternative	   C	   pathway.	   C3(H2O)	   exposes	   new	   binding	  sites	  and	  binds	  factor	  B,	  which	  in	  the	  presence	  of	  factor	  D	  is	  cleaved	  to	  Bb.	  The	  C3(H2O)Bb	  complex	  functions	  as	  a	  soluble	  C3	   convertase	   producing	   C3b	   which	   subsequently	   binds	  covalently	  to	  nearby	  surfaces.	  On	  the	  surface,	  the	  C3b	  again	  binds	   factor	   B	   forming	   the	   surface-­‐bound	   C3bBb	   complex,	  also	  known	  as	  the	  C3	  convertase	  of	  the	  alternative	  pathway	  [10].	  The	  C3b	   formed	  can	  again	  bind	  new	  factor	  B	  molecules	  and	   form	   even	   more	   C3-­‐convertases.	   Thus	   the	   alternative	  pathway	  functions	  as	  a	  very	  efficient	  amplification	  loop	  and	  can	   enhance	   C	   activation	   created	   by	   auto-­‐hydrolysis	   or	   by	  utilizing	  the	  C3b	  formed	  by	  the	  classical	  and	  lectin	  pathways,	  reviewed	  in	  [59].	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Figure	  2:	  The	  complement	  system.	  	  
A)	   Activation.	   Classical	   pathway:	   C1-­‐complex	   (light	   blue)	   binds	   to	  
IgG/IgM	   (blue)	   or	   CRP/pentraxins	   (red)	   on	   the	   target	   surfaces.	  
Lectin	   pathway:	   MBL/Ficolins-­‐MASP	   complex	   (green)	   binds	  
carbohydrate	   structures	  on	   the	   target	   surface	   (xxx).	   For	   the	   lectin	  
and	   classical	   pathways,	   activation	   involves	   the	   cleavage	   of	   C4	   and	  
C2,	  which	  generates	  the	  C3	  convertase	  C4b2a	  on	  the	  target	  surface.	  
Alternative	   pathway:	   In	   the	   fluid	   phase	   C3	   auto-­‐hydrolyses	   to	  
C3(H2O).	   It	   binds	   factor	   B,	   which	   in	   the	   presence	   of	   factor	   D	   is	  
activated	  to	  form	  the	  C3(H2O)Bb	  complex.	  	  
B)	  Amplification.	   Surface-­‐bound	  C4b2a	  and	   fluid-­‐phase	  C3(H2O)Bb	  
cleave	   C3	   to	   C3a	   and	   C3b.	   C3b	   is	   deposited	   on	   the	   nearby	   surface	  
where	  it	  binds	  factor	  B.	  Factor	  D	  cleaves	  factor	  B	  to	  form	  a	  surface-­‐
bound	  C3bBb	  complex,	  which	  is	  further	  stabilized	  by	  properdin	  (P,	  
blue	   triangle).	   This	   complex	   is	   a	   C3	   convertase	   enzyme	   able	   to	  
cleave	  new	  C3	  molecules	  thus	  amplifying	  the	  signal.	  	  
C)	  Terminal	  pathway.	  Newly	  created	  C3b	  can	  attract	  C5	  to	  cleavage	  
by	  C4b2a	  or	  C3bBb.	  C5	  is	  cleaved	  to	  C5a	  and	  C5b.	  C5b	  binds	  C6,	  C5b-­‐
6	   binds	   C7	   and	   C8	   whereby	   the	   complex	   is	   inserted	   into	   the	   cell	  
membrane.	   Finally	   C9	   is	   recruited	   to	   form	   a	   pore	   that	   allows	  
exchange	   of	   ions	   and	   small	   molecules	   through	   the	   double	  
phospholipid	  membrane.	  	  	  The	  formation	  of	  C3	  convertases	  (either	  C4b2a	  or	  C3bBb)	  on	  target	  surfaces	  pave	  the	  way	  for	  the	  initiation	  of	  the	  terminal	  pathway,	   shared	   by	   all	   three	   activation	   cascades.	   The	   C3	  convertases	   bind	   C3b	   and	   form	   the	   C5	   convertase	  (C4b2aC3b	  or	  C3bBb3b).	  C5	  is	  cleaved	  leading	  to	  generation	  of	   C5b	   and	   release	   of	   the	   anaphylatoxin	   C5a	   in	   the	   fluid	  phase	   [117,	  162].	   The	  deposited	  C5b	   can	  now	  bind	  C6	  and	  C7,	  whereafter	  the	  C5b-­‐7	  complex	  can	  bind	  to	  a	  membrane	  and	  recruit	   C8.	   Together	   they	   form	   a	   complex	   that	   is	   inserted	  into	   double	   phospholipid	   cell	   membranes.	   Finally	   multiple	  molecules	   of	   C9	   are	   inserted	   into	   a	   ring-­‐like	   structure	  forming	   the	   C5b-­‐9	   complex,	   or	   the	   membrane	   attack	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complex	   (MAC).	   The	   ring	   structure	   is	   essentially	   a	   pore	   in	  the	   cell	   membrane	   allowing	   free	   movement	   of	   water	   and	  other	  solutes.	  Calcium	  and	  sodium	  influx	  into	  the	  cells	  causes	  activation	  of	  many	   intracellular	   processes.	  After	   having	   the	  cell	   surface	   covered	  with	  MAC	   the	   osmotic	   gradient	   of	   the	  cell	  is	  destroyed	  and	  it	  ruptures	  and	  dies	  [132].	  	  	  	  
Complement regulation The	  unstable	  nature	  of	  C3	  allows	   it	   to	  constantly	  probe	   the	  surfaces	   of	   the	   immediate	   surroundings.	  When	   the	   soluble	  C3bBb	  convertase	   is	  active,	  C3	   is	   cleaved	   in	   the	   fluid	  phase	  and	   deposited	   on	   a	   nearby	   surface.	   On	   foreign	   or	  modified	  host	  surfaces	  this	  signal	  can	  be	  quickly	  multiplied.	  However,	  on	   our	   own	   healthy	   cells,	   several	   strong	   complement	  regulators	   exist	   and	   more	   can	   be	   recruited.	   Basically	   the	  complement	   regulation	   can	   be	   divided	   into	   five	   main	  mechanisms;	   inhibition	  of	  C3	  convertase	   formation,	   factor	   I	  cofactor	   activity,	   decay-­‐accelerating	   activity	   for	   the	   C3	  convertase,	   inhibition	   of	   lysis	   and	   finally	   cleavage	   of	  anaphylatoxins,	   reviewed	   in	   [40].	   Some	   regulators	   are	   found	  on	   the	   cell	   membrane	   of	   the	   human	   cells	   such	   as	   CD46,	  CD55,	  CD59,	  Complement	  receptor	  (CR)	  type	  1	  and	  CR	  of	  the	  immunoglobulin	   superfamily	  CRIg	   [219].	  Others	   are	   found	   in	  the	  fluid	  phase	  and	  recruited	  to	  the	  C	  targeted	  cell	  surfaces.	  These	   include	   factor	   H	   that	   controls	   the	   amplification	   loop	  and	   C1	   inhibitor	   and	   C4b	   binding	   protein	   (C4BP),	   which	  inhibit	  both	  the	  classical	  and	  the	  lectin	  pathway	  [219].	  Factor	  I	  is	  a	  fluid	  phase	  serine	  esterase	  enzyme	  recruited	  to	  C3b	  and	  C4b	  on	  self	  surfaces	  by	  interaction	  with	  the	  regulators	  CD46,	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CR1	  C4BP	  and	  factor	  H.	  The	  binding	  leads	  to	  the	  cleavage	  of	  C3b	  first	   to	   iC3b,	  and	  subsequently	  to	  C3c	  and	  C3dg.	  C4b	   is	  degraded	  to	  C4c	  and	  C4d.	  CR1,	  C4BP	  	  and	  factor	  H	  inhibit	  the	  formation	   of	   new	   C3	   convertases.	   CD55,	   CR1,	   C4BP	   and	  factor	   H	   have	   decay	   accelerating	   activity.	   Formation	   of	   the	  MAC	   complex	   is	   inhibited	   by	   CD59	   on	   cell	  membranes	   and	  by	   vitronectin	   and	   clusterin	   in	   the	   fluid	   phase.	   Finally,	   the	  signaling	   properties	   of	   the	   fluid-­‐phase	   anaphylatoxins,	   C3a	  and	   C5a,	   are	   influenced	   by	   cleavage	   with	   specific	  carboxypeptidases.	  The	  regulation	  of	  C	  has	  been	  reviewed	  in	  [40].	  	  
Complement receptors Both	   the	   soluble	   and	   the	   surface-­‐bound	   complement	  activation	   products	   have	   several	   receptors	   on	   various	  immune	   and	   non-­‐immune	   cells.	   CR1	   binds	   C4b	   and	   C3b	  deposited	   on	   e.g.	   microbial	   surfaces.	   CR1	   also	   acts	   as	   a	  cofactor	   for	   factor	   I	   [93].	   The	   iC3b	   formed	   after	   C3b	  inactivation	   by	   factor	   I	   is	   a	   ligand	   for	   CR3	   and	   CR4	   on	  phagocytes	  [199].	  This	  enhances	  phagocytosis	  and	  in	  the	  case	  of	   CR3	   helps	   to	   induce	   cytokine	   production,	   leukocyte	  trafficking	  and	  even	  synapse	  modeling	  [199].	  CR2	  is	  found	  on	  B-­‐cells,	   where	   it	   interacts	   with	   both	   iC3b	   and	   the	   further	  degradation	  products	  C3dg	  and	  C3d	  [206].	  Stimulation	  of	  this	  receptor	  acts	  as	  a	  co-­‐stimulatory	  signal	   for	  B-­‐cell	  activation	  [206].	  C3a	  and	  C5a	  are	  bound	  by	  specific	  receptors	  (C3aR	  and	  C5aR1	   and	   C5aR2,	   respectively)	   expressed	   e.g.	   by	  endothelial	   cells	   and	  many	   types	  of	   leukocytes	   [207].	   Finally,	  even	  the	  initial	  PRMs	  such	  as	  C1q	  and	  MBL	  have	  receptors	  of	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their	   own.	   However,	   to	   this	   date	   the	   specific	   interactions	  necessary	   for	  binding	  of	   these	  molecules	   to	   their	   receptors	  are	  only	  poorly	  understood	  [139].	  	  	  	  
Functions of complement It	   can	   be	   deduced	   from	   the	   above	   that	   the	   physiological	  functions	   of	   C	   span	   far	   wider	   then	   just	   insertion	   of	   lytic	  pores	   into	   the	  membranes	   of	   foreign	   pathogens.	   Alas,	   only	  few	   examples	   exist	   of	   this	   being	   an	   effective	   killing	  mechanism	   of	   microbes,	   e.g.	   Neisseriae	   [155].	   Instead	  inflammatory	   signaling	   and	   opsonization	   for	   phagocytosis	  are	  key	  elements	  of	  the	  anti-­‐microbial	  functions	  of	  C	  [203].	  At	  the	  site	  of	   infection	  where	  C	   is	   first	  activated,	   several	  of	   its	  components	   are	   bound	   by	   receptors	   on	  APCs.	   Both	   foreign	  and	  host	  cells	  and	  other	  structures	  coated	  with	  C3b	  and	  C4b	  become	   targets	   for	   phagocytosis	   by	   the	   dendritic	   cells	   and	  macrophages	   through	   direct	   binding	   to	   receptors	   on	   the	  surfaces	  of	  the	  phagocytes	  [199].	  	  	  Although	  C	  is	  mainly	  considered	  a	  part	  of	  the	  innate	  immune	  response,	   it	   is	  becoming	  evident	  that	  C	  also	  acts	  as	  a	  bridge	  to	  adaptive	  immunity	  and	  even	  the	  coagulation	  system	  [114].	  Simultaneous	  activation	  of	  the	  C3aR/C5aR	  and	  TLRs	  of	  APCs	  strongly	   enhances	   the	   danger-­‐signaling	   and	   subsequent	  production	   of	   pro-­‐inflammatory	   cytokines	   [218].	   The	  stimulation	  of	  APCs	   coordinated	  by	   complement	  affects	   the	  activation	  of	  T-­‐cells.	  However,	  in	  addition	  to	  modulating	  the	  APC-­‐T-­‐cell	  interactions,	  C	  has	  also	  been	  suggested	  to	  interact	  with	   receptors	   on	   the	   T-­‐cells	   directly.	   T-­‐cells	   respond	   by	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altered	  proliferation	  and	  differentiation	  to	  ligand	  binding	  to	  surface	  receptors	  such	  as	  the	  anaphylatoxin	  receptors	  C3aR	  and	  C5aR	  and	  also	   the	  complement	   regulators	  CD46,	  CD55,	  CD59	  and	  CR1	  [39].	  	  In	  addition,	  direct	  binding	  of	  C1q	  or	  C1q-­‐coated	  immune	  complexes	  also	  affects	  the	  function	  of	  T-­‐cells	  [28,	  76].	  	  Complement	  was	   initially	   named	   based	   on	   the	   observation	  that	   it	   “complements”	   the	   function	   of	   antibodies	   in	   cell	  killing.	   The	   C	   receptors	   CR1	   and	   CR2	   are	   found	   on	   the	  surfaces	   of	   B-­‐cells.	   Here	   they	   function	   as	   co-­‐receptors,	   e.g.	  the	   CR2-­‐CD19-­‐CD81	   co-­‐receptor	   complex,	   and	   allow	  stronger	   stimulation	   of	   B-­‐cell	   receptors	  when	   they	   bind	   an	  antigen	   coated	   with	   C	   [206].	   In	   addition,	   CR1	   and	   CR2	   on	  follicular	   dendritic	   cells	   in	   the	   germinal	   centers	   are	  responsible	   for	   long-­‐term	   retention	   of	   antigens	   and	   thus	  stimulate	  the	  B	  memory	  cell	  generation	  [40,	  47].	  	  	  In	  addition	  to	  the	  C	  functions	  described	  above,	  the	  released	  anaphylatoxins,	  C3a	  and	  especially	  C5a	  are	  powerful	  effector	  molecules.	   They	   stimulate	   the	   local	   endothelium	   to	   induce	  integrin	  expression	  allowing	  the	  recruitment	  of	  lymphocytes	  to	   the	   tissue	  and	   local	  activation	  of	   the	  coagulation	  system,	  thus	   helping	   to	   contain	   a	   possible	   infecting	   pathogen	   [114].	  Finally,	   they	   exert	   chemoattractant	   effects	   by	   binding	   to	  their	   respective	   receptors	   on	   neutrophils,	   monocytes	   and	  macrophages	   attracting	   the	   cells	   to	   the	   site	   of	   infection	   or	  inflammation,	  and	  subsequently	  activating	  them	  [207].	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Importantly,	   complement	   does	   not	   only	   function	   in	  orchestrating	  an	  anti-­‐microbial	  defense.	  It	  is	  also	  involved	  in	  the	   resolution	   of	   inflammation	   and	   removal	   of	   apoptotic	  cells.	   Complement	   is	   primarily	   activated	   on	   the	   surface	   of	  apoptotic	  cells	  through	  targeting	  by	  C1q,	  which	  leads	  to	  C3b	  and	  C4b	  deposition	  and	  subsequent	  phagocytosis	   [48].	  A	  key	  feature	  of	  this	  process	  is	  the	  clear	  difference	  in	  action	  seen	  in	  the	  very	  strong	  anti-­‐microbial	  response	  and	  the	  more	  gentle	  response	   utilized	   in	   clearance	   of	   endogenous	   material.	   An	  example	   is	   C-­‐reactive	   protein	   (CRP),	   which	   binds	   to	  apoptotic	   cell	   surfaces.	  CRP	  mediates	   the	  binding	  of	  C1q	   to	  the	   surface,	   and	   thus	   initiates	   complement	   activation.	  However,	   simultaneously,	   CRP	   binds	   factor	   H	   and	   thus	  inhibits	  activation	  of	  C3	  and	  the	  terminal	  pathway	  [72].	  Dying	  cells	  may	  shed	  the	  membrane	  regulatory	  molecules	  such	  as	  CD46,	   CD55	   and	   CD59	   allowing	   C	   attack	   against	   the	   cell	  surface	  [42].	  However,	  residual	  presence	  of	  regulators	  on	  the	  surface	   and	   in	   the	   immediate	   surrounding	   fluid	   phase	   help	  to	   keep	   the	   activation	   at	   a	  minimum	   [162,	  219].	   Finally	   C	   has	  been	  shown	  to	  affect	  tissue	  repair	  by	  neovascularization	  and	  to	   stimulate	   the	   mobilization	   of	   hematopoetic	  stem/progenitor	   cells	   from	   the	   bone	   marrow	   to	   replenish	  the	  pool	  of	  immune	  cells	  in	  blood	  [71,	  137].	  	  	  
Complement and mucosal surfaces Although	   C	   is	   present	   mainly	   in	   blood,	   it	   is	   also	   found	   in	  serous	   exudates	   on	   mucosal	   surfaces,	   such	   as	   in	   the	   oral	  cavity	  or	  the	  airways	   [16,	  147].	  This	   is	  particularly	  seen	  under	  pathological	   conditions,	   for	   example	   in	  mechanical	   damage	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or	  during	  infection,	  e.g.	  periodontal	  disease	  [33].	  When	  serous	  exudates	   enter	   the	   mucosal	   surfaces,	   innate	   immune	  proteins	   interact	   with	   mucosal	   surface	   proteins,	   and	  together	   these	   molecules	   create	   a	   specific	   interplay	   of	  defense	  mechanisms	  against	  invading	  microorganisms.	  	  
Placenta 
Placental anatomy and development After	   the	   human	   egg	   is	   fertilized	   it	   travels	   through	   the	  Fallopian	   tube	   to	   the	   site	   of	   implantation	   in	   the	   uterus.	  During	   this	   journey	  mitotic	   divisions	   of	   the	   original	   zygote	  divide	   the	   early	   embryo	   into	   an	   inner	   cell	   mass,	   the	  embryoblast,	   and	   an	   outer	   peripheral	   cell	   layer,	   the	  trophectoderm.	  In	  time,	  the	  trophectoderm	  develops	  into	  the	  placental	   and	   amniotic	   membrane	   tissues	   [156].	   During	   the	  actual	   implantation	   the	   trophectoderm	   interacts	   with	   the	  maternal	   decidua	   through	   expression	   of	   several	   mediators	  such	   as	   cytokines,	   prostaglandins,	   selectins,	   integrins	   and	  many	  more	  [6].	  As	  the	  invasion	  proceeds	  the	  cytotrophoblasts	  of	   the	   trophectoderm	   fuse	   to	   form	   the	   syncytiotrophoblast	  layer	   (Figure	   3).	   This	   cell	   layer	   has	   direct	   contact	  with	   the	  maternal	   tissue,	   and	   later	   with	   the	   maternal	   blood.	   The	  syncytium	   forms	   trabeculae	   that	   protrude	   from	   the	  developing	   fetus.	   These	   are	   eventually	   filled	   with	   fetal	  vessels	  (Fv)	  and	  form	  the	  placental	  villous	  trees	  [156].	  	  	  Initially,	   the	   fetus	   is	   nourished	   from	   the	   uterine	   glands.	  Specialized	   endovascular	   cytotrophoblasts	   invade	   further	  into	  the	  decidua	  early	  on,	  and	  block	  the	  maternal	  vessels.	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Figure	  3:	  Anatomy	  of	  the	  human	  placenta.	  	  
During	   placentation	   extravillous	   trophoblasts	   (green)	   invade	   into	  
the	   maternal	   decidua.	   The	   outer	   cell	   layer	   fuses	   to	   form	   the	  
syncytiotrophoblast	   layer	   (blue)	   and	   forms	   trabeculae,	   which	  
anchor	   to	   the	   maternal	   tissue.	   In	   time	   these	   are	   filled	   with	   fetal	  
vessels	   (Fv)	   and	   make	   up	   the	   structural	   unit	   of	   the	   placenta,	   the	  
villous	   tree.	   After	   approximately	   10-­‐12	   weeks	   of	   gestation	   the	  
extravillous	   trophoblasts	   transform	   the	   maternal	   spiral	   arteries	  
(SA)	   and	   open	   up	   the	   blood	   flow	   into	   the	   intervillous	   space	   (IVS).	  
From	  here	  on	  the	  exchange	  of	  nutrients	  and	  waste	  products	  occurs	  
across	   the	   syncytiotrophoblast	   layer.	   In	   case	   of	   syncytial	   damage,	  
fibrinoids	   form	   at	   the	   barrier	   between	   fetal	   and	   maternal	   tissue	  
(marked	  as	  XXX).	   Fibrinoids	   are	   also	   found	  at	   other	   locations,	   e.g.	  
surrounding	   invading	   trophoblasts,	   at	   the	   anchoring	   sites	   of	   the	  
villi	  and	  covering	  the	  chorionic	  plate.	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Only	   after	   10-­‐12	   weeks	   of	   gestation	   is	   the	   maternal	   blood	  flow	  released	   into	  the	   intervillous	  space	  of	   the	  placenta	   [69].	  As	   pregnancy	   continues,	   the	   villous	   trees	   evolve	  continuously.	   The	   syncytiotrophoblast	   layer	   is	   replenished	  from	   the	   proliferating	   cytotrophoblasts,	   while	   the	   aging	  nuclei	  of	  the	  syncytium	  are	  shed	  from	  the	  villous	  surface	  and	  into	   the	   maternal	   circulation.	   During	   pregnancy	   high	  amounts	   of	   fragmented	   syncytiotrophoblasts	   and	  cytotrophoblasts	   are	   found	   in	   the	   maternal	   circulation	   [88].	  Often	   this	   shedding	   along	   with	   other	   injuries	   of	   the	  syncytium	   leaves	   the	   fetal	   tissue	   exposed.	   These	   areas	  become	  covered	  in	  a	  fibrin-­‐rich	  matrix	  called	  fibrinoid	  which	  is,	   amongst	   other	   things,	   used	   as	   a	   scaffold	   for	   re-­‐epithelialization	  of	  the	  syncytium-­‐void	  areas	  [136].	  	  
Immunology of the placenta  Because	   of	   the	   fetal	   expression	   of	   paternal	   antigens,	   the	  direct	   contact	   between	   fetal	   and	   maternal	   tissue	   poses	   a	  great	   immunological	   challenge.	   Thus,	   the	  maternal	   decidua	  is	  populated	  with	  a	  great	  number	  of	   immunological	  cells	  all	  displaying	   an	   immunosuppressive	   phenotype	   	   [26].	  Furthermore,	   the	   fetal	   tissue	   is	   enclosed	   in	   a	   coat	   of	  multinucleated	   trophoblast	   cells,	   the	   syncytiotrophoblast,	  which	   functions	  as	  a	  physical	  barrier,	  blocking	  migration	  of	  maternal	   leukocytes	   into	   the	   fetal	   tissue.	  Together	  with	   the	  invading	  extravillous	  cytotrophoblast	  cells	  these	  are	  the	  only	  fetal	   tissues	   in	   direct	   contact	   with	   the	   maternal	   immune	  system.	  Unlike	  most	  other	  eukaryotic	  cells	  the	  trophoblast	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cells	   are	   negative	   for	   the	  major	   histocompatibility	   complex	  (MHC)	   class	   I	   (HLA-­‐A,	   HLA-­‐B)	   and	   class	   II	   (HLA-­‐DP,	   -­‐DQ,	   -­‐DR)	  antigens,	  which,	  when	  carrying	  foreign	  peptides,	  are	  the	  targets	  for	  cytotoxic	  and	  T	  helper	  lymphocytes	  [68].	   	  Instead,	  the	  trophoblast	  cells	  express	  HLA-­‐G	  and	  HLA-­‐E	  antigens	  that	  suppress	   activities	   of	   e.g.	   natural	   killer	   (NK)	   cells.	   In	  addition,	   the	   trophoblast	   cells	   actively	   secrete	   various	  immunosuppressive	   molecules	   such	   as	   progesterone,	  prostaglandins	   and	   cytokines	   Il-­‐4	   and	   IL-­‐10	   [68].	   A	  disadvantage	  of	  the	  decreased	  immunological	  activity	  at	  the	  fetomaternal	   interface	   is	   an	   increased	   susceptibility	   to	  uterine	  and	  other	  maternal	  infections.	  This	  may	  progress	  to	  intra-­‐amniotic	   infection	  often	   leading	   to	  preterm	  birth,	   and	  possibly	  other	  pregnancy	  complications	  [52].	  	  	  	  	  
Complement in the placenta The	   placental	   syncytiotrophoblast,	   and	   in	   cases	   where	   the	  syncytiotrophoblast	  is	  damaged,	  the	  intravillous	  tissue	  is	  in	  a	  direct	   contact	   with	   maternal	   blood.	   Thus,	   the	   potential	  activation	   of	   the	   C	   system	   against	   the	   “foreign”	   fetal	   tissue	  poses	   a	   great	   threat	   to	   the	   fetus	   [108].	   The	  syncytiotrophoblast	   layer	   of	   the	   placenta	   has	   a	   high	  turnover.	   As	   described	   above,	   C	   activation	   is	   involved	   in	  clearance	   of	   apoptotic	   cells.	   Therefore,	   it	   is	   not	   surprising	  that	  C	  activation	  is	  observed	  in	  a	  normal	  healthy	  pregnancy	  [161,	   205].	   This	   makes	   C	   regulation	   essential	   in	   the	   placenta	  [191].	   Indeed,	   dysregulated	   C	   activation	   could	   contribute	   to	  placental	   damage	   in	   many	   pregnancy	   complications,	  including	   pre-­‐eclampsia	   (PE).	   Early	   C	   activation	  was	   found	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to	  be	  a	  predictor	  of	  PE	  [107].	  Of	  specific	  interest	  to	  our	  study,	  increased	   deposition	   of	   the	   C5b-­‐9	   terminal	   complex	   on	  trophoblasts	   has	   been	   found	   associated	   with	   fibrinoid	  deposits	   at	   sites	   of	   villous	   injury,	   especially	   in	   complicated	  pregnancies	  such	  as	  PE	  and	  intra-­‐uterine	  growth	  restriction	  (IUGR)	  [157].	  	  	  
SALSA protein 
Discovery The	  protein	   salivary	   scavenger	  and	  agglutinin	   (SALSA)	  was	  first	  described	  as	  a	  300-­‐400	  kDa	  streptococcal	  agglutinating	  agent	   from	   saliva,	   and	  named	   salivary	   agglutinin	   (SAG)	   [45].	  Later,	   others	   isolated	   a	   similar	   340	   kDa	   glycoprotein	   from	  bronchoalveolar	   lavage	   fluid	   after	   co-­‐purification	   with	  surfactant	   protein	   D	   (SpD).	   This	   glycoprotein	   was	   named	  gp340	   [65].	   At	   the	   same	   time,	   another	   study	   found	   the	   gene	  for	   SALSA	   deleted	   in	   several	   brain	   tumors,	   suggesting	   a	  tumor-­‐suppressor	   function	   for	   the	   protein,	   and	   named	   it	  ‘deleted	   in	   malignant	   brain	   tumors	   1’	   (DMBT1).	   The	   gene	  was	   accordingly	   named	   DMBT1	   [119].	   Only	   later	   was	   it	  realized	  that	  SAG	  and	  gp340	  are	  variant	  proteins	  encoded	  by	  the	   same	   gene,	   DMBT1,	   in	   different	   tissues	   [66,	   102,	   152].	  Because	  of	  the	  discrepancies	  of	  names	  mentioned	  above	  we	  suggested	   the	   name	   SALSA	   (Salivary	   scavenger	   and	  agglutinin)	   for	   this	   protein	   based	   on	   its	   initial	   discovery	   in	  saliva	  and	  its	  function	  as	  a	  scavenger	  and	  agglutinin.	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DMBT1 gene The	   DMBT1	   gene	   spans	   more	   than	   80	   kb	   of	   the	   human	  genome	   and	   contains	   at	   least	   54	   expressed	   exons	   [120].	   The	  gene	   encodes	   13	   highly	   conserved	   scavenger	   receptor	  cysteine-­‐rich	  (SRCR)	  domains.	  These	  109	  amino	  acid	  motifs	  are	   found	   as	   pearls	   on	   a	   string	   separated	   by	   SRCR	  interspersed	   domains	   (SIDs)	   (Figure	   4).	   The	   stretch	   of	   13	  SRCR	  domains	  is	  followed	  by	  two	  C1r/C1s,	  urchin	  embryonic	  growth	   factor	   and	   bone	   morphogenetic	   protein-­‐1	   (CUB)	  domains	   encompassing	   a	   14th	   SRCR	   domain.	   Finally	   a	   zona	  pellucida	   (ZP)	   domain	   is	   found	   in	   the	  most	   C-­‐terminal	   end	  [66,	   120].	   However,	   the	   actual	   expressed	   DMBT1	  mRNA	   and	  protein	   products	   have	   been	   found	   to	   display	   a	   great	  variation	   from	  the	   full	  gene.	  The	  DBMT1	   gene	   is	  built	  up	  of	  specific	  locus	  repeats	  of	  3-­‐4	  kb	  with	  up	  to	  99.8	  %	  homology.	  These	   repeats	   each	   encode	   a	   SRCR	   domain	   and	   a	   SID	  domain.	   The	   highly	   repetitive	   sequence	   is	   believed	   to	  facilitate	  alternative	  splicing	  leading	  to	  expression	  of	  several	  SALSA	   protein	   isoforms	   [125].	   This	   is	   indeed	   observed	   in	  several	  cases	  with	  mRNA	  transcripts	  encoding	  between	  8-­‐13	  	  of	  the	  N-­‐terminal	  SRCR	  domains	  [66,	  120,	  124].	  Variations	  in	  the	  amounts	  of	  expressed	  repeats	  have	  been	  found	  in	  up	  to	  28	  %	  of	  normal	   individuals	   [121].	  All	   in	   all	   the	   genetic	   analyses	   so	  far	  reveal	  at	  least	  seven	  distinct	  alleles.	  These	  are	  present	  in	  a	   highly	   unstable	   genetic	   region,	   where	   the	   loss	   of	  heterogeneity	   contributes	   to	  making	   these	   variations	  more	  readily	  expressed	  [125,	  213].	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Figure	  4:	  SALSA	  structure.	  
Shown	   is	   the	   domain	   structure	   of	   SRCR	   superfamily	   (SRCR-­‐SF)	  
proteins,	   including	  SALSA	  and	  SALSA	  orthologs.	   Some	  proteins	  are	  
found	   in	   secretions	  while	   others	   contain	   a	   transmembrane	   region	  
and	  are	  anchored	  into	  the	  cell	  membrane.	  	  
Glycosylation of the SALSA protein It	  has	  been	  estimated	  that	  up	  to	  25-­‐45	  %	  (w/w)	  of	  SALSA	  is	  carbohydrate	   [45,	   66].	   SALSA	   contains	   all	   the	   major	   sugar	  components	   including	   glucose,	   galactose,	   fucose,	   mannose,	  N-­‐acetylglucosamine,	   N-­‐acetylgalactosamine,	   sialic	   acid	   and	  many	   of	   their	   derivatives	   [46,	   61,	   141].	   Sequence	   analysis	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revealed	  14	  putative	  N-­‐glycosylation	   sites	   and	  a	  number	  of	  O-­‐glycosylation	   sites	   situated	   primarily	   in	   the	   SIDs	   [66,	   180].	  Based	   on	   this	   it	   has	   been	   suggested	   that	   the	   heavy	  glycosylation	   may	   force	   the	   SIDs	   into	   an	   extended	  conformation	  as	  observed	   for	  mucins	   [166].	  Thus	  alternating	  stretches	   of	   SIDs	   and	   globular	   SRCR	   domains	   would	  constitute	   the	  structural	   layout	  of	  SALSA.	   In	  addition	  to	   the	  above-­‐described	  variations	  in	  SALSA	  mRNA	  transcripts	  from	  the	  DMBT1	  gene,	   further	  protein	  variation	   is	   seen	  with	   the	  glycosylation	   patterns.	   Differences	   in	   saliva-­‐derived	   SALSA	  were	  found	  to	  correlate	  to	  secretor	  (Se(+))	  and	  non-­‐secretor	  (Se(-­‐))	   status	   (±	  expression	  of	   the	  α1-­‐2fucosyl-­‐transferase).	  The	  blood	  group	  antigens,	  ABO,	  and	  Lewis	  antigens	  b	  and	  y	  (Leb	  and	  Ley)	  were	   found	  on	  SALSA	   from	  Se(+)	   individuals.	  In	   contrast,	   SALSA	   from	   Se(-­‐)	   individuals	   did	   not	   contain	  ABO,	   Leb	   nor	   Ley	   antigens.	   Instead	   Lewis	   antigens	   a	   and	   x	  (Lea	   and	   Lex)	   were	   present	   [46,	   98].	   In	   addition,	   the	   SALSA	  glycosylation	  patterns	  varied	   further	   in	  different	   secretions	  [46,	   180].	   Finally,	   variations	   correlating	   to	   hormonal	   changes	  during	   the	   menstrual	   cycle	   were	   found	   in	   the	   MECA-­‐79	  carbohydrate	   epitope,	   which	   is	   also	   found	   on	   SALSA	   [153].	  Taken	  together,	  SALSA	   is	  a	  highly	  glycosylated	  protein.	  The	  specific	  glycosylation	  patterns	  vary	  between	  individuals	  and	  even	   with	   hormonal	   variations.	   Furthermore,	   SALSA	  expressed	   in	   different	   tissues	   also	   displays	   varying	  glycosylation.	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SALSA across species The	   SALSA	   protein	   consists	   of	   SRCR,	   CUB	   and	   ZP	   domains.	  All	   of	   these	   are	   evolutionarily	   highly	   conserved	   units	   and	  present	  in	  a	  multitude	  of	  proteins	  with	  varying	  functions	  [18,	  19,	   79,	   80,	   176].	   SALSA	   orthologs	   have	   been	   described	   in	   the	  mouse	   (CRP-­‐ductin,	   vomeroglandin,	   muclin,	   apactin),	   rat	  (ebnerin),	  rabbit	  (hensin),	  cow	  (bovine	  gall	  bladder	  mucin),	  pig	  (porcine	  dmbt1)	  and	  rhesus	  monkey	  (H3)	  [1,	  30,	  35,	  56,	  97,	  115,	  138,	   187,	   189].	   The	   described	   proteins	   show	   variation	   in	   the	  number	  of	  SRCR	  and	  CUB	  domains,	  but	  all	  contain	  only	  one	  C-­‐terminal	  ZP	  domain	  (Figure	  4)	  [100,	  101].	  	  	  SALSA	   orthologs	   have	   been	   found	   expressed	   at	   various	  epithelial	   surfaces	   such	   as	   in	   the	   mouse	   pancreas	   and	  intestine,	  as	  well	  as	  in	  monkey	  and	  rat	  uterine	  epithelium	  [1,	  30,	  35,	  110,	  198].	  The	  SALSA	  orthologs	  were	  involved	  in	  bacterial	  binding,	   actin	   skeleton	   remodelling	   and	   pheromone	   and	  taste	  perception	  [97,	  110,	  115,	  189].	  The	  rabbit	  ortholog	  for	  SALSA,	  hensin,	  was	  shown	  to	  directly	  influence	  the	  differentiation	  of	  stem	  cells	  and	  epithelial	  cells	  [188].	  The	  specific	  mechanism	  of	  hensin	   function	   involves	   hensin	   polymerization	   through	  interactions	   with	   galectin-­‐3	   and	   integrins	   followed	   by	  incorporation	  into	  the	  extracellular	  matrix	  (ECM)	  [63,	  64,	  200].	  	  	  
SALSA expression in humans The	  animal	  data	  above	  indicate	  that	  SALSA	  is	  expressed	  in	  a	  variety	  of	  tissues	  throughout	  the	  body.	  The	  same	  holds	  true	  for	  SALSA	  expression	  in	  humans.	  RT-­‐PCR	  analyses	  originally	  showed	   that	   the	   main	   tissues	   of	   expression	   are	   the	   lung,	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trachea,	  salivary	  glands,	  small	   intestine	  and	  stomach	  [66,	  119].	  These	  are	  all	   tissues	  with	  a	  mucosal	   surface.	  At	   the	  protein	  level	   further	   analysis	   by	   immunohistochemistry	   identified	  SALSA	  in	  secretory	  glands	  and	  associated	  with	  the	  epithelial	  layer	  in	  the	  lungs,	  oral	  cavity,	  trachea,	  gastrointestinal	  tract,	  pancreas,	  mammary	  glands,	  vagina	  and	  cervix	  [21,	  66,	  83,	  121,	  122,	  185,	   195].	   In	   addition	   to	   the	   mucosal	   surfaces	   and	   secretory	  tissues,	   SALSA	   has	   been	   found	   in	   the	   heart,	   liver,	   skin	   and	  tonsils	   [122,	   129].	   Several	   soluble	   forms	   of	   SALSA	   have	   been	  found	   in	   body	   fluids	   lining	   the	   mucosal	   surfaces	   such	   as	  saliva,	   tear	   fluid,	   respiratory	   mucosal	   secretions	   and	  pancreatic	  juice	  [45,	  54,	  65,	  180,	  195].	  Notably,	  SALSA	  has	  not	  been	  observed	  in	  human	  blood	  or	  plasma.	  For	  an	  overview	  of	  the	  current	  knowledge	  of	  SALSA	  expression,	  see	  Table	  1.	  	  	  To	   date,	   limited	   quantitative	   data	   on	   the	   levels	   of	   secreted	  SALSA	   is	   available.	   One	   of	   the	   early	   studies	   estimated	   that	  SALSA	  makes	  up	  less	  than	  0.5	  %	  of	  the	  total	  protein	  content	  of	  saliva.	  As	  the	  salivary	  protein	  amount	  has	  been	  estimated	  to	  be	  1.4	  ±	  0.2	  mg/ml,	  this	  would	  mean	  approximately	  7	  μg	  /ml	   for	  SALSA	  concentration	   [45,	  183].	  This	  was	  supported	  by	  later	   studies	   suggesting	  a	   concentration	  of	  1-­‐10	  μg/ml	   [185].	  Analysis	   of	   SALSA	   in	   tear	   fluid	   describes	   it	   to	   be	   more	  abundant	  than	  mucins,	  but	  without	  more	  specific	  data	  [180].	  	  	   	  SALSA	   is	   highly	   expressed	   in	   proliferating	   and	   developing	  epithelia	   [85,	   121,	   123].	   In	   addition,	   an	   induced	   expression	   of	  SALSA	  in	  infected	  and	  inflamed	  tissues	  has	  been	  observed.	  In	  the	   gut	   increased	   expression	   was	   found	   to	   associate	   with	  inflammatory	   bowel	   disease	   and	   especially	   Crohn’s	   disease	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[58,	   160].	   Immunohistochemistry	   showed	   only	   sporadic	  staining	  of	   SALSA	   in	   the	   connective	   tissue,	   endothelial	   cells	  and	  myocytes	   in	  healthy	  myocardium.	  However,	   in	  cases	  of	  endocarditis,	  SALSA	  expression	  was	  greatly	  increased	  in	  the	  local	   areas	   of	   bacterial	   colonization.	   Specifically,	  granulocyte-­‐depleted	   fibrin	   formations	   were	   positive	   [129].	  Finally,	   SALSA	   was	   found	   weakly	   expressed	   by	   biliary	  epithelial	   cells	   in	   the	   liver,	   but	   increased	   expression	   was	  observed	   under	   certain	   pathological	   conditions	   such	   as	  hepatolithiasis	  [177].	  	  	  SALSA	   was	   early	   on	   described	   as	   a	   tumor	   suppressor	   in	  malignant	   brain	   tumors	   [119].	   Since	   then	   altered	   expression	  has	   been	   found	   in	   a	   number	   of	   tumors.	   Genetic	   variations	  were	  found	  in	  up	  to	  89	  %	  of	  tested	  lung	  and	  brain	  cancer	  cell	  lines	   [121].	  Healthy	  tumor-­‐flanking	  tissue	  had	  elevated	   levels	  of	   SALSA	   compared	   to	   healthy	   tissue.	   However,	   down-­‐regulation	   of	   SALSA	   was	   observed	   in	   lung	   and	   mammary	  gland	   tumors	   compared	   to	   the	   tumor-­‐flanking	   tissue	   [21,	  123,	  124,	  126].	  Similarly,	   salivary	  gland	   tumors	  were	   found	   to	  have	  decreased	   SALSA	   expression	   compared	   to	   both	   normal	  tumor-­‐flanking	   tissue	   and	   healthy	   tissue	   [12,	   14].	   In	   the	  esophagus,	   squamous	   cell	   carcinomas	   had	   reduced	   SALSA	  expression,	  whereas	  adenocarcinomas	  appeared	   to	  have	  an	  increased	  expression	  of	  SALSA	  [122].	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Table	  1:	  SALSA	  expression	  in	  human	  tissues	  and	  secretions	  
 
Tissue	   	  	  	  	  	  	  	  Location	  	  	  	  	  	  	  	  	   Evidence	  
	  
Adult	  Bone	  marrow	   Not	  known	   RT-­‐PCR	  [121]	  Brain	   Purkinje	  cells,	  granular	  layer,	  some	  astrocytes	  and	  neuronal	  cells,	  perivascular	  macrophages	  	  
RT-­‐PCR,	  IHC	  [66,	  119,	  121]	  
Colon	   Epithelium	   IHC	  [122]	  Duodenum	   Enterocytes,	  crypt	  cells,	  Brunner’s	  glands	   IHC	  [122]	  Esophagus	   Epithelium,	  mucus	  glands	   IHC	  [122,	  123]	  Eye	   Acinar	  cells	  of	  lacrimal	  glands,	  conjunctival	  epithelium	  
RT-­‐PCR,	  IHC	  [81]	  
Female	  genital	  tract	   Epithelium	   IHC	  [185]	  Gallbladder	   Epithelium	   IHC	  [123]	  Heart	  tissue	   Endothelium,	  myocytes	   RT-­‐PCR	  [129]	  Kidney	   Collecting	  duct	  epithelium	   RT-­‐PCR	  [66]	  Liver	   Hepatocytes	   IHC	  [122]	  Lung	   Epithelium,	  macrophages	  	   RT-­‐PCR,	  IHC	  [66,	  119]	  Lymph	  node	   Not	  known	   RT-­‐PCR	  [121]	  Mammary	  gland	   Epithelium	   RT-­‐PCR,	  IHC	  [21,	  66]	  Pancreas	   Langerhans	  islets,	  exocrine	  acinar	  cells,	  pancreatic	  ducts	   RT-­‐PCR,	  IHC	  [66,	  122,	  122]	  Prostate	   Not	  known	   RT-­‐PCR	  [66]	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Salivary	  glands	   Epithelium	  	   RT-­‐PCR,	  IHC	  [66,	  122]	  Sinus	   Serous	  glands	   RT-­‐PCR,	  IHC	  [89]	  Skin	   Epithelium	   IHC	  [123]	  Small	  intestine	   Epithelium	   RT-­‐PCR,	  NB,	  IHC	  [66,	  119]	  Spleen	   Not	  known	   RT.PCR	  [121]	  Stomach	   Epithelium,	  gastric	  glands	   RT-­‐PCR,	  IHC	  [66,	  122,	  123]	  Testis	   Not	  known	   RT-­‐PCR	  [66]	  Thymus	   Not	  known	   RT-­‐PCR	  [121]	  Tonsils	   Epithelium	   IHC	  [123]	  Trachea	   Serous	  cells	   RT-­‐PCR,	  IHC	  [66,	  195]	  Uterus	   Not	  known	   RT-­‐PCR	  [66]	  
	  
Fetus	  Intestine	   Epithelium	   IHC	  [121]	  Kidney	   Collecting	  duct	  epithelium	   IHC	  [121]	  Lung	   Not	  known	   NB	  [119]	  Skin	   Epithelium,	  epidermis	   IHC	  [121,	  123]	  
	  
Secretions	  Bronchoalveolar	  lavage	   	   WB	  [65]	  Pancreatic	  juice	   	   MS	  [54]	  Respiratory	  mucosal	  secretions	   	   WB	  [195]	  Saliva	   	   MS	  [102]	  Sinus	  mucosa	   	   WB	  [89]	  Tear	  fluid	   	   MS	  [180]	  
	  	  
IHC,	   Immunohistochemistry;	   NB,	   Northern	   blotting;	   WB,	   Western	  
blotting;	  RT-­‐PCR,	  Reverse	  transcriptase	  polymerase	  chain	  reaction;	  
MS,	  Mass	  spectrometry.	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Based	  on	   the	   location	  and	  differential	  expression	  described	  above,	   it	   has	   been	   suggested	   that	   SALSA	   functions	   in	  epithelial	   homeostasis,	   immunological	   surveillance	   and	  tumor	  suppression	  [84,	  100,	  111].	  	  	  
Functions of SALSA 
SALSA and epithelial differentiation 
SALSA	  expression	  in	  non-­‐differentiated	  cells	  By	  comparing	  SALSA	   levels	  between	  adult	  and	  fetal	   tissues,	  e.g.	  skin	  and	  the	  intestine,	  both	  an	  induced	  expression	  and	  a	  different	   subcellular	   localization	   were	   found	   in	   the	   fetal	  tissues	  [121,	  123].	  Together	  with	  its	  location	  in	  the	  proliferating	  intestinal	  and	  gastric	  mucosa,	  this	  finding	  suggests	  a	  role	  for	  SALSA	  in	  the	  development	  of	  epithelial	  tissues	  [85,	  121].	  SALSA	  was	  primarily	  found	  in	  stem/progenitor	  cells	  rather	  than	  in	  terminally	   differentiated	   cells	   [30,	   83,	   121].	   Analysis	   of	   the	  gastric	   adenocarcinoma	   cell	   line	  AGS	   revealed	   that	  phorbol	  12-­‐myristate	   13-­‐acetate	   (PMA)	   stimulation	   led	   to	   down-­‐regulation	   of	   SALSA	   expression.	   It	   was	   shown	   that	   SALSA	  expression	   correlated	  with	   the	   change	   from	   a	   proliferating	  phenotype	   towards	   a	   cell-­‐differentiating	   phenotype.	  Subsequently,	   SALSA	   expression	  was	   down-­‐regulated	   again	  prior	   to	   terminal	   differentiation	   [83,	   85].	   The	   involvement	   in	  the	   regulation	   of	   the	   epithelial	   cell-­‐cycle	   is	   further	  substantiated	  by	  observations	  of	  altered	  regulation	  of	  SALSA	  in	  a	  number	  of	  epithelial	  cancers	  [21,	  123].	  	  	  	  	  	  	  
Literature	  review	  
	   	  57	  
SALSA	  and	  cell	  polarization	  In	   Japanese,	   hensin,	   the	   name	   of	   the	   SALSA	   ortholog	   in	  rabbit,	   means	   “change	   in	   shape”.	   Extensive	   work	   has	   been	  performed	   to	   elucidate	   the	   mechanisms	   involved	   in	   rabbit	  kidney	   epithelial	   cell	   differentiation,	   and	   hensin	  was	   found	  to	  play	  a	  key	  role	  [3].	  It	  was	  shown	  that	  hensin	  is	  secreted	  as	  a	  monomer.	   It	   then	  polymerizes	  and	  deposits	   into	   the	  ECM	  [63].	   	  The	  polymerization	  occurs	  through	  interactions	  with	  at	  least	   three	   other	   proteins:	   integrins,	   cyclophilin	   A	   and	  galectin-­‐3	  [64,	  146,	  201].	  The	  suggested	  mode	  of	  action	  was	  that	  hensin	   through	   its	   SRCR	  domains	  binds	   to	   integrins	   on	   the	  cell	   surface.	  Galectin-­‐3	   and	   cyclophorin	  A	   then	  mediate	   the	  polymerization	  and	  deposition	  into	  the	  ECM	  of	  hensin,	  which	  finally	  allows	   for	   the	  signalling	   to	   the	  cell.	  This	  provides	  an	  insight	   into	   how	   SALSA	   in	   humans	   may	   function	   in	   the	  epithelial	  differentiation.	  	  
Functions of SALSA in the innate immune system 
Interactions	  with	  endogenous	  molecules	  It	  has	  been	  observed	   that	  native	  SALSA	   found	   in	  saliva	  and	  pulmonary	  secretions	  polymerizes	  into	  large	  complexes	  [111,	  141,	   216].	   SALSA	   has	   been	   found	   to	   interact	   with	   numerous	  endogenous	   proteins	   such	   as	   surfactant	   proteins	   A	   (SpA)	  and	   D,	   secretory	   IgA,	   lactoferrin,	   fibrin/fibrinogen,	   trefoil	  factor	   2,	  mucin-­‐5B	   and	   C1q	   [17,	  65,	  129,	  142,	  172,	  194-­‐196].	   A	   list	   of	  SALSA	  ligands	  is	  shown	  in	  Table	  2.	  The	  native	  form	  of	  SALSA	  in	  saliva	   is	   found	  in	  a	  complex	  with	  IgA	   [45].	  The	   interaction	  between	   IgA	   and	   SALSA	   was	   calcium-­‐dependent	   and	   was	  shown	  to	  mediate	  the	  agglutination	  of	  Streptococcus	  mutans	  [99,	  141,	  172].	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relevance	  SpD	   SpD	  globular	  domain	   Microbial	  agglutination	  [65]	  SpA	   SpA	  globular	  domain	   Microbial	  	  agglutination	  [196]	  IgA	   SRCRP2	  of	  SALSA	   Microbial	  agglutination	  [45]	  C1q	   Globular	  domain	  of	  C1q	   C	  activation	  [17]	  Lactoferrin	   SRCRP2	  of	  SALSA	   Mucosal	  surfaces,	  bacterial	  binding	  [118]	  DNA	   Phosphate	  groups	  of	  DNA	   Inflammation	  [44]	  Heparan	  sulfate	   Sulfated	  groups	  of	  heparan	  sulfate	   Inflammation	  [44]	  Trefoil	  factors	   Not	  known	   Tissue	  homeostasis	  [194]	  MUC5B	   Not	  known	   Microbial	  agglutination	  [210]	  Fibrin	   Not	  known	   Not	  known	  [129]	  Fibrinogen	   Not	  known	   Not	  known	  [129]	  Erythrocytes	   Not	  known	   Aggregation	  [129]	  Platelets	   Not	  known	   Aggregation	  [129]	  
	  
SRCRP2,	   the	   bacterial	   binding	   peptide	   sequence	   of	   the	   SRCR	  
domains,	  see	  below.	  	  The	  IgA	  binding	  site	  on	  SALSA	  was	  identified	  as	  the	  bacterial	  binding	   SRCR	   peptide	   2	   (SRCRP2)	   although	   IgA	   and	   S.	  
mutans	  did	   not	   appear	   to	   be	   competing	   for	   SALSA	   binding	  [99].	  The	   complex	   formation	  between	  SALSA	  and	   IgA	  has	  an	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enhancing	   effect	   on	   bacterial	   agglutination,	   but	   the	   main	  binding	  ability	  was	  ascribed	  to	  SALSA	  [172].	  	  	  The	   C1q	   molecule	   consists	   of	   18	   polypeptide	   chains	   held	  together	   by	   disulfide	   bridges	   to	   form	   a	   bouquet-­‐like	  structure.	  Each	  chain	  contains	  a	  collagen	  domain	  (stalk)	  and	  a	   carboxy-­‐terminal	   globular	   domain	   (the	   flowers)	   [159,	   181].	  The	  globular	  domain	  is	  used	  for	  target	  recognition	  while	  the	  collagen	   domains	   bind	   the	   enzymes	   C1r	   and	   C1s.	  Conformational	   changes	   occurring	   by	   ligand	   binding	   of	   the	  globular	   regions	   lead	   to	   activation	   of	   C1r/s	   followed	   by	  activation	   of	   the	   classical	   pathway	   of	   C	   [49,	   202].	   C1q	   binds	  specifically	   the	   immunoglobulin	   classes	  M	   and	   G,	   however,	  other	   endogenous	   non-­‐immunoglobulin	   ligands	   have	   been	  found,	   e.g.	   SALSA	   [17].	   C1q	   is	   a	   key	   PRM	   known	   to	   interact	  with	   microbial	   ligands	   directly,	   such	   as	   LPS	   of	   Salmonella	  Typhimurium,	   but	   also	   through	   interaction	   with	  immunoglobulins	  bound	  on	  the	  pathogen	  surface	  [162,	  171].	   In	  addition,	   an	   important	   function	   of	   C1q	   is	   clearance	   of	  apoptotic	   cells	   [190].	   Detailed	   studies	   have	   shown	   that	   C1q	  binds	  SALSA	   through	   the	  globular	  domain	   in	  a	   region	  close	  to	   the	   immunoglobulin	   binding	   site.	   	   [91].	   It	   was	   suggested	  that	   the	   interaction	  between	  C1q	  and	  SALSA	   could	   activate	  the	  C	  system	  [17].	  	  	  SALSA	   also	   interacts	   directly	   with	   the	   two	   collagen-­‐containing	   lectins	  SpA	  and	  SpD	   [65,	  196].	  The	   interactions	  are	  mediated	  through	  the	  carbohydrate	  binding	  globular	  domain	  of	   SpD	   and	   SpA	   and	   as	   for	   IgA,	   these	   interactions	   are	  calcium-­‐dependent	   [65,	   196].	   As	   described	   below,	   SALSA	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agglutinates	   bacteria.	   SpD	   and	   SpA	   are	   also	   molecules	  expressed	   at	   the	   mucosal	   surfaces	   with	   known	   bacterial	  agglutinating	  functions	  [57].	  It	  has	  been	  shown	  that	  the	  three	  proteins	  have	  a	  co-­‐operative	  effect	  against	  influenza	  A	  virus	  (IAV)	   [208].	   This	   was	   shown	   by	   viral	   agglutination,	  hemagglutinin	  inhibition	  and	  viral	  neutralization	  assays	  [208].	  	  	  Lactoferrin	   is	   an	   iron-­‐chelating	   protein	   sharing	   many	  properties	  with	  SALSA.	  Lactoferrin	  is	  expressed	  on	  mucosal	  surfaces,	   and	   has	   been	   suggested	   to	   be	   involved	   in	   cellular	  growth	  and	  differentiation,	   in	  defense	  against	  bacterial	  and	  viral	   infection,	   and	   in	   dampening	   inflammation	   [204].	   SALSA	  has	  been	  shown	  to	  interact	  directly	  with	  both	  the	  human	  and	  bovine	   form	   of	   the	   protein	   [43,	  118].	   Lactoferrin	  mediates	   its	  immune	   functions	   directly	   by	   chelating	   iron	   from	   the	   local	  mucosal	  environment,	  thus	  depriving	  the	  microorganisms	  of	  this	   essential	   factor.	   Furthermore,	   it	   has	   been	   shown	   that	  proteolytic	  degradation	  of	  lactoferrin	  leads	  to	  the	  release	  of	  antimicrobial	  peptides	  	  [53,	  182].	  	  	  Another	  important	  defense	  molecule	  at	  the	  mucosal	  surfaces	  is	   the	   mucin	   MUC5B.	   This	   protein	   forms	   large	   protein	  aggregates	   in	   the	  mucosal	   secretions	   and	   inhibits	   bacterial	  colonization.	  SALSA	  has	  been	  shown	  to	  bind	  MUC5B	  in	  both	  respiratory	   secretions	  and	   saliva	   [195,	  210].	   It	   is	   currently	  not	  known	  what	  the	  in	  vivo	  outcome	  is	  of	  the	  interplay	  between	  these	  two	  molecules	  at	  the	  mucosal	  surfaces.	  	  SALSA	  has	  so	  far	  not	  been	  described	  free	  in	  serum.	  However,	  in	   addition	   to	   the	   interaction	  with	   plasma	  C1q,	   it	   has	   been	  described	   that	   SALSA	   binds	   to	   both	   fibrin	   and	   fibrinogen.	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Furthermore,	   SALSA	   was	   found	   to	   bind	   to	   platelet	   and	  erythrocyte	   surfaces,	   and	   directly	   mediate	   erythrocyte	  aggregation	   [129].	   No	   further	   studies	   have	   been	   done	   on	  SALSA	  in	  cardiovascular	  diseases.	  However,	  the	  endogenous	  ligand	  SpD	  has	  been	  suggested	  to	  influence	  the	  development	  of	  atherosclerosis	  in	  mice	  [184].	  	  	  	  
SALSA	  in	  infection	  and	  inflammation	  The	  very	  first	  isolation	  of	  SALSA	  from	  saliva	  was	  done	  using	  
S.	  mutans	  [45].	  Since	  then	  a	  great	  number	  of	  bacterial	  species	  has	  been	  added	  to	  the	  list	  of	  SALSA	  binding	  partners.	  Based	  on	   the	   broad	   bacterial	   binding	   properties	   of	   SALSA,	   it	   has	  been	   described	   as	   a	   PRM,	   however,	   no	   actual	   receptor	  functions	   have	   been	   described	   yet	   [44,	   100,	   104].	   SALSA	   binds	  both	   Gram-­‐positive	   and	   Gram-­‐negative	   bacteria,	   including	  
Bifidobacterium	   lactis,	   Staphylococcus	   aureus,	   H.	   pylori,	  
Actinomyces	   odontolyticus,	   Salmonella	   enterica	   serovar	  Typhimurium,	  several	  lactobacillus	  strains	  and	  as	  well	  a	  long	  list	   of	   streptococcal	   species	   (Table	   3)	   [62,	   81,	   103,	   152,	   168].	  Furthermore,	  the	  viruses	  IAV	  and	  human	  immunodeficiency	  virus	  type	  1	  (HIV-­‐1)	  have	  been	  shown	  to	  bind	  SALSA	  [60,	  133].	  In	  addition,	  orthologs	  of	  SALSA	  in	  other	  mammalian	  species	  have	  been	  shown	  to	  bind	  Haemophilus	  influenzae,	  Klebsiella	  
oxytoca	   and	   Streptococcus	   pneumoniae	   [110].	   The	   broad	  bacterial	   binding	   property	   of	   SALSA	   has	   been	   assigned	   to	  one	   particular	   peptide	   sequence	  within	   each	   SRCR	   domain	  (RVEVLYxxxSW),	   designated	   SRCR-­‐peptide	   2	   (SRCRP2)	   [13,	  94].	  The	  presence	  of	  several	  SRCR	  domains	  in	  SALSA	  possibly	  allows	  for	  a	  multivalent	  binding	  interaction	  with	  bacteria.	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Table	  3:	  Detected	  microbial	  ligands	  of	  human	  SALSA	  	  
Microbe	   Specific	  strains	  Streptococcal	  strains:	   S.	  pyogenes,	  S.	  agalactiae,	  S.	  pneumoniae,	  S.	  mutans,	  S.	  mitis,	  S.	  
oralis,	  S.	  salivarius,	  S.	  gordoni,	  S.	  crista,	  
S.	  parasanguis,	  S.	  vestibularis,	  S.	  
intermedius,	  S.	  anginosus,	  S.	  suis	  [103,	  110,	  152]	  Lactobacillar	  strains:	   L.	  rhamnosus,	  L.	  casei,	  L.reuteri,	  L.	  lactis	  [62]	  Other	  bacteria:	   Staphylococcus	  aureus,	  Bifidobacterium,	  Actinomyces,	  
Salmonella	  enterica	  serovar	  Typhimurium,	  Helicobacter	  pylori,	  
Haemophilus	  influenzae,	  Klebsiella	  
oxytoca	  	  [39,	  62,	  81,	  103,	  110,	  152,	  168]	  Viruses:	   HIV,	  IAV	  [60,	  133]	  
	  
The	   microbial	   ligands	   found	   to	   bind	   either	   human	   SALSA,	   the	  
murine	  ortholog	  of	  SALSA	  or	   the	  recombinantly	  expressed	  peptide	  
SRCRP2.	  	  	  The	   above	   mentioned	   binding	   studies	   suggest	   that	   SALSA	  simply	   functions	   by	   agglutinating	   microorganisms	   at	   the	  mucosal	   surfaces,	   thus	   keeping	   them	   from	   infecting	   the	  tissue,	  as	  has	  been	  observed	  for	  S.	  enterica,	  HIV-­‐I	  and	  IAV	  [60,	  133,	  168,	  214].	  However,	   the	   role	  of	  SALSA	   is	  more	  complicated	  than	   that.	   In	   the	   body	   SALSA	   is	   found	   both	   adhered	   to	   e.g.	  epithelial	   and	   tooth	   surfaces	   and	   secreted	   into	   the	   fluid	  phase	  [103].	  The	  epithelium-­‐attached	  localization	  of	  a	  protein	  with	   a	   solely	   bacterial	   agglutinating	   function	   would	   not	  appear	  to	  be	  beneficial	  for	  the	  human	  host.	  This	  paradox	  has	  been	   made	   clear	   by	   studies	   showing	   that	   SALSA	   in	   some	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cases	  may	  be	  utilized	  directly	  by	  invading	  microbes.	  A	  study	  of	   dental	   caries	   showed	   that	   certain	   SALSA-­‐phenotypes	  correlated	   positively	   with	   S.	   mutans	   adhesion	   to	   SALSA-­‐coated	   hydroxyapatite	   surfaces	   and	   the	   development	   of	  dental	   caries.	   Other	   SALSA	   phenotypes	   displayed	   the	  opposite	   correlation	   [78].	   	   In	   the	  case	  of	  HIV-­‐1	   infection,	   the	  salivary	  secreted	  SALSA	  protein	  was	  found	  to	  interfere	  with	  oral	  transmission.	  However,	  SALSA	  expressed	  on	  the	  vaginal	  epithelia	   had	   an	   enhancing	   effect	   on	   the	   infectivity	   of	   the	  virus	   [185].	   	  These	  findings	  suggest	  that	  some	  microbes	  have	  evolved	   mechanisms	   to	   utilize	   SALSA	   to	   infect	   the	   human	  body.	  	  	  Interestingly,	   the	   specific	  bacterial	  binding	  ability	  of	   SALSA	  has	  been	  found	  to	  depend	  not	  only	  on	  the	  phenotype	  of	  the	  protein	   but	   also	   on	   the	   location	   of	   the	  protein.	   Fluid-­‐phase	  SALSA	   can	   bind	   and	   aggregate	   some	   streptococcal	   strains,	  while	   SALSA	   coated	   to	   a	   hydroxyapatite	   surface	   does	   not.	  Other	  species	  were	  only	  bound	  by	  surface-­‐associated	  SALSA.	  This	  variation	  was	  observed	  for	  strains	  even	  within	  the	  same	  streptococcal	  species	  [103].	  	  	  	  	  In	  addition	  to	  the	  specific	  localization	  of	  SALSA,	  it	  seems	  that	  also	   the	   temporal	   expression	   may	   be	   crucial	   for	   the	  immunological	   function	   of	   the	   protein.	   Studies	   have	   shown	  that	   SALSA	   can	   be	   strongly	   induced	   by	   various	  immunological	   stimuli.	   In	   several	   chronic	   inflammatory	  conditions,	   the	   expression	   of	   SALSA	   was	   found	   to	   be	  upregulated	   [89,	   160].	   The	   increased	   levels	   of	   SALSA	   in	   the	  intestinal	   epithelium	   of	   patients	   with	   inflammatory	   bowel	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disease,	  including	  Crohn’s	  disease,	  and	  in	  the	  ethmoid	  sinus	  mucosa	  of	  patients	  with	  chronic	  sinusitis	  suggest	  that	  SALSA	  expression	  is	  part	  of	  the	  mucosal	  inflammatory	  response	  [58,	  89,	  160].	  In	  addition,	  a	  study	  of	  preterm	  infants	  revealed	  a	  clear	  increase	   in	   the	   pulmonary	   SALSA	   levels	   as	   a	   response	   to	  neonatal	  infection	  [128].	  	  	  Further	   studies	   have	   been	   done	   to	   investigate	   the	  involvement	   of	   SALSA	   in	   the	   mucosal	   epithelial	  inflammatory	   response.	   PMA	   and	   dextran	   sulfate	   sodium	  (DSS)	  are	   chemicals	  used	   to	   incite	  epithelial	   cell	  damage	   to	  mimic	  pathologic	  inflammatory	  conditions.	  PMA	  stimulation	  of	   the	   pulmonary	   epithelial	   cell	   line	   A549	   led	   to	   increased	  expression	   of	   SALSA.	   This	   coincided	   with	   induction	   of	   the	  inflammatory	   cytokines	   IL-­‐6	   and	   IL-­‐8	   [83].	   DSS	  was	   used	   to	  stimulate	   colitis	   in	   a	   mouse	   model.	   Here	   increased	   SALSA	  levels	   were	   found	   specifically	   in	   the	   damaged	   intestinal	  epithelium	   [160].	   Similar	   enhanced	   expression	  of	   SALSA	  was	  observed	   by	   epithelial	   cells	   after	   stimulation	   with	   the	  proinflammatory	  stimuli	  LPS,	  muramyl	  dipeptide	  and	  tumor	  necrosis	  factor	  α	  (TNF-­‐α)	  [168].	  It	  was	  further	  shown	  that	  the	  signalling	   cascade	   utilized	   nucleotide-­‐binding	  oligomerization	   domain	   2	   (NOD2)	   and	   TLR4	   activation	   of	  NFκB	  to	  alter	  DMBT1	  gene	  activity.	  Interestingly,	  a	  feedback	  loop	  seemed	  to	  exist,	  as	  secreted	  SALSA	  was	  able	   to	   inhibit	  the	   epithelial	   response	   to	   S.	   enterica-­‐derived	   LPS	   and	  muramyl	  dipeptide	  [168].	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Aims of the study 	  The	   overall	   aim	   of	   this	   thesis	   work	   was	   to	   investigate	   the	  function	  of	  the	  SALSA	  protein.	  Based	  on	  the	  expression	  of	  the	  protein	  we	  sought	  to	  understand	  how	  SALSA	  interacts	  with	  the	  innate	  immune	  defense	  system	  and	  exerts	  its	  role	  at	  the	  mucosal	  surfaces	  and	  in	  tissues.	  	  The	  specific	  aims	  were:	  1. To	   analyze	   the	   expression	   of	   SALSA	   in	   tissues	   and	  secretions	  related	  to	  early	  life	  (II,	  III)	  2. To	  identify	  novel	  ligands	  of	  SALSA	  (I,	  III)	  3. To	   investigate	   interactions	   between	   SALSA	   and	   the	  complement	  system	  (I,	  III)	  4. To	   understand	   the	   functional	   relevance	   of	   SALSA	   in	  the	  placenta	  and	  amniotic	  fluid	  (II,	  III)	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Materials and Methods 	  The	  methods	  used	  in	  this	  work	  are	  described	  in	  detail	  in	  the	  original	  publications	  I-­‐III.	  However,	   in	   the	   following	  section	  a	  general	  overview	  of	  the	  techniques	  will	  be	  given.	  The	  used	  techniques,	   biological	   materials,	   proteins,	   antibodies,	   and	  buffers	  are	  listed	  in	  Tables	  4-­‐7.	  	   Table	  4:	  Overview	  of	  techniques	  used	  in	  this	  thesis	  	  
Technique	  used	   Article	  	  SDS-­‐PAGE	  and	  Western	  blotting	   	  I,	  II	  ELISA	   I,	  II,	  III	  Flow	  cytometry	   I	  Complement	  activation	  assays	   I	  Glycoprotein	  and	  lectin	  staining	   II	  LC-­‐MS/MS	   II	  SALSA-­‐bacterial	  binding	  assay	   II	  Immunohistochemistry	   III	  Coagulation	  assays	   III	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Human samples 
Amniotic fluid Amniotic	  fluid	  (AF)	  samples	  were	  collected	  at	  the	  Obstetrics	  and	   Neonatology	   Units	   of	   Hospital	   Universitario	   Doce	   de	  Octubre,	  Madrid,	  Spain	  (n	  =	  9),	  and	  at	  the	  Women’s	  Clinic	  of	  the	  Helsinki	  University	  Hospital,	  Helsinki,	   Finland	   (n	  =	  98).	  Term	   AF	   samples	   were	   collected	   in	   the	   third	   trimester	   by	  amniocentesis	  or	  needle	  aspiration	  during	  caesarean	  section	  (n	  =	  46)	  or	  vaginal	  (n	  =	  27)	  delivery.	  In	  some	  cases	  mode	  of	  delivery	   was	   not	   registered	   (n	   =	   34).	   The	   samples	   were	  collected	   from	  healthy	  controls	  and	  women	  diagnosed	  with	  PE,	   IUGR,	   diabetes	   mellitus	   type	   1	   (DM)	   and	   gestational	  diabetes	  mellitus	  (GDM).	  In	  addition,	  samples	  were	  collected	  in	  second	  trimester	  (17.2	  ±	  2.5	  gestational	  weeks).	  These	  are	  referred	   to	   as	   early	   pregnancy	   samples.	   After	   collection,	  samples	  were	  immediately	  frozen	  and	  stored	  at	  -­‐20°C.	  	  
Intestinal samples Meconium	  (n	  =	  9)	  and	   fecal	   (n	  =	  9)	  samples	  were	  collected	  from	   healthy	   term	   newborns	   at	   the	   Obstetrics	   and	  Neonatology	   Units	   of	   Hospital	   Universitario	   Doce	   de	  Octubre,	  Madrid,	  Spain.	  Meconium	  was	  collected	  within	   the	  first	  2	  hours	  from	  birth	  and	  before	  feeding	  was	  started.	  Fecal	  samples	   were	   collected	   one	   week	   after	   birth.	   Prior	   to	  comparison	   of	   AF,	   meconium	   and	   fecal	   samples,	   proteins	  were	   extracted	   as	   described	   [92].	   Dried	   AF	   or	   thawed	  meconium	  and	  fecal	  samples	  were	  re-­‐suspended	  in	  PBS	  and	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Table	  5:	  Human	  fluids	  and	  tissues	  used	  in	  this	  thesis	  	  
Material	   Origin	   Article	  	  Normal	  human	  serum	  (NHS)	   Pool	  from	  healthy	  volunteers	   I	  MBL-­‐deficient	  serum	  	   Obtained	  from	  an	  individual	  found	  to	  lack	  MBL	  in	  a	  screen	  of	  healthy	  volunteers	   I	  MgEGTA-­‐serum	   NHS	  containing	  10	  mM	  EGTA	  and	  5	  mM	  MgCL2	   I	  Heat-­‐inactivated	  serum	  (HIS)	   NHS	  incubated	  at	  56	  °C	  for	  30	  min.	  	   I	  Citrated	  plasma	   Plasma	  collected	  in	  citrate-­‐containing	  tubes	  and	  pooled	  (n	  ≥	  2)	   III	  Saliva	   Pool	  from	  healthy	  volunteers	   I,	  II	  Amniotic	  fluid	  	   Collected	  at	  the	  Obstetrics	  or	  Neonatology	  Units	  of	  Hospital	  Universitario	  Doce	  de	  Octubre,	  Madrid,	  Spain.	  
II	  
Amniotic	  fluid	   Collected	  at	  the	  Women’s	  Clinic	  of	  Helsinki	  University	  Hospital,	  Helsinki,	  Finland	   III	  Meconium	   Collected	  at	  the	  Obstetrics	  or	  Neonatology	  Units	  of	  Hospital	  Universitario	  Doce	  de	  Octubre,	  Madrid,	  Spain.	  
II	  
Feces	   Collected	  at	  the	  Obstetrics	  or	  Neonatology	  Units	  of	  Hospital	  Universitario	  Doce	  de	  Octubre,	  Madrid,	  Spain.	  
II	  
Placenta	  (frozen	  tissue)	   Obtained	  from	  the	  Finnish	  Genetics	  of	  Preeclampsia	  Consortium	  (FINNPEC)	   III	  Placenta	  (paraffin	  embedded	  tissue)	  
Obtained	  from	  Medical	  University	  of	  Graz,	  Austria	   III	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sonicated.	  The	  samples	  were	  then	  subjected	  to	  a	  FastPrep	  24	  (MP	   Biomedicals,	   California,	   USA)	   according	   to	   the	  manufacturer’s	   instructions.	   The	   resulting	   protein	   extracts	  were	  stored	  at	  -­‐80°C.	  	  
Placental samples Paraffin	   embedded	   placental	   samples	   were	   obtained	   from	  the	   Department	   of	   Obstetrics	   and	   Gynaecology,	   Medical	  University	  Graz,	  Austria	  and	  frozen	  sections	  from	  the	  Finnish	  Genetics	   of	   Preeclampsia	   Consortium	   (FINNPEC)	   cohort.	  Samples	   were	   collected	   at	   gestational	   weeks	   8-­‐11	   (1st	  trimester	   placentas),	   29-­‐34	   (early	   onset	   PE	   and	   control	  pregnancies)	  or	  36-­‐40	  (healthy	   term	  pregnancies).	  Detailed	  description	   of	   the	   FINNPEC	   cohort	   has	   been	   reported	  previously	  [105].	  	  	  
Protein level measurements 
Quantification of SALSA in amniotic fluid by ELISA  To	   quantify	   the	   levels	   of	   SALSA	   in	   protein	   extracts	   (AF,	  meconium	   and	   feces)	   and	   in	   non-­‐treated	   AF	   samples	   an	  enzyme	   linked	   immuno-­‐sorbent	   assay	   (ELISA)	   was	   set	   up.	  The	   samples	   were	   diluted	   in	   TBS/Ca2+	   and	   coated	   onto	  Maxisorp	  plates	   (Nunc,	  Roskilde,	  Denmark).	  SALSA	  purified	  from	  saliva	  was	  used	  as	  a	  protein	  concentration	  standard.	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Table	  6:	  Proteins	  and	  antibodies	  used	  in	  this	  thesis	  	  
Material	   Origin	   Article	  Recombinant	  SALSA	  (rSALSA)	   Expressed	  in	  CHO	  cells	  and	  purified	  by	  bacterial	  binding	  and	  EDTA-­‐elution	  [152]	   I	  Saliva-­‐SALSA	   Purified	  by	  bacterial	  binding	  and	  EDTA-­‐elution	  [152]	   I,	  II	  	  AF-­‐SALSA	  	   Purified	  by	  bacterial	  binding	  and	  EDTA-­‐elution	  [152]	   II,	  III	  Recombinant	  MBL	  (rMBL)	   Expressed	  according	  to	  previously	  described	  [75]	   I,	  II	  Recombinant	  M-­‐ficolin	  (rM-­‐ficolin)	   Expressed	  according	  to	  previously	  described	  [212]	   I	  Plasma	  purified	  L-­‐ficolin	   Purified	  according	  to	  previously	  described	  [217]	   I	  Plasma	  purified	  H-­‐ficolin	   Purified	  according	  to	  previously	  described	  [115]	   I	  Recombinant	  MASP-­‐2	  (rMASP-­‐2)	   Expressed	  according	  to	  previously	  described	  [193]	   I	  Plasma	  purified	  C4	   Purified	  according	  to	  previously	  described	  [38]	   I	  Plasma	  purified	  C3	   Purified	  according	  to	  previously	  described	  [186]	   I	  C1q	   Quidel,	  USA	   I,	  II	  IgA	   Sigma-­‐aldrich	   II	  Plasma	  purified	  fibronectin	   Chemicon,	  USA	   III	  mAb	  Mouse	  anti-­‐SALSA	  (Hyb	  213-­‐06)	   Bioporto,	  Denmark	   I,	  II,	  III	  mAb	  Mouse	  anti-­‐M-­‐ficolin	  (7G1)	   Produced	  according	  to	  previously	  described	  [212]	   I	  mAb	  Mouse	  anti-­‐MBL	  (Hyb	  131-­‐01)	   Bioporto,	  Denmark	   I	  mAb	  Mouse	  anti-­‐H-­‐ficolin	  (4H5)	   Hycult	  Biotechnology,	  The	  Netherlands	   I	  mAb	  Rat	  anti.MASP-­‐2	  (8B5)	   Hycult	  Biotechnology	   I	  pAb	  Rabbit	  anti-­‐C3c	   Dako	   I	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pAb	  Rabbit	  anti-­‐C4c	   Dako	   I	  pAb	  Rabbit	  anti-­‐C1q	   Dako	   I,	  III	  HRP	  rabbit	  anti-­‐mouse	  IgG	   Jackson	  ImmunoResearch	  Laboratories,	  USA	   I,	  II,	  III	  HRP	  goat	  anti-­‐rabbit	  IgG	   Jackson	  ImmunoResearch	  Laboratories	   I	  	  Alexa	  488	  goat	  anti-­‐mouse	  IgG	  	   Invitrogen,	  USA	   I,	  III	  Alexa	  546	  goat	  anti-­‐mouse	  IgG	  	   Invitrogen	   III	  Alexa	  488	  goat	  anti-­‐rabbit	  IgG	  	   Invitrogen	   I,	  III	  	  	   	   	  Table	  7:	  Buffers	  used	  in	  this	  thesis	  	  
Buffer	   Content	   Article	  Coating	  buffer	   15	  mM	  Na2CO3,	  35	  mM	  NaHCO3,	  pH	  9.6	   I,	  II,	  III	  Phosphate-­‐buffered	  	  saline	  (PBS)	   137	  mM	  NaCl,	  2.7	  mM	  KCl,	  10	  mM	  Na2HPO4,	  18.8	  mM	  KH2PO4,	  pH	  7.4	   I,	  II,	  III	  Tris-­‐buffered	  saline	  	  (TBS)	   140	  mM	  NaCl,	  5	  mM	  Tris,	  pH	  7.4	   I,	  II,	  III	  TBS/Ca	   140	  mM	  NaCl,	  5	  mM	  Tris,	  1	  mM	  Ca2+,	  pH	  7.4	   I,	  II,	  III	  TBS/Ca/Tween	   140	  mM	  NaCl,	  5	  mM	  Tris,	  1	  mM	  Ca2+,	  0.05	  %	  Tween-­‐20,	  pH	  7.4	   I,	  II,	  III	  TBS/EDTA/Tween	   140	  mM	  NaCl,	  5	  mM	  Tris,	  10	  mM	  EDTA,	  0.05	  %	  Tween-­‐20,	  pH	  7.4	   I,	  II,	  III	  TTSB	  buffer	   0.5	  mM	  NaCl,	  20	  mM	  Tris,	  0.05%	  Tween	  20,	  pH	  7.4	   III	  Veronal	  buffered	  	  saline	  (VBS)	   142	  mM	  NaCl,	  5.0	  mM	  sodium	  barbital,	  pH	  7.4	   I	  VBS/Ca	   142	  mM	  NaCl,	  5.0	  mM	  sodium	  barbital,	  1	  mM	  Ca2+,	  pH	  7.4	   I	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After	   blocking	   and	   washing	   SALSA	   was	   detected	   using	   a	  monoclonal	   (mAb)	   anti-­‐SALSA	   Hyb	   213-­‐06	   and	   HRP-­‐conjugated	   rabbit	   anti-­‐mouse	   antibodies.	   For	   development	  1,2-­‐phenylenediamine	  (OPD)	  tablets	  (Dako,	  Denmark)	  were	  used.	  The	  resulting	  color	  was	  measured	  at	  an	  OD	  of	  492	  nm	  by	   an	   iEMS	   Reader	  MF	   (Labsystems,	   Espoo,	   Finland).	   Data	  points	  were	   obtained	   from	   a	   dilution	   series	   to	   ensure	   that	  the	   readings	   were	   within	   a	   linear	   range.	   The	   resulting	  protein	   level	   measurements	   were	   based	   on	   a	   minimum	   of	  three	   separate	   readings.	   In	   some	   cases	   the	   protein	   levels	  were	   correlated	   to	   the	   total	   protein	   amount	   of	   the	   sample,	  which	  was	  measured	  by	  NanoDrop	  (Thermo	  Scientific).	  	  	  
LC-MS/MS Mass Spectrometry Relative	  peptide	  abundance	  was	  used	  to	  quantify	  the	  amount	  of	   either	   SALSA	   protein	   or	   specific	   peptide-­‐containing	  regions	   of	   SALSA	   protein	   in	   protein	   extracts	   from	   AF,	  meconium	   and	   fecal	   samples.	   The	   samples	  were	   separated	  by	  gel	  electrophoresis	  and	  divided	  into	  four	  smaller	  regions.	  NanoLC	   and	   LTQ-­‐Orbitrap-­‐MS	   analyses,	   including	   quality	  checks	   and	   machine	   calibrations,	   were	   performed	   as	  described	   [106].	   An	   in-­‐house	   database	   based	   on	   protein	  sequences	  expected	  to	  be	  present	  in	  the	  infant	  gut	  was	  used	  for	  MS/MS	  spectral	  identifications.	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Protein visualization assays 
Western blotting  To	  detect	  SALSA	  by	  Western	  blotting,	  samples	  were	  diluted	  in	   and	   mixed	   with	   non-­‐reducing	   SDS-­‐PAGE	   loading	   buffer.	  Thereafter,	   the	   samples	   were	   run	   into	   a	   4-­‐12	   %	   gradient	  SDS-­‐PAGE	   gel	   (Life	   Technologies)	   and	   the	   proteins	   were	  transferred	   onto	   a	   nitrocellulose	   membrane	   (Life	  Technologies).	   After	   blocking,	   SALSA	   was	   detected	   using	  anti-­‐SALSA	   (Hyb	   213-­‐06)	   and	   HRP-­‐conjugated	   rabbit	   anti-­‐mouse	   IgG	   antibodies.	   The	   bands	   were	   visualized	   by	  electrochemiluminescence.	  	  
Glycoprotein	  and	  lectin	  staining	  Purified	  SALSA	  was	  run	  into	  an	  SDS-­‐PAGE	  gel.	  The	  resulting	  gel	  was	  split	  in	  three	  parts	  and	  stained	  with	  silver	  nitrate	  or	  Periodic-­‐acid	   Schiff	   reagent	   (Glycoprotein	   Staining	   Kit,	  Pierce).	   In	   addition	   a	   part	   of	   the	   gel	   was	   blotted	   onto	   a	  PVDF-­‐membrane	  (Amersham)	  for	  staining	  with	  DIG-­‐labelled	  sialic	   acid-­‐specific	   Sambucus	   Nigra	   lectin	   (DIG	   Glycan	  Differentiation	   Kit,	   Boehringer	   Mannheim).	   After	   blocking	  the	  membrane	  was	  incubated	  with	  the	  lectin.	  Lectin	  binding	  was	  detected	  with	  anti-­‐DIG-­‐AP	  according	   to	  manufacturer’s	  instructions.	  	  	  
Immunohistochemistry Paraffin	  embedded	  tissue	  sections	  (5	  μm)	  were	  subjected	  to	  standard	   de-­‐paraffination	   followed	   by	   antigen	   retrieval	  treatment.	   The	   kit	   UltraVision	   LP	   Large	   Volume	   Detection	  System	   (HRP	   Polymer	   Ready-­‐To-­‐Use,	   ThermoFisher	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Scientific)	  was	  used.	  mAb	  anti-­‐SALSA	  was	  added	  (10	  μg/ml)	  in	  antibody	  diluent	  (Dako).	  The	  sections	  were	  then	  subjected	  to	   incubations	   with	   primary	   antibody	   enhancer,	   HRP	  Polymer,	   3-­‐Amino-­‐9-­‐Ethylcarbazole	   (both	   from	  ThermoFisher	   Scientific)	   and	   finally	   counterstained	   by	  Mayer's	   hematoxylin	   and	   eosin.	   The	   sections	   were	   treated	  with	   ammonium	   and	   mounted	   using	   Aquatex	   (Merck,	  Germany).	  	  	  For	  fluorescence	   immunohistochemistry	  paraffin	  embedded	  sections	   were	   prepared	   as	   above.	   Frozen	   sections	   (5	   μm)	  were	   prepared	   by	   cryosectioning	   of	   freshly	   frozen	   samples	  and	  blocked	  with	  bovine	   serum	  albumin	   (BSA).	  Anti-­‐SALSA	  was	  diluted	  to	  10	  μg/ml	  and	  incubated	  with	  the	  samples.	  For	  co-­‐localization	   studies	   rabbit-­‐anti	   cellular	   fibronectin	  (ab299,	   Abcam,	   UK)	   and	   rabbit	   anti-­‐C1q	   (Dako)	   antibodies	  were	   used	   1:1000	   in	   Dako	   antibody	   diluent.	   Alexa	   488-­‐labeled	   goat	   anti-­‐rabbit	   and	   Alexa	   546-­‐labeled	   goat	   anti-­‐mouse	   antibodies	   (Invitrogen,)	   were	   used	   diluted	   1:300	   in	  PBS.	  When	  ex	  vivo	  SALSA	  binding	  was	  tested,	  an	  overlay	  was	  performed	  with	  non-­‐diluted	  AF.	  	  	  
Protein interaction assays 
ELISA binding assays  Binding	   of	   SALSA	   to	   a	   range	   of	   endogenous	   ligands	   was	  tested	  in	  an	  ELISA	  set	  up.	  Binding	  was	  tested	  to	  recombinant	  MBL	   (rMBL),	   rM-­‐ficolin,	  L-­‐ficolin,	  H-­‐ficolin,	  C1q,	  C4,	  C3,	   IgA	  and	  fibronectin.	  The	  proteins	  were	  diluted	  in	  a	  coating	  buffer	  into	   concentrations	  varying	  between	  1	  and	  10	  µg/ml.	  After	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coating,	  the	  wells	  were	  washed	  with	  TBS/Tween	  containing	  either	  1	  mM	  Ca2+	  or	  10	  mM	  EDTA.	  For	  fibronectin	  the	  TTSB	  buffer	   was	   used	   for	   washing.	   SALSA	   protein	   was	   added	   at	  0.5-­‐1	   µg/ml.	   The	   Ca2+-­‐dependency	   of	   the	   binding	   was	  investigated	  by	  adding	  10	  mM	  EDTA	  and	  omitting	  Ca2+	  from	  the	   buffer	   (fibronectin	   only).	   After	   incubation	   binding	   was	  detected	  using	  anti-­‐SALSA	  Hyb	  213-­‐06	  and	  HRP-­‐conjugated	  rabbit	   anti-­‐mouse	   antibodies.	   The	   color	   reaction	   was	  developed	  as	  described	  above.	  	  	  
ELISA competition assays  Competition	   of	   binding	   between	   SALSA,	   MBL,	   MASP2	   and	  carbohydrate	   ligands	   was	   tested	   by	   ELISA.	   In	   one	   assay	  rSALSA	  (0.1	  µg/ml)	  was	  coated	  on	  microtiter	  plates.	  rMBL	  (1	  
µg/ml)	  was	  mixed	   in	  the	   fluid	  phase	  with	  mannose,	  GlcNAc	  or	   glucose	   (all	   from	   Sigma)	   in	   concentrations	   ranging	  between	   0-­‐100	   mM	   in	   TBS/Ca2+.	   The	   samples	   were	  incubated	   in	   the	   SALSA-­‐coated	   wells.	   In	   another	   assay	  mannan	   (10	   µg/ml)	   was	   coated	   on	   the	   plate.	   rMBL	   (0.5	  
µg/ml	   )	  was	  mixed	  with	   rMASP-­‐2	   (0.1	  µg/ml)	   in	   TBS/Ca2+	  and	   rSALSA	   was	   added	   in	   final	   concentrations	   ranging	  between	  0-­‐1.5	  µg/ml.	  The	   samples	  were	   then	   incubated	  on	  the	   plate.	   For	   both	   assays	   binding	  was	   detected	  with	   anti-­‐MBL	   and/or	   anti-­‐MASP2	   and	   HRP-­‐conjugated	   rabbit	   anti-­‐mouse	   IgG	  antibodies.	  The	  color	   reaction	  was	  developed	  as	  described	  above.	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Complement assays 
Measurement of complement activation by SALSA in 
solution The	   effect	   of	   fluid-­‐phase	   SALSA	   on	   C	   activation	  was	   tested	  using	  the	  Wieslab®	  Complement	  System	  Screen	  ELISA	  assay	  (Euro	   Diagnostica,	   Sweden).	   SALSA	   (0-­‐10	   µg/ml)	   was	  diluted	   in	  normal	  human	  serum	  (NHS)	  and	  added	   to	  ELISA	  wells	  coated	  with	  specific	  activators	  for	  the	  three	  different	  C	  pathways.	  Activation	  of	  C	  was	  measured	  as	  generation	  of	  the	  C5b-­‐9	  complex	  onto	  the	  activating	  surfaces	  according	  to	  the	  manufacturer’s	  instructions.	  	  
Measurement of complement activation by surface-
coated SALSA In	  an	  ELISA	  assay	  mannan	  (10	  µg/ml)	  or	  rSALSA	  (0.5	  µg/ml)	  were	   coated	   on	   Maxisorp	   plates	   as	   described	   above.	   NHS,	  MBL-­‐deficient	   serum,	   MgEGTA-­‐serum	   and	   heat-­‐inactivated	  serum	   (HIS)	   were	   diluted	   1:10	   and	   added.	   C4	   and	   C3	  deposition	  was	  detected	  by	  incubation	  with	  polyclonal	  (pAb)	  anti-­‐C4c	   and	   C3c	   antibodies	   (Dako),	   followed	   by	   HRP-­‐conjugated	   goat	   anti-­‐rabbit	   antibody.	   The	   enzyme	   reaction	  was	  developed	  as	  described	  above.	  	  	  
Effect of SALSA on complement activation by C. 
albicans The	  effect	  of	  SALSA	  on	  C	  activation	  by	   the	  yeast	  C.	  albicans	  was	  measured	   in	   a	   flow	   cytometry	   assay.	  C.	  albicans	  was	   a	  clinical	   blood	   culture	   isolate	   from	   the	   Helsinki	   University	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Hospital	   laboratory	   (HUSLAB),	   identified	   using	   routine	  microbiological	   techniques.	  C.	  albicans	  was	   grown	   in	   yeast-­‐extract	   peptone	   dextrose	   medium	   overnight	   at	   30°C	   with	  shaking,	  washed	  and	  resuspended	  to	  5	  ×	  107	  cells/ml.	  100	  µl	  of	   this	   dilution	  was	   used	   for	   each	   sample.	   rSALSA	   (0	   –	   1.5	  
µg/ml)	   was	   diluted	   in	   10	   %	   NHS,	   MBL-­‐deficient	   serum,	  MgEGTA-­‐serum	  or	  HIS	  and	  incubated	  with	  C.	  albicans	  for	  30	  min	   at	   37°C.	   C4b	   and	   C3b	   deposition	   was	  measured	   using	  anti-­‐C4c	  and	  anti-­‐C3c	  antibodies	  followed	  by	  detection	  using	  Alexa	   488-­‐conjugated	   goat-­‐anti	   rabbit	   IgG	   antibody.	   The	  yeast	  cells	  were	  fixed	  in	  1	  %	  paraformaldehyde	  and	  analyzed	  by	   CyAn	  ADP	   (Dako).	   Forward	   and	   sideward	   scatters	  were	  used	   to	   define	   the	   cell	   population	   and	   10	   000	   events	  were	  routinely	   counted.	   The	   mean	   fluorescence	   intensity	   (MFI)	  values	  were	  used	  for	  quantification	  of	  the	  data.	  
	  
Bacterial binding assays 
Bacterial	  culturing	  Group	   A	   streptococcus	   (GAS;	   ATCC	   19615),	   group	   B	  streptococcus	   (GBS),	   ATCC	   T15508	   and	   two	   clinical	   blood	  isolates,	   identified	   at	   HUSLAB	   and	   S.	   gordonii,	   DL1	   Challis	  (20),	  were	  grown	  in	  Todd-­‐Hewitt	  media	  O/N	  at	  37°C.	  E.	  coli	  (urine	   isolate)	   and	   Salmonella	   serovar	   Typhimurium	   (fecal	  isolate)	  were	  grown	  O/N	  at	  37°C	  with	  shaking	  in	  Luria	  broth.	  
	  
Binding	  of	  SALSA	  to	  bacteria	  	  SALSA	  binding	  to	  GBS	  was	  studied	  in	  a	  flow	  cytometry	  assay.	  GBS	  was	  grown	  as	  described	  above	  and	  resuspended	  to	  1	  ×	  106	  cells/ml.	  Volumes	  of	  100	  µl	  of	  these	  dilutions	  were	  used	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for	   each	   sample.	   AF-­‐purified	   SALSA	   (0-­‐3	   µg/ml)	   was	  incubated	   with	   the	   microbes	   followed	   by	   washing	   with	  VBS/Ca2+.	   SALSA	   binding	   was	   detected	   using	   mAb	   anti-­‐SALSA	  (Hyb	  213-­‐06)	  and	  Alexa	  488-­‐coupled	  goat-­‐anti	  mouse	  IgG	   antibodies.	   The	   microbes	   were	   fixed	   in	   1	   %	  paraformaldehyde	  and	  analyzed	  by	  CyAn	  ADP	  as	  described	  above.	  	  Bacterial	   binding	   of	   SALSA	   from	   biological	   fluids	   was	  analyzed	   in	   a	  Western	   blotting-­‐based	   assay.	   AF,	  meconium	  or	   fecal	   protein	   extracts	   were	   diluted	   to	   a	   final	   SALSA	  concentration	  of	  0.5	  μg/ml	  and	  incubated	  with	  109	  bacterial	  cells.	   After	   centrifugation	   (10	   000	   g)	   the	   supernatants	   and	  pellets	  were	  collected.	  The	  bacteria	  were	  incubated	  in	  50	  μl	  non-­‐reducing	   SDS-­‐PAGE	   loading	   buffer	   (Life	   Technologies)	  containing	   10	  mM	  EDTA.	  Using	  Western	   blotting,	   SALSA	   in	  the	   original	   solution	   was	   compared	   to	   SALSA	   in	   the	  supernatants	   after	   absorption	   with	   bacteria	   and	   after	  treatment	  with	  10	  mM	  EDTA.	  	  	  
SALSA-mediated inhibition of MBL binding to 
microorganisms The	  effect	  of	  SALSA	  on	  the	  binding	  of	  MBL	  to	  C.	  albicans	  and	  
E.	  coli	  was	  studied	  in	  a	  flow	  cytometry	  assay.	  C.	  albicans	  and	  
E.	   coli	   were	   grown	   as	   described	   above.	   C.	   albicans	   was	  resuspended	   to	   5	   ×	   107	   cells/ml	   and	   E.	   coli	   to	   2.4	   ×	   108	  cells/ml.	  Volumes	  of	  100	  µl	  of	  these	  dilutions	  were	  used	  for	  each	  sample.	   rMBL	  (0.9	  µg/ml)	  was	  mixed	  with	  rSALSA	  (0-­‐4.5	  µg/ml)	  and	   incubated	  with	   the	  microbes.	  After	  washing	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with	  VBS/Ca2+	  MBL	  binding	  was	  detected	  using	  an	  anti-­‐MBL	  antibody	   and	   Alexa	   488-­‐coupled	   goat-­‐anti	   mouse	   IgG	  antibody.	  The	  microbes	  were	  fixed	  in	  1	  %	  paraformaldehyde	  and	  analyzed	  by	  CyAn	  ADP	  as	  described	  above.	  	  
Coagulation assays 
Effect of soluble SALSA on coagulation Basic	   coagulation	   assays	   such	   as	   Thrombin	   Time	   and	  Activated	  Prothrombin	  Time	  measurements	  were	  performed	  using	   a	   coagulometer	   as	   described	   [8].	   For	   thrombin	   time	  measurements	   100	   μl	   BC	   Thrombin	   reagent	   (Siemens,	  Germany)	  was	  added	  to	  40	  μl	  citrated	  plasma	  (at	  37°C).	  For	  activated	  prothrombin	  time	  measurements	  50	  μl	  Dade	  Actin	  FSL	  reagent	  (Siemens)	  was	  mixed	  with	  50	  μl	  citrated	  plasma	  (at	  37°C).	  After	  a	  3	  minute	  incubation	  50	  μl	  of	  25	  mM	  CaCl2	  was	   added	   to	   initiate	   coagulation.	   For	   both	   assays,	   SALSA	  was	  mixed	  with	  plasma	  in	  the	  fluid	  phase	  prior	  to	  initiation	  of	  coagulation	  at	  concentrations	  of	  0	  –	  5	  μg/ml.	  	  
Coagulation in the presence of surface-coated SALSA The	   effect	   of	   surface-­‐coated	   SALSA	   on	   coagulation	   was	  tested	   in	  an	  assay	  modified	   from	  the	  protocol	  published	  by	  Rose	   and	  Babensee	   [167].	   SALSA	   (1	   μg/ml)	  was	   coated	   on	   a	  Maxisorp	  plate	  as	  described	  above.	  Citrated	  plasma	  (100	  μl,	  at	   37	   °C)	   and	   BC	   Thrombin	   reagent	   (100	   μl)	   were	   added	  whereby	   coagulation	   was	   initiated.	   OD405	   measurements	  were	   made	   at	   20s	   intervals	   for	   30	   min	   using	   a	   FLUOstar	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optima	   reader	   (BMG	   Labtech,	   Germany).	   An	   increase	   in	  absorbance	  corresponded	  to	  the	  formation	  of	  the	  clot.	  	  	  
Statistical analysis Student’s	   paired,	   two-­‐tailed	   t-­‐test	   was	   used	   to	   calculate	  statistical	   significance	   of	   differences	   when	   comparing	  numerical	   values	   of	   SALSA	   protein	   levels,	   complement	  activation	  and	  coagulation.	  SALSA	  levels	  in	  AF	  samples	  from	  various	   disease	   groups	   were	   related	   to	   a	   list	   of	   clinical	  features.	   For	   this	   both	   a	   Pearson	   product-­‐moment	  correlation	  test	  and	  a	  Spearman’s	  rank	  correlation	  test	  were	  performed.	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Results and Discussion 	  This	  study	  has	  mainly	  focused	  on	  understanding	  the	  function	  of	   the	   SALSA	  protein,	   especially	   in	   the	   context	   of	   early	   life.	  We	   have	   analyzed	   certain	   expression	   patterns,	   identified	  novel	   ligands	   and	   found	   functional	   relevance	   in	  immunological	  systems,	  such	  as	  the	  complement	  system.	  An	  overview	  of	  the	  main	  results	  is	  given	  in	  Table	  8.	  	   Table	  8:	  Main	  results	  obtained	  in	  this	  thesis	  	  
Finding	   Article	  
	  Secreted	  SALSA	  is	  found	  abundantly	  in	  amniotic	  fluid,	  meconium	  and	  feces	   	  II,	  III	  	  SALSA	  levels	  in	  amniotic	  fluid	  increase	  during	  pregnancy 	   III	  	  SALSA	  is	  found	  in	  placental	  syncytiotrophoblasts	  and	  fibrinoids	   	   III	  	  SALSA	  is	  found	  in	  decidual	  endothelium	   	   III	  	  SALSA	  binds	  to	  MBL,	  ficolins	  and	  fibronectin	   	   I,	  III	  	  SALSA	  regulates	  complement	  activation	   	   I	  	  Variations	  in	  isoforms	  and	  glycosylations	  may	  affect	  SALSA	  function	   	   II	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SALSA in body fluids 
SALSA in amniotic fluid (II, III) This	  project	  was	  initiated	  by	  performing	  a	  screen	  of	  several	  body	   fluids	   for	   the	   presence	   of	   SALSA	   and	   led	   to	   the	  discovery	  of	  SALSA	  expression	  in	  amniotic	  fluid.	  This	  adds	  a	  new	   dimension	   to	   the	   potential	   functions	   of	   SALSA,	   which	  has	   earlier	   primarily	   been	   described	   in	   respiratory	  secretions	  (Table	  1).	  To	  study	   the	  novel	   finding	   in	  greater	  detail	   we	   collected	   AF	   samples	   from	   women	   with	   normal	  healthy	  pregnancies	  undergoing	  routine	  screening	  or	  at	  term	  and	   investigated	   SALSA	   protein	   expression	   by	   Western	  blotting,	  ELISA	  and	  mass	  spectrometry.	  	  	  The	   analysis	   of	   SALSA	   in	   AF	   revealed	   great	   individual	  variations.	   In	  Western	  blotting	  we	  observed	   size	   variations	  of	   the	   SALSA-­‐positive	   bands	   in	   different	   AF	   samples	   (II,	  Figure	  1).	  Furthermore,	  SALSA	  in	  several	  samples	  appeared	  as	   a	   single	   band	   and	   in	   others	   as	   a	   double	   band.	   SALSA	  presented	   either	   as	   very	   distinct	   bands	   or	   as	   smear	   of	  varying	  sizes	  on	  the	  blot.	  The	  AF	  samples	  were	  stained	  with	  Periodic-­‐Acid	   Schiff	   and	   the	   sialic	   acid-­‐specific	   Sambucus	  
nigra	   lectin	   to	   visualize	   glycosylation.	   We	   observed	   a	  positive	   response	   indicating	   that	  SALSA	   in	  AF,	   like	   in	  other	  tissues,	   is	   glycosylated	   and	   contains	   carbohydrates	   with	  terminal	  sialic	  acids.	  	  	  Size	   polymorphisms	   of	   SALSA	   have	   been	   described	   before	  and	  used	  to	  classify	  individuals	  into	  four	  groups	  [46,	  103].	  This	  grouping	   was	   shown	   to	   correlate	   with	   Lewis-­‐antigen	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expression,	   secretor	   status	   (expression	   of	   the	   α1-­‐2fucosyl-­‐transferase)	   and	   bacterial	   binding	   properties	   [46].	   The	  individual	   variations	   in	   SALSA	   observed	   in	   AF	   support	   the	  findings	   from	   saliva	   and	   lung	   aspirations	   and	   may	   indeed	  reflect	  such	  grouping	  in	  AF	  as	  well.	  In	  the	  future	  it	  will	  be	  of	  interest	   to	   compare	   purified	   AF-­‐SALSA	   from	   individuals	   to	  search	   for	   a	   similar	   grouping	   and	   furthermore	   analyze	   if	  such	   grouping	   has	   a	   functional	   relevance	   for	   the	   SALSA	  protein	   found	   in	   AF.	   A	   thorough	   analysis	   would	   require	  larger	  volumes	  of	  the	  individual	  samples	  than	  we	  obtained	  in	  this	  study	  (only	  app.	  10	  ml	  per	  sample).	  	  	  Individual	  variation	  was	  also	  found	  in	  the	  protein	  amount.	  In	  the	   ELISA	   analysis	   the	   concentrations	   of	   SALSA	   at	   term	   in	  the	   Spanish	   cohort	   ranged	   between	   0-­‐11.5	   μg/ml	   (n	   =	   14,	  mean:	   2.1	   ±	   3.7	   μg/ml)	   (II,	   Figure	   2).	   The	   finding	   of	   very	  similar	   SALSA	   concentrations	   in	   the	   Finnish	   cohort	   (n	   =	   9,	  mean:	  2.1	  ±	  1.6	  μg/ml)	  (III,	  Figure	  1)	  increases	  the	  validity	  of	  the	  measured	   levels.	   To	   further	   understand	   the	   expression	  of	  SALSA	  during	  the	  course	  of	  the	  pregnancy,	  samples	  were	  also	  collected	  at	  an	  earlier	  time	  point	  (before	  gestation	  week	  20,	  n	  =	  20).	  Here	   the	  SALSA	  concentration	   ranged	  between	  0-­‐1.8	   μg/ml	   (mean:	   0.7	   ±	   0.5).	   The	   general	   protein	   level	   in	  AF	  is	  known	  to	  vary	  during	  the	  course	  of	  pregnancy	  and	  the	  SALSA	   concentrations	   were	   therefore	   related	   to	   the	   total	  protein	   amount.	   This	   led	   to	   the	   finding	   that	   the	   relative	  SALSA	   levels	   doubled	   from	   0.15	  ‰	   to	   0.3	  ‰	   of	   the	   total	  protein	  amount	  from	  the	  first	  to	  the	  third	  trimester	  (p<0.05)	  (III,	  Figure	  1A).	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Amniotic fluid SALSA levels in normal and 
complicated pregnancies (II, III) Dysregulated	  immunological	  responses	  have	  been	  suspected	  to	   be	   involved	   in	   the	   pathogenesis	   of	   certain	   pregnancy	  complications.	  Therefore	  we	  investigated	  the	  levels	  of	  SALSA	  in	   AF	   from	   patients	   with	   PE,	   IUGR,	   GDM	   or	   DM	   diagnosed	  prior	   to	   the	   pregnancy.	   Included	   in	   the	   analysis	   were	  additional	  samples	  taken	  before	  20	  weeks	  of	  gestation	  from	  patients	   who	   later	   developed	   PE.	   The	   concentrations	   of	  SALSA	   were	   related	   to	   the	   total	   protein	   amount	   in	   the	  samples	   and	   compared	   to	   AF	   samples	   from	   healthy	   age-­‐matched	  controls.	  	  	  At	  the	  early	  stage	  of	  pregnancy	  the	  concentrations	  of	  SALSA	  were	  0.7	  ±	  0.5	  μg/ml	  (n	  =	  18)	  for	  the	  control	  group	  and	  1.4	  ±	  1.4	   μg/ml	   (n	   =	   9)	   for	   the	   PE	   group	   (p	   =	   0.09).	   When	   the	  values	   were	   related	   to	   the	   total	   protein	   levels	   the	   values	  were	  0.17	  ±	  0.18	  ‰	  for	  controls	  and	  0.29	  ±	  0.29	  ‰	  for	  PE	  (III,	   Figure	   1B).	   Possibly	   because	   of	   the	   small	   number	   of	  samples,	   these	   differences	  were	   not	   statistically	   significant.	  Nevertheless,	   they	   suggest	   a	   trend	   of	   increased	   levels	   of	  SALSA	  at	   an	   early	   time	  point	  of	  patients	  who	   later	  develop	  PE	  and	  warrant	  studies	  in	  a	  larger	  population.	  Predictors	  of	  PE	  would	  be	  desperately	  needed.	  When	  we	  compared	  SALSA	  levels	   in	   the	   various	   pregnancy	   groups	   close	   to	   term,	   no	  significant	   differences	   were	   seen	   (III,	   Figure	   1C).	   We	   also	  tested	  association	  between	  certain	  size	  polymorphisms	  and	  disease	   groups	   by	   Western	   blotting,	   but	   found	   no	  correlation.	  In	  both	  PE	  groups	  (early	  and	  at	  term)	  both	  high	  and	   low	   levels	   of	   SALSA	   were	   observed.	   This	   inter-­‐group	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variation	   still	   lacks	   an	   explanation,	   but	   could	   indicate	   the	  existence	   of	   different	   disease	   subgroups	   with	   different	  pathological	   mechanisms.	   We	   tested	   if	   the	   SALSA	   levels	  correlated	   to	   the	   severity	   of	   the	  disease.	  However,	   no	   such	  link	  was	  found.	  	  	  AF	  is	  a	  bioactive	  medium	  with	  constituents	  actively	  secreted	  by	   cells	   lining	   the	   amniotic	   cavity	   and,	   during	   the	   early	  stages,	   liquid	   filtered	   from	   the	   maternal	   blood	   [20].	   As	  gestation	   progresses,	   AF	   includes	   a	   significant	   volume	   of	  fetal	  urine	  (up	  to	  50%)	  [20].	  We	  tested	  adult	  urine	  but	  did	  not	  detect	   SALSA	   protein	   expression.	   The	   origin	   and	   thus	   the	  specific	  function	  of	  SALSA	  in	  AF	  is	  not	  yet	  clear.	  In	  this	  work	  we	   found	   several	   indications	   of	   placental	   production	   of	  SALSA	  (III,	  Figure	  2).	  However,	  to	  fully	  determine	  the	  origin	  of	  SALSA	  in	  AF,	  the	  glycosylations	  could	  be	  studied	  in	  detail.	  Differences	   in	   e.g.	   the	   secretor	   status	   between	   the	   mother	  and	  the	  child	  would	  help	  to	  specify	  which	  tissue	  (maternal	  or	  fetal)	  produced	  the	  protein.	  Despite	  the	  fact	  that	  there	  can	  be	  differences	  in	  glycosylation	  even	  within	  the	  same	  individual,	  certain	  Lewis	  antigens	   found	  on	  SALSA	   in	   the	  AF	  of	   a	   Se(-­‐)	  mother,	  would	  directly	   tell	   that	   SALSA	   is	  produced	  by	   fetal	  tissue.	  	  	  The	   function	   of	   SALSA	   has	   been	   linked	   to	   both	   innate	  immunity	  and	  epithelial	  differentiation	  [111,	  121].	  Both	  types	  of	  functions	  could	  be	  mediated	  by	  SALSA	  in	  AF.	  In	  mice,	  a	  clear	  role	   of	   SALSA	   in	   epithelial	   differentiation	   from	  trophectoderm	  to	  fully	  differentiated	  cells,	  including	  specific	  interactions	   with	   integrins	   and	   galectin-­‐3	   has	   been	  
Results	  and	  discussion	  
	   	  86	  
described	   [3].	   SALSA	   knock-­‐out	   proved	   to	   be	   lethal	   for	   the	  developing	  fetus	  in	  a	  mouse	  model	  [188].	  In	  addition,	  seeding	  of	   mouse	   embryonic	   stem	   cells	   on	   a	   matrix	   of	   the	   rabbit	  SALSA	   ortholog,	   hensin,	   induced	   development	   of	   columnar	  epithelia	   [188].	  This	   suggests	   that	   the	  developing	   cells	   in	   the	  human	   fetus	   could	   utilize	   SALSA	   in	   a	   similar	   way.	   The	  developing	  fetus	  could	  thus	  be	  the	  source	  of	  SALSA	  in	  the	  AF.	  The	   function	   would	   then	   be	   linked	   to	   epithelial	   cell	  differentiation.	  	  In	  contrast,	   if	   the	  SALSA	   levels	  are	   indeed	  elevated	   in	  early	  pregnancy	   of	   women	   who	   later	   develop	   PE,	   this	   will	   most	  likely	   be	   a	   reflection	   of	  what	   happens	   at	   the	   feto-­‐maternal	  interface	  in	  the	  placenta.	  An	  unbalanced	  meeting	  of	  fetal	  and	  maternal	  tissue	  could	  affect	  production	  of	  SALSA.	  This	  would	  support	   the	   hypothesis	   that	   SALSA	   is	   produced	   in	   the	  placenta	  and	  transported	  into	  the	  AF.	  This	  type	  of	  secretion	  is	  more	  suggestive	  of	  an	  immunoprotective	  role	  towards	  the	  fetus,	   perhaps	   helping	   to	   keep	   the	   AF	   sterile	   by	   the	   anti-­‐microbial	   functions	   of	   SALSA.	   Thus	   we	   do	   not	   expect	   that	  elevated	  levels	  of	  SALSA	  in	  AF	  would	  be	  directly	  involved	  in	  the	  etiology	  of	  PE.	  	  Intriguingly,	   the	   relative	   levels	   of	   SALSA	   increase	   towards	  parturition.	   This	   suggests	   that	   the	   role	   of	   SALSA	   becomes	  increasingly	  important.	  From	  an	  immunological	  perspective,	  it	   would	   be	   relevant	   to	   coat	   the	   fetus	   in	   anti-­‐microbial	  effector	  molecules,	  such	  as	  SALSA,	  before	  it	  leaves	  the	  sterile	  amniotic	   cavity	   and	  encounters	   the	   first	  microorganisms	  of	  the	   maternal	   vagina	   and	   the	   surrounding	   environment.	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Likewise,	   an	   increase	   in	   SALSA	   levels	   would	   match	   the	  increase	  of	  cells	  in	  the	  developing	  fetus.	  Towards	  parturition	  SALSA	   could	   be	   produced	   mainly	   by	   the	   fetal	   mucosal	  tissues,	  which	  are	  constantly	  secreting	  molecules	  and	  fluids	  into	  the	  AF	  [20].	  	  	  Studies	   have	   shown	   that	   SALSA	   levels	   correlate	   with	   lung	  maturity.	   Premature	   newborns	   had	   lower	   SALSA	   levels	   in	  tracheal	   aspirates	   right	   after	   birth	   compared	   to	   full	   term	  babies	   [128].	  However,	   the	  same	  study	  showed	  that	  neonatal	  infection	   led	   to	   increased	   lung	   SALSA	   levels	   at	   birth	   [128].	  Preterm	   infections	   are	   a	   known	   cause	   of	   premature	   birth	  and	  fetal	  death	  [52].	  Interestingly,	  the	  surfactant	  proteins	  SpA	  and	   SpD,	   known	   ligands	   of	   SALSA,	   have	   been	   described	   to	  have	  a	  direct	   effect	   on	   the	  outcome	  of	  pregnancy	   in	  mouse	  models.	  Mice	  overexpressing	  rat	  SpA	  or	  rat	  SpD	  were	  found	  to	   have	   increased	   AF	   levels	   of	   the	   immunosuppressive	  cytokine	   IL-­‐10	   and	   the	   inflammatory	   marker	   TNF-­‐α	   after	  LPS-­‐induced	  preterm	  birth.	  Furthermore,	  preterm	  birth	  was	  induced	  with	  a	  lower	  dose	  of	  LPS	  in	  mice	  overexpressing	  rat	  SpD	  compared	   to	  controls	   [173,	  174].	   Supporting	   this,	  a	   recent	  study	  found	  SpA/D	  double	  knock-­‐out	  mice	  to	  have	  a	  delayed	  parturition,	   and	   an	   altered	   expression	   of	   several	  inflammatory	  markers	  in	  the	  myometrium	  [127].	  It	  is	  possible	  that	  SALSA	  in	  AF	  interact	  with	  these	  molecules	  to	  exert	  their	  functions	  	  	  The	  adaptive	  immune	  system	  of	  the	  fetus	  and	  newborn	  is	  not	  fully	   developed.	   Therefore,	   they	   rely	   mostly	   on	   the	   innate	  immune	  system	  to	  defend	  against	  microbial	  invasion.	  At	  the	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same	   time,	   the	   interaction	   with	   the	   epithelium	   and	   the	  microbiota	   has	   been	   shown	   to	   be	   essential	   for	   the	  development	   of	   the	   epithelium	   [23].	   Given	   the	   previously	  described	   functions	  of	  SALSA	   it	   is	  very	   likely	   that	  SALSA	   in	  AF	  plays	  a	  role	   linking	  these	  two	  effects.	  As	  such,	   it	  may	  be	  produced	  both	  by	   the	   epithelia	   of	   the	  developing	   fetus	   and	  by	  the	  amniotic	  epithelium.	  Solutions	  containing	  the	  protein	  would	   bathe	   all	   the	   mucosal	   surfaces	   and	   the	   developing	  epithelium	  and	  support	  the	  correct	  epithelial	  differentiation.	  Simultaneously,	   SALSA	   would,	   with	   its	   bacterial	   binding	  abilities,	  help	  to	  keep	  the	  AF	  sterile.	  In	  addition,	  the	  presence	  of	   the	   protein	   already	   from	   birth	   would	   allow	   SALSA	   to	  interact	  with	   the	   initial	   colonizing	  microbiota	   and	   possibly	  link	   the	   interaction	   between	   the	   microbiota	   and	   the	  developing	  neonatal	  epithelium.	  
 
SALSA in the infant intestine (II) While	   studying	   AF,	   we	   also	   collected	   samples	   from	   other	  mucosal	   surfaces	   of	   the	   infants.	   From	   a	   total	   of	   nine	  individuals	  meconium	  was	  collected	  approximately	  2	  hours	  after	  birth	  and	   fecal	  samples	  were	  obtained	  one	  week	  after	  birth.	   Using	   Western	   blotting	   we	   identified	   SALSA	   in	   the	  samples,	   again	   exhibiting	   great	   individual	   variation.	   The	  protein	   levels	   were	   determined	   by	   ELISA	   and	   LC-­‐MS/MS	  mass	  spectrometry	  (II,	  Figure	  2).	  The	  protein	  concentration	  measurements	   obtained	   by	   ELISA	   gave	   average	   values	   of	  45.8	  μg/ml	  (range	  2.8-­‐294.6	  μg/ml)	  for	  meconium	  and	  22.4	  μg/ml	  (range	  0.1-­‐62.9	  μg/ml)	  for	  feces.	  The	  relative	  protein	  abundance	   of	   SALSA	   in	   the	   samples	  was	   obtained	   by	  mass	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spectrometry.	  Interestingly	  we	  found	  the	  levels	  to	  be	  4.16	  %	  for	   meconium	   and	   2.81	   %	   for	   feces.	   In	   some	   meconium	  samples	  SALSA	  was	  the	  most	  abundant	  protein	  overall.	  	  	  During	  fetal	  development	  AF	  enters	  the	  gastrointestinal	  tract	  and	   contributes	   to	   the	   composition	   of	   meconium	   [175].	   The	  gastrointestinal	  tract	  undergoes	  rapid	  growth	  from	  the	  fifth	  week	  of	  gestation	  through	  birth.	  During	  this	  phase	  AF	  flows	  through	  the	  digestive	  tract.	  Studies	  of	  infants	  with	  intestinal	  atresias	  and	  animal	  models	  have	  revealed	  that	  AF	  has	  both	  a	  physical	  and	  a	  trophic	  effect	  on	  the	  intestinal	  maturation	  [15,	  175].	   Thus,	   even	   during	   the	   later	   stages,	   the	   presence	   of	  SALSA	  at	   the	   fetal	  mucosal	   surfaces	   could	  be	   important	   for	  the	  development.	  	  A	   key	   feature	   of	   the	   innate	   defense	   system	   is	   to	  accommodate	   the	   change	   from	   the	   sterile	   fetal	   life	   to	   the	  encounter	   with	   the	   first	   colonizing	   microbiota	   at	   a	   time	  when	   the	   adaptive	   immune	   system	   is	   still	   immature.	   Given	  the	  bacterial	  binding	  abilities	  of	  SALSA,	  and	  the	  finding	  that	  it	   is	   one	   of	   the	   most	   abundant	   proteins	   in	   the	   infant	   gut,	  SALSA	  may	  play	   an	   important	   role	   in	   the	   early	   selection	  of	  the	   colonizing	   microbes.	   Immunological	   molecules	   are	  present	   in	   the	   breast	   milk	   provided	   by	   the	   mother	   [24].	  Evidence	   for	   the	   presence	   of	   SALSA	   in	   human	   breast	   milk	  has	  proven	  to	  be	  controversial.	  In	  one	  report	  no	  SALSA	  was	  detected,	  whereas	  a	  more	  recent	  study	  found	  high	  amounts	  of	   SALSA	   in	  breast	  milk	   [34,	  165].	  Most	   likely	   the	  discrepancy	  arises	   from	   individual	   variations,	   which	   we	   have	   also	  observed	   in	   our	   samples.	   Indeed,	   if	   SALSA	   is	   present	   in	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breast	  milk,	   it	   should	   also	   show	   up	   in	   the	   fecal	   samples.	   A	  preliminary	  study	  following	  SALSA	  in	  the	  gut	  of	  4	  infants	  in	  the	  first	  100	  days	  of	  life	  showed	  a	  difference	  in	  SALSA	  levels	  between	   breastfed	   (n	   =	   2)	   and	   formula-­‐fed	   (n	   =	   2)	   infants	  (manuscript	   in	   preparation).	   This	   supports	   the	   hypothesis	  that	  maternal	  breast	  milk	  contributes	   to	   the	  SALSA-­‐content	  in	  the	  intestines	  of	  the	  newborn.	  Regardless	  of	  the	  origin,	   it	  appears	  that	  SALSA	  is	  an	  important	  molecule	  at	  the	  mucosal	  surfaces	  in	  early	  life.	  
 
Comparison of SALSA in amniotic fluid, meconium 
and feces (II) To	  understand	  the	  expression	  of	  SALSA	  at	  different	  mucosal	  surfaces,	   we	   compared	   the	   levels	   and	   the	   peptide	  composition	  of	   the	  protein	   in	  AF,	  meconium	  and	   feces.	   Just	  like	   we	   had	   observed	   individual	   differences	   in	   the	  presentation	   of	   SALSA	   in	   Western	   blotting	   from	   different	  individuals,	   we	   also	   observed	   differences	   between	   SALSA	  from	   different	   body	   compartments,	   even	   for	   the	   same	  individual.	  The	  protein	  abundance	  was	  0.53	  %	  for	  AF,	  4.16	  %	  for	  meconium	  and	  2.81	  %	   for	   feces	   (II,	   Figure	  2).	  Although	  the	   largest	  pool	  of	  SALSA	   is	   found	   in	   the	  gut	  after	  birth,	  AF	  still	  constitutes	  one	  of	  the	  largest	  physiological	  reservoirs	  of	  SALSA	   (~1.5	   mg)	   because	   of	   its	   large	   volume	   during	   late	  pregnancy	   (~700	  ml	  at	  birth)	   [20,	  66,	  121].	   So	   far	   the	  scientific	  community	  has	  primarily	  used	  SALSA	  purified	  from	  saliva	  as	  a	   source	   for	   experimental	  work.	   In	   the	   future	  AF	  may	  be	   a	  more	   easily	   accessible	   source	   of	   the	   physiological	   and	  functionally	  active	  form	  of	  the	  protein.	  Using	  AF	  rather	  than	  
Results	  and	  discussion	  
	   	  91	  
saliva	   will	   also	   allow	   purification	   of	   higher	   amounts	   of	  SALSA	  protein	  from	  a	  single	  person.	  This	  will	  make	  it	  easier	  to	  analyze	  the	  individual	  differences	  in	  the	  protein.	  	  	  	  As	   described	   in	   the	   literature	   review,	   several	   isoforms	   and	  glycoforms	   of	   SALSA	   have	   been	   described	   in	   tissues.	  However,	   SALSA	   has	   never	   before	   been	   compared	   in	  different	   mucosal	   compartments	   from	   the	   same	   person.	   It	  would	  have	  added	  great	  value	  to	  include	  maternal	  and	  fetal	  saliva	   samples	   in	   this	   study.	   However,	   unfortunately,	   the	  sampling	   protocol	   was	   decided	   before	   the	   SALSA-­‐studies	  were	   planned,	   and	   we	   were	   not	   able	   to	   collect	   the	   saliva	  samples.	   Similarly,	   analysis	   of	   correlating	   breast	   milk	  samples	   would	   have	   been	   interesting	   for	   this	   study.	   These	  were	  not	  collected	  for	  the	  same	  reasons.	  In	  this	  study	  a	  clear	  difference	  between	  the	  proteins	  found	  in	  AF,	  meconium	  and	  feces	  were	  observed.	  Overall,	  SALSA	  in	  meconium	  appeared	  with	   a	   smaller	  molecular	  weight	   than	   that	   in	  AF.	  The	   same	  seemed	   to	   be	   the	   case	   for	   fecal	   SALSA.	   However,	   the	  difference	  to	  AF	  SALSA	  was	  not	  so	  clear-­‐cut	  (II,	  Figure	  1).	  A	  possible	   explanation	   for	   this	   difference	   could	   be	   that	   AF	  SALSA	   is	   more	   extensively	   glycosylated	   than	   the	   intestinal	  form	   of	   the	   protein.	   In	   other	   tissues	   polymorphisms	   have	  been	   ascribed	   to	   differences	   in	   both	   glycosylations	   and	   the	  protein	   backbone	   [46,	   66,	   98,	   120,	   124].	   ABO	   and	   sialyl-­‐Lex	  carbohydrate	   antigens	   have	   been	   found	   to	   vary	   on	   SALSA	  found	   in	  saliva,	   respiratory	  secretions	  and	   tear	   fluid	   [46,	  180].	  However,	   in	   these	   studies	   the	   samples	   were	   not	   collected	  from	   the	   same	   individuals.	   It	   is	   therefore	   difficult	   to	  conclude	   if	   the	   observed	   differences	   originate	   from	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individual	   glycosylation	   differences	   or	   from	   tissue-­‐specific	  differences.	  	  	  The	  proteomics	  data	  obtained	  allowed	  us	  to	  analyze	  in	  detail	  the	   polypeptide	   composition	   of	   SALSA	   molecules	   from	  different	   sources.	   This	   revealed	   a	   difference	   in	   the	  abundance	   of	   certain	   peptides	   within	   the	   expected	   full-­‐length	   transcript	   of	   SALSA	   (II,	   Figure	   3).	   Some	   peptides	  (found	  in	  the	  ZP	  domain)	  were	  relatively	  more	  abundant	   in	  the	  AF	  samples,	  whereas	  some	  peptides	  (found	  in	  the	  SRCR	  domains)	   appeared	   comparatively	   more	   abundant	   in	   the	  intestinal	   samples.	  This	   finding	   suggests	   that	   in	   addition	   to	  the	   above	   described	   glycosylation	   differences,	   the	   size	  polymorphisms	   observed	   in	   the	   different	   tissues	   are	   also	   a	  result	   of	   differences	   in	   the	   protein	   backbone.	   Thus,	   we	  conclude	   that	   the	   size	   polymorphisms	   of	   SALSA	   arise	   from	  differential	   protein	   glycosylations	   and	   peptide-­‐composition	  variations	   between	   AF,	   meconium	   and	   fecal	   SALSA,	   even	  within	  a	  single	  individual.	  	  	  By	   comparison	   to	   crystal	   structures	   of	   domains	   found	   for	  homologs	   of	   SALSA	   we	   could	   link	   the	   differences	   in	   the	  peptide	   sequences	   to	   the	   potential	   established	   functions	   of	  SALSA	   (II,	   Figure	   4).	   	   Interestingly,	  we	   discovered	   that	   the	  peptide	   sequence	   more	   often	   found	   in	   intestinal	   samples	  overlapped	  with	  the	  bacterial	  binding	  sequence	  of	  the	  SRCR	  domains,	   RVEVLYxxxSW.	   The	   peptide	   that	   was	   more	  abundant	   in	   the	  AF	  samples	  was	   found	  within	  a	   loop	  of	   the	  ZP	   domain	   believed	   to	   be	   responsible	   for	   protein	  dimerization.	   Our	   analysis	   of	   the	   relative	   abundance	   of	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certain	   peptide	   sequences	   thus	   suggests	   the	   existence	   of	  structural	   differences	   between	   AF-­‐	   derived	   and	   intestine	  (meconium	   and	   fecal)	   -­‐derived	   SALSA	   in	   regions	   with	   a	  direct	   link	   to	   suggested	   protein	   functions,	   i.e.	   binding	   to	  bacteria	   via	   the	   SRCR	   domain	   and	   extracellular	  communication/polymerization	  via	  the	  ZP	  domain.	  	  	  The	   mechanism	   of	   epithelial	   differentiation	   by	   the	   SALSA	  ortholog	  hensin	  has	  been	  described	  in	  detail	  in	  the	  rabbit	  [4].	  An	   essential	   factor	   for	   the	   function	   of	   SALSA	   was	   the	  polymerization	  of	  hensin	  mediated	  by	  galectin-­‐3.	  Since	  then,	  human	   SALSA	   and	   galectin-­‐3	   have	   been	   shown	   to	   interact	  and	   co-­‐localize	   in	   the	   intestine,	   thus	   supporting	   a	   similar	  function	   for	   SALSA	   in	   the	   human	   gut	   [169].	   ZP	   domains	   are	  found	   in	   hundreds	   of	   extracellular	   matrix	   proteins.	   Often	  these	  proteins	  polymerize	  through	  the	  ZP	  domain	  into	  fibrils	  or	   matrices	   and	   aid	   in	   transforming	   the	   cell	   shape	   and	   in	  creating	   polarization	   [150].	   The	   ZP	   domain	   is	   therefore	   a	  potential	   site	   for	   the	   polymerization	   interactions	   when	  SALSA	  is	  deposited	  into	  the	  ECM.	  	  Differences	   in	   specific	   expression	   patterns	   of	   SALSA,	  showing	   varying	   numbers	   of	   SRCR	   domains,	   have	   been	  described.	   However,	   all	   mRNA	   transcripts	   and	   proteins	  analyzed	  in	  various	  tissues	  by	  others,	  so	  far,	  have	  been	  found	  to	   display	   a	   ZP	   domain	   [120,	   121,	   151].	   Our	   peptide	   results,	  showing	  a	  lower	  abundance	  of	  ZP	  domain-­‐containing	  SALSA	  in	  the	  gut,	  do	  not	  necessarily	  mean	  that	  the	  ZP	  domain	  is	  not	  expressed	   here.	   It	   is	   possible,	   that	   the	   SALSA	   we	   find	  excreted	   with	   the	   feces	   after	   the	   passage	   through	   the	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gastrointestinal	  tract	  has	  become	  modified.	  For	  example,	  the	  protein	  deposited	   into	  the	  ECM	  could	  have	  been	  cleaved	  by	  enzymes	  of	  the	  host	  or	  microbes.	  Structurally	  the	  ZP	  domain	  is	  found	  in	  the	  most	  C-­‐terminal	  part	  of	  the	  protein,	  with	  the	  SRCR	  domains	  protruding	  from	  that.	  An	  electron	  microscopy	  picture	  revealed	  that	  polymerized	  SALSA	  is	   tied	  together	   in	  one	   end,	   with	   the	   rest	   of	   the	   protein	   extending	   into	   the	  surrounding	   space	   [111].	   Indeed,	   the	   utilization	   of	   the	   ZP-­‐domain	   in	   polymerization	   and	   deposition	   into	   the	   ECM	  would	  shield	  it	  from	  the	  gut	  lumen,	  while	  the	  SRCR	  parts	  of	  the	  protein	  extend	  into	  the	  mucus	  layer.	  Here	  they	  would	  be	  accessible	   by	   colonizing	   bacteria	   but	   also	   degrading	  enzymes.	  	  	  
Ligand binding by SALSA 
Novel ligands of SALSA (I, II, III) This	   thesis	  work	   identified	   three	   new	   ligands	   of	   SALSA.	   In	  addition,	   we	   have	   confirmed	   previously	   described	  interactions.	   We	   have	   shown	   binding	   of	   purified	   or	  recombinant	   SALSA	   to	   MBL,	   M-­‐ficolin	   and	   fibronectin	   (I,	  Figure	   2	   and	   III,	   Figure	   7).	   All	   interactions	   were	   calcium-­‐dependent.	   The	   previously	   described	   binding	   to	   C1q	   was	  confirmed.	   Binding	   was	   also	   observed	   to	   H-­‐	   and	   L-­‐ficolin,	  however	  with	   an	   apparently	  weaker	   affinity.	   In	   our	   assays	  we	   coated	   polystyrene	   plates	   with	   similar	   concentrations	  (w/w)	   of	   complement	   proteins	   and	   detected	   the	   bound	  SALSA	   with	   the	   same	   anti-­‐SALSA	   antibody.	   The	   use	   of	   the	  same	   antibody	   allowed	   us	   to	   compare	   the	   signal	   from	   one	  protein	   to	   another.	   However,	   many	   of	   the	   complement	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proteins	   such	   as	   C1q,	   MBL	   and	   ficolins	   exist	   in	   various	  multimeric	   forms,	   making	   it	   difficult	   to	   assess	   the	   actual	  molar	   ratios	   of	   the	   interactions.	   In	   addition,	   the	   coating	   of	  these	  molecules	  on	  a	  plastic	   surface	  may	   interfere	  with	   the	  SALSA	  binding.	  Thus,	  it	  is	  possible	  that	  the	  binding	  of	  SALSA	  to	   H-­‐	   and	   L-­‐ficolin	   is	   as	   strong,	   or	   even	   stronger,	   than	   the	  MBL	  and	  C1q	  binding.	  	  	  In	  addition	  to	  the	  binding	  assays	  using	  purified	  proteins,	  we	  also	  tested	  the	  ability	  of	  SALSA	  in	  AF	  and	  meconium	  to	  bind	  to	   IgA,	   MBL	   and	   C1q.	   Interestingly,	   SALSA	   in	   the	   intestine	  showed	   diminished	   ligand	   interactions.	   Only	   SALSA	   in	   AF	  retained	  the	  binding	  ability	  (II,	  Figure	  6).	  	  	  Simultaneously	   with	   our	   studies,	   other	   novel	   ligands	   for	  SALSA	   have	   been	   described	   by	   others.	   These	   include	  galectin-­‐3,	   vascular	   endothelial	   growth	   factor,	   the	   growth	  factor	  Delta-­‐like	  4	  and	  trefoil	  factor	  3	  [112,	  130,	  164].	  SALSA	  has	  so	   far	   had	   a	   great	   number	   of	   endogenous	  binding	  partners	  described.	  However,	   as	  mentioned	  above,	   it	   can	  be	  difficult	  to	   determine	   the	   strength	   and	   thus	   physiological	   relevance	  of	   these	   interactions.	  Microscale	   thermophoresis	   is	   a	   novel	  technique	   designed	   to	   measure	   protein	   interactions	   in	   the	  fluid	   phase	   [87].	   In	   the	   future	   it	   will	   be	   relevant	   to	   test	  separate	  Kd-­‐values	  of	  the	  SALSA-­‐ligand	  binding	  alone	  and	  in	  the	  presence	  of	  competing	  ligands.	  This	  will	  provide	  a	  more	  physiological	  view	  of	  the	  relevant	  SALSA	  binding	  partners.	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SALSA-MBL interaction (I) C1q	  was	  shown	  to	  bind	  SALSA	  through	  the	  globular	  domain	  in	  a	   region	  close	   to	   the	   immunoglobulin-­‐ligand	  binding	  site	  [91].	   In	   order	   to	   investigate	   if	   MBL	   interacts	   with	   the	  glycosylated	  structures	  of	  SALSA,	  the	  MBL-­‐SALSA	  interaction	  was	  compared	  to	  the	  binding	  of	  MBL	  to	  known	  carbohydrate	  ligands	   of	   its	   carbohydrate	   recognition	   domain	   (CRD).	   We	  coated	  SALSA	  on	  a	  plate	  in	  the	  presence	  of	  mannose,	  GlcNAc	  or	   glucose.	   Even	   at	   100	   mM	   concentrations	   we	   found	   no	  effect	   on	   the	   MBL	   binding	   (I,	   Figure	   3B).	   However,	   when	  others	  performed	  a	  similar	  assay,	   they	  saw	  more	  than	  60%	  inhibition	  of	  the	  SALSA-­‐MBL	  interaction	  when	  5	  mM	  fucose	  was	  added	  to	  the	  fluid	  phase.	  They	  also	  observed	  inhibition	  with	   galactose	   and	   glucose	   [55].	   One	   explanation	   for	   the	  discrepancy	  of	   the	  effect	  of	  glucose	  could	  be	  that	  Gunput	  et	  
al.	   only	   used	   SALSA	   purified	   from	   a	   single	   donor,	   whereas	  we	   used	   SALSA	   purified	   from	   a	   saliva	   pool.	   Based	   on	   the	  individual	   glycosylation	   patterns	   described	   above,	   our	  SALSA	   samples	   are	  more	   likely	   to	   contain	   several	   different	  carbohydrate	   structures.	   The	   inhibition	   of	   the	   protein	  binding	  by	  fucose	  and	  for	  some	  individuals	  also	  glucose	  lead	  us	   to	   conclude	   that	   these	   sugar	  moieties	   are	   important	   for	  the	  binding	  of	  MBL	  to	  SALSA.	  	  	  We	  also	  performed	  a	  reversed	  assay.	  Here	  the	  effect	  of	  fluid-­‐phase	  SALSA	  on	   the	  binding	  of	   the	  MBL-­‐MASP2	  complex	   to	  its	  carbohydrate	  ligands	  was	  tested	  (I,	  Figure	  4).	  Addition	  of	  SALSA	   to	   the	   fluid	   phase	   interfered	   with	   the	   carbohydrate	  binding	   of	   the	   MBL-­‐MASP2	   complex.	   This	   suggests	   that	  SALSA	   binds	   directly	   to	   the	   carbohydrate	   binding	   site	   of	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MBL.	  Alternatively,	  SALSA	  may	  bind	  to	  the	  CRD	  in	  a	  fashion	  that	   disrupts	   the	   carbohydrate	   binding	   through	   steric	  hindrance.	  It	  was	  recently	  shown,	  that	  MBL	  binds	  to	  the	  Leb	  antigen,	   a	   fucose	   containing	   oligosaccharide,	   which	   is	   also	  found	  on	   the	  surface	  of	  SALSA	   from	  secretors	   [55].	  Together	  these	   findings	  strongly	  suggest	   that	  MBL	  binds	  via	   the	  CRD	  to	  the	  Leb	  antigen	  of	  SALSA.	  However,	  in	  the	  presence	  of	  100	  μg/ml	   competing	   Leb,	   residual	   binding	  between	   SALSA	   and	  MBL	  was	  still	  observed,	  and	   thus	  other	  sugar	  structures	  on	  SALSA	  are	  most	  likely	  also	  involved	  [55].	  	  	  MBL	   belongs	   to	   a	   group	   of	   structurally	   similar	   proteins	  called	   collectins.	   SpA	   and	   SpD	   also	   belong	   to	   this	   group	   of	  proteins	   [57].	   Furthermore,	   C1q	   shares	   a	   great	   deal	   of	  structural	   resemblance	   with	   the	   collectins.	   There	   may	  therefore	   also	   be	   similarities	   in	   how	   these	   proteins	   exert	  their	   functions	   in	   concert	   with	   SALSA.	   SALSA	   binds	   to	   the	  CRD	   of	   SpD,	   however	   to	   a	   site	   different	   from	   the	  carbohydrate-­‐binding	   site	   [208].	   The	   glycosylation	   of	   SALSA	  was	   directly	   implicated	   in	   this	   interaction	   [61].	   The	   co-­‐operative	  effects	  of	  SpA,	  SpD	  and	  SALSA	  on	  agglutination	  of	  microbes,	   viral	   neutralization	   as	   well	   as	   inhibition	   of	  hemagglutination	   were	   shown	   [208].	   However,	   it	   was	   found	  that	   this	   effect	   was	   not	   dependent	   on	   the	   protein	  interactions.	   For	   some	   donors	   certain	   glycosylations	   of	  SALSA	   increased	   the	   affinity	   of	   SALSA	   towards	   SpD,	  which	  resulted	   in	   an	   inhibition	   of	   the	   anti-­‐microbial	   effect.	   In	  contrast,	   other	   donors	   had	   a	   normal	   anti-­‐microbial	  	  	  response	   [61].	   As	   described	   above	   for	   MBL,	   the	   different	  outcomes	   of	   SALSA-­‐ligand	   interactions	   are	   strongly	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dependent	   on	   the	   glycosylation	   of	   SALSA.	   In	   most	   of	   our	  assays	   we	   used	   pooled	   samples	   of	   SALSA	   for	   the	   protein	  interaction	   studies.	   However,	   it	   is	   possible	   that	   we	   could	  have	  found	  clearer	  differences	  in	  the	  protein	  interactions,	   if	  we	  had	   selected	  our	   samples,	   e.g.	   based	  on	   Se(+)	   and	   Se(-­‐)	  status.	  When	  we	  used	  individual	  AF	  and	  meconium	  samples	  for	  ligand	  binding	  studies	  (II,	  Figure	  6),	  we	  did	  observe	  both	  glycosylation	   differences	   and	   differences	   in	   protein	  interactions.	   However,	   the	   differences	   were	   related	   to	   the	  tissue-­‐origin	   of	   the	   SALSA	   sample	   (AF	   vs.	   meconium)	   and	  not	  to	  variations	  between	  the	  different	  donors.	  	  	  	  	  The	   interplay	   between	   SALSA	   and	   its	   many	   endogenous	  ligands	  is	  evidently	  complex.	  It	  appears	  that	  sugar	  structures	  on	   SALSA	   are	   often	   part	   of	   the	   ligand	   binding.	   This	   is	  observed	  especially	  for	  the	  structurally	  similar	  collectins	  and	  C1q.	  Depending	  on	  the	  specific	  phenotype	  of	  SALSA,	  this	  can	  have	  adverse	  outcomes	  on	  the	  anti-­‐microbial	  activity.	  Taken	  together,	   it	   is	   obvious	   that	   a	   better	   understanding	   of	   the	  specific	   interactions	  of	  the	  various	  forms	  of	  SALSA	  with	  the	  many	   endogenous	   ligands	  will	   help	   to	   understand	   how	   the	  innate	   immune	   defense	   system	   orchestrates	   its	   anti-­‐microbial	  responses	  at	  the	  mucosal	  surfaces.	  	  	  
Complement regulation by SALSA 
Complement activation by surface-bound SALSA (I) To	   see	   the	   effect	   of	   surface-­‐coated	   SALSA	   on	   C	   activation	  rSALSA	   was	   coated	   on	   a	   microtiter	   plate,	   and	   C4	   and	   C3	  deposition	   was	   measured	   after	   incubation	   of	   10	   %	   NHS,	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MBL-­‐deficient	   serum,	   MgEGTA-­‐serum	   or	   HIS.	   A	   parallel	  experiment	  was	  done	  using	  a	  mannan-­‐coated	  plate	  (I,	  Figure	  6).	  We	  observed	  C	   activation	  on	  both	   SALSA-­‐	   and	  mannan-­‐coated	   plates.	   Complement	   activation	   was	   reduced	   when	  MBL-­‐deficient	   serum	   was	   used,	   but	   not	   abolished.	   When	  MgEGTA-­‐serum	   was	   used,	   C4	   and	   C3	   deposition	   to	   both	  SALSA	   and	  mannan	  was	   almost	   completely	   eliminated.	  We	  thus	  observed	  SALSA-­‐mediated	  activation	  of	  C	  both	  through	  the	  classical	  and	  the	  lectin	  pathways	  of	  C.	  	  	  Approximately	  30	  %	  of	   the	   total	  C	  activation	  was	  based	  on	  the	   presence	   of	   MBL,	   confirming	   the	   relevance	   of	   our	  observed	  interaction	  between	  SALSA	  and	  MBL.	  However,	  the	  finding	   of	   residual	   C	   activation	   occurring	   even	  when	  MBL-­‐deficient	  serum	  was	  used	  supports	  the	  previously	  described	  SALSA-­‐mediated	  C	   activation	   through	  C1q	   and	   the	   classical	  pathway	   [17].	   In	   addition,	   the	   interaction	   with	   the	   ficolins	  may	  also	  be	  a	  source	  of	  C4	  and	  C3	  deposition.	  As	  described,	  the	   primary	   expression	   of	   SALSA	   is	   found	   at	   the	   mucosal	  surfaces.	   Complement	   proteins	   are	   found	  mainly	   in	   serum.	  However,	   when	   damage	   occurs	   to	   the	   epithelium,	   tissue	  components	   such	  as	  C1q	  and	  MBL	  mix	  with	  components	  of	  the	   mucosal	   surfaces	   [16,	   147].	   It	   may	   be	   in	   these	   particular	  scenarios	   that	   SALSA	   and	   C	   work	   together	   in	   the	   defense	  against	  invading	  microbes.	  	  
 
Complement activation by fluid-phase SALSA (I) To	   evaluate	   the	   effect	   of	   SALSA	   free	   in	   solution,	   the	   C	  regulating	   properties	   were	   studied	   in	   an	   ELISA	   assay	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(Wieslab).	   Here	   we	   found	   that	   the	   presence	   of	   SALSA	   in	  serum	  inhibited	  the	  lectin	  pathway	  mediated	  C	  deposition	  in	  a	  dose-­‐dependent	  way.	  No	  effect	  was	  seen	  on	  the	  classical	  or	  the	  alternative	  activation	  pathways	  (I,	  Figure	  1).	  	  
	  To	  further	  analyze	  this	  effect	  we	  used	  a	  flow	  cytometry	  assay	  to	  measure	  C4	  and	  C3	  deposition	  on	  a	  microbial	  surface	  that	  does	  not	  bind	  SALSA	  (I,	  Figure	  7).	  C.	  albicans	  was	  used	  as	  a	  model	  organism	  in	  the	  presence	  of	  varying	  concentrations	  of	  SALSA.	   NHS,	   MBL-­‐deficient	   serum,	   MgEGTA-­‐serum	   or	   HIS	  (all	   at	   10	  %)	  were	   used.	  When	  using	  MBL-­‐deficient	   serum,	  MgEGTA-­‐serum	   or	  HIS	   little	   or	   no	   C	   deposition	  was	   found.	  When	   NHS	   was	   used,	   we	   observed	   C	   activation	   against	   C.	  
albicans.	   The	   effect	   of	   adding	   varying	   concentrations	   of	  rSALSA	  showed	  a	  weak	  inhibition	  of	  the	  C4	  deposition	  and	  a	  clear	   dose-­‐dependent	   decrease	   of	   the	   C3	   deposition.	   These	  data	  suggested	  that	  the	  presence	  of	  SALSA	  in	  the	  fluid	  phase	  inhibits	   the	   activation	   of	   MBL-­‐mediated	   complement	  activation	  and	  subsequent	  deposition	  of	  complement	  factors	  C4	  and	  C3	  on	  C.	  albicans.	  	  	  The	  effects	  of	  SALSA	  on	  the	  C	  system	  appear	  contradictory	  at	  first	   glance.	   However,	   the	   discrepancy	   between	   activation	  and	  inhibition	  can	  be	  explained	  by	  the	  localization	  of	  SALSA.	  We	  found	  surface-­‐coated	  SALSA	  to	  activate	  the	  complement	  system,	   in	   line	  with	   others	   [16,	  55,	  95].	   However,	  when	   SALSA	  was	   present	   in	   the	   fluid	   phase,	   we	   observed	   a	   weaker	  deposition	   of	   C	   components	   on	   the	   relevant	   targets,	   e.g.	   C.	  
albicans.	   What	   we	   saw	   is	   most	   likely	   a	   result	   of	   SALSA	  binding	   to	   C1q	   and	   MBL	   in	   the	   fluid	   phase.	   The	   two	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outcomes	  of	  this	  can	  be	  an	  excessive	  fluid	  phase	  C	  activation,	  thus	   locally	   depleting	   the	   C	   components,	   or	   simply	   that	  initial	   binding	   of	   SALSA	   to	   C1q	   and	  MBL	   keeps	   them	   from	  binding	   to	   their	   targets.	   This	   would	   suggest	   that	   both	   the	  MBL-­‐SALSA	   and	   the	   C1q-­‐SALSA	   interactions	   are	   similar	   to	  the	   lactoferrin-­‐SALSA	   interaction	   in	   the	   sense	   that	   a	  decreased	  bacterial	  binding	  is	  observed	  [118,	  142].	  	  	  	  Recently,	   it	  has	  been	  shown	  that	  the	  activation	  of	   the	   lectin	  pathway	  by	  SALSA	  is	  dependent	  on	  the	  expression	  of	  specific	  Lewis	   antigens.	   SALSA	   activation	   of	   C	   from	   people	   with	   a	  Se(+)	  status	  was	  significantly	  higher	  than	  that	  of	  people	  with	  a	  Se(-­‐)	  status	  [55].	  In	  the	  future	  it	  will	  be	  interesting	  to	  see	  if	  this	  activation	  is	  also	  observed	  when	  SALSA	  is	  present	  in	  the	  fluid	  phase.	  	  	  
Binding of SALSA to bacteria 
Bacterial binding by purified SALSA GBS	   are	   major	   neonate	   pathogens,	   leading	   to	   sepsis,	  pneumonia	   and	   meningitis	   [82].	   Due	   to	   the	   abundance	   of	  SALSA	   in	   early	   life	  we	   tested	   the	   binding	   of	   SALSA	   to	  GBS.	  Purified	   SALSA	   was	   incubated	   with	   GBS	   and	   binding	   was	  measured	   in	   a	   flow	   cytometry	   assay.	   This	   revealed	   a	   dose-­‐dependent	   binding	   of	   SALSA	   to	   GBS	   (Figure	   5).	   A	   recent	  study	  showed	  that	  surface-­‐bound	  SALSA	  bound	  to	  the	  pili	  of	  different	   GBS	   strains,	   and	   that	   fluid-­‐phase	   SALSA	  mediated	  agglutination	   [25].	   Given	  our	   findings	   of	   SALSA	   in	   the	   gut	   of	  newborns,	  and	  the	  binding	  of	  SALSA	  to	  several	  GBS	  strains,	  we	  hypothesize	  that	  SALSA	  plays	  a	  role	  in	  the	  innate	  defense	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Figure	  5:	  SALSA	  binding	  to	  GBS.	  
Flow	  cytometry	  analysis	  measuring	  SALSA	  binding	  to	  GBS.	  GBS	  (105	  
cells	   in	   100	  µ l)	  was	   incubated	  with	   varying	   concentrations	   of	   AF-­‐
purified	   SALSA.	   Binding	   was	   detected	   using	   anti-­‐SALSA	   (Hyb213-­‐
06)	   and	   Alexa-­‐488	   coupled	   rabbit	   anti-­‐mouse	   IgG.	   Displayed	   are	  
averages	  and	  SD’s	  of	  two	  experiments.	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situation,	  SALSA	  may	  also	  be	  part	  of	  the	  response	  against	  the	  invading	  pathogen.	  Like	  SALSA,	  MBL	  is	  also	  found	  in	  the	  AF	  [113].	   The	   physiological	   relevance	   of	   the	   SALSA-­‐mediated	  inhibition	   of	   MBL-­‐ligand	   binding	   was	   tested	   in	   a	   flow	  cytometry	   assay	   using	   C.	   albicans	   and	   E.	   coli	   (I,	   Figure	   5).	  MBL	  bound	  to	  both	  strains,	  but	  SALSA	  did	  not.	  Recombinant	  SALSA	   and	   recombinant	   MBL	   were	   mixed	   and	   then	  incubated	  with	  the	  microbes.	  We	  found	  that	  SALSA	  mediated	  a	   dose-­‐dependent	   inhibition	   of	   MBL	   binding	   to	   C.	   albicans	  and	   E.	   coli.	   It	   appears	   that	   the	   binding	   of	   SALSA	   to	   MBL	  directly	  interferes	  with	  the	  binding	  of	  MBL	  to	  the	  surface	  of	  the	   pathogen.	   This	   observation	   thus	   further	   supports	   that	  the	  inhibition	  of	  complement	  activation	  against	  C.	  albicans	  is	  partly	  mediated	  by	  SALSA	  blocking	  the	  binding	  of	  MBL	  to	  its	  target,	  as	  suggested	  above.	  	  	  IgA	   and	   lactoferrin	   are	   two	   endogenous	   ligands	   of	   SALSA	  with	   structures	   different	   from	   the	   collectins.	   Both	   IgA	   and	  lactoferrin	   were	   found	   to	   bind	   to	   the	   SRCRP2	   peptide	  sequence	   of	   SALSA	   rather	   than	   to	   sugar	   structures	   [99,	   118].	  Controversially,	   the	   SALSA-­‐lactoferrin	   interaction	   inhibits	  the	   binding	   of	   SALSA	   to	   bacteria,	   whereas	   the	   SALSA-­‐IgA	  interaction	   enhances	   the	   bacterial	   agglutination	   [99,	   118,	   172].	  	  Thus,	   our	   finding	   of	   SALSA	   inhibiting	   the	   anti-­‐bacterial	  function	  of	  MBL	  adds	  to	  the	  list	  of	  protein	  interactions	  with	  potentially	   adverse	   functional	   outcomes.	   Although	   SALSA,	  IgA,	  lactoferrin	  and	  MBL	  are	  all	  anti-­‐microbial	  proteins,	  they	  do	   not	   necessarily	   cooperate	   to	   enhance	   the	   anti-­‐microbial	  response.	   One	   reason	   for	   this	   could	   be	   that	   the	   innate	  defense	   system	  has	   evolved	   a	  more	   fine-­‐tuned	   response	   to	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pathogens.	   A	   full	   binding	   and	   downstream	   activation	   of	   C	  could	   lead	   to	   excessive	   immune	   response,	   in	   situations	  where	  it	  is	  not	  needed,	  e.g.	  on	  the	  mucosal	  surfaces.	  	  	  The	  binding	  of	  the	  SALSA	  ligand	  SpD	  to	  influenza	  A	  virus	  has	  been	  shown	  to	  induce	  a	  strong	  respiratory	  burst	  response	  in	  neutrophils	   in	   vitro.	   This	   response	   was	   reduced	   by	   the	  addition	  of	  SALSA	  [209].	  It	  has	  been	  suggested	  that	  this	  allows	  a	   regulated	   response	  by	   the	  neutrophils,	  with	   an	   increased	  uptake	   of	   IAV	   but	   without	   an	   excessive	   and	   potentially	  harmful	  burst	  response	  [111].	  We	  suggest	  that	  the	  interactions	  between	   SALSA	   and	  MBL	  may	   exert	   a	   similar	   regulation	   to	  suppress	  excessive	  C	  activation.	  	  	  
Bacterial binding by SALSA in biological fluids (II) We	  tested	  the	  bacterial	  binding	  ability	  of	  native	  SALSA	  found	  in	  biological	  fluids.	  In	  a	  Western	  blot-­‐based	  assay	  we	  tested	  binding	  to	  GAS,	  GBS,	  S.	  gordonii,	  E.	  coli	  (a	  urine	  isolate)	  and	  S.	  Typhimurium	  (a	  fecal	  isolate).	  SALSA	  from	  AF	  bound	  to	  GAS,	  GBS,	  S.	  gordonii,	  and	   the	  E.	  coli	   test	   strain.	  We	  observed	  no	  binding	  of	  SALSA	   from	  AF	   to	  S.	  Typhimurium	  (II,	  Figure	  5A	  and	   E),	   The	   binding	   of	   SALSA	   from	   intestinal	   samples	  was	  also	   tested.	   In	   contrast	   to	   AF-­‐SALSA	   we	   observed	   no	  bacterial	  binding	  by	  SALSA	   in	  meconium	  (II,	   Figure	  5B	  and	  F).	  The	  SALSA	   found	   in	   fecal	   samples	   taken	  one	  week	  after	  birth	  showed	   individual	  differences	   in	   the	  bacterial	  binding	  ability.	  SALSA	  in	  one	  sample	  showed	  a	  clear	  binding	  to	  GAS	  and	  S.	  gordonii,	  and	  a	  weaker	  binding	  to	  GBS	  (II,	  Figure	  5C).	  
Results	  and	  discussion	  
	   	  105	  
In	   contrast,	   SALSA	   in	   feces	   from	  another	   individual	  did	  not	  bind	  to	  any	  of	  the	  three	  streptococcal	  strains	  (II,	  Figure	  5D).	  	  	  	  When	  we	  measured	  SALSA	  binding	  from	  biological	  solutions,	  we	   used	   Western	   blotting	   instead	   of	   flow	   cytometry.	   The	  Western	  blotting	  assay	  is	  easy	  to	  use	  for	  a	  general	  screen	  of	  binding.	   However,	   the	   data	   outcome	   is	   only	  semiquantitative.	   In	   certain	   cases	   we	   observed	   a	   complete	  clearance	  of	  SALSA	   from	  the	   initial	  biological	  material	  after	  incubation	   with	   the	   microbes	   (II,	   Figure	   5A).	   However,	   in	  other	  samples	  we	  saw	  some	  elution	   from	  the	  bacteria	  even	  though	  SALSA	  was	  not	  completely	  cleared	  from	  the	  starting	  material	   (II,	   Figure	   5C).	   Although	   the	   conclusion	   is	   that	  SALSA	  in	  this	  sample	  binds	  to	  the	  bacteria,	  in	  this	  case	  GBS,	  it	   does	   suggest	   a	  weaker	   binding	   compared	   to	   the	   samples	  where	   SALSA	   was	   completely	   cleared.	   In	   these	   situations,	  flow	  cytometry	  would	  have	  provided	  more	  quantifiable	  data.	  However,	  even	  after	  protein	  extraction,	  the	  materials	  such	  as	  meconium	  and	  feces	  are	  difficult	  to	  work	  with.	  In	  our	  hands	  it	  was	   not	   feasible	   to	   utilize	   them	   in	   flow	   cytometry.	   Thus,	  the	  conclusions	  were	  based	  on	  data	  obtained	  by	  the	  Western	  blotting	  assays.	  	  	  In	   line	   with	   the	   above	   described	   variations	   in	   SALSA	  interactions	   with	   endogenous	   molecules,	   and	   the	   adverse	  effect	   on	   microbial	   binding,	   it	   is	   not	   surprising	   that	   we	  observed	   differential	   binding	   between	   SALSA	   from	   AF	   and	  the	   intestine.	   SALSA	  was	   the	  most	   abundant	   protein	   in	   the	  meconium	  of	  some	  individuals	  (II,	  Figure	  3).	  The	  high	  levels	  of	   SALSA	   in	   the	   intestines	   of	   the	   newborns	   indicate	   an	  important	   function	   for	   SALSA.	   From	   the	   moment	   we	   are	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born,	   the	   bacterial	   colonization	   of	   the	   gut	   starts,	   and	   a	  specific	   individual	  microbiome	   is	   selected.	   For	   this,	   several	  different	   mechanisms,	   e.g.	   the	   interplay	   with	   the	   innate	  immune	   defense	   system	   at	   the	   mucosal	   surfaces	   will	   be	  utilized	   [197].	  Given	   the	  high	  expression	  of	  SALSA	   in	   the	  gut,	  the	   specific	   bacterial	   binding	   abilities	   of	   the	   protein	   must	  affect	   the	   colonizing	   bacteria.	   We	   observed	   individual	  
differences	   in	   the	   phenotype	   of	   SALSA	   and	   an	   individual	  specific	  selection	  of	  bacterial	  ligands.	  It	  is	  therefore	  possible	  that	  SALSA	  found	  at	  the	  mucosal	  surfaces	  could	  be	  a	  part	  of	  the	  interaction	  between	  the	  colonizing	  bacteria	  and	  the	  host,	  and	   thus	   aid	   in	   the	   selection	   of	   a	   specific	   composition	   of	  microbes.	  	  	  
SALSA at the feto-maternal interface  
SALSA localization in placenta (III) After	   discovering	   SALSA	   in	   AF,	   we	   investigated	   its	  expression	   in	   the	   surrounding	   tissues.	   We	   found	   SALSA	  expression	  in	  both	  the	  placenta	  and	  in	  the	  maternal	  decidua.	  We	   analyzed	   the	   specific	   localization	   of	   the	   protein	   using	  immunohistochemistry	   on	   frozen	   and	   paraffin	   embedded	  sections	  of	  healthy	   term	  placenta,	  PE	   term	  placenta	  and	  1st	  trimester	  placenta	  (III,	  Figures	  2-­‐4).	  	  	  In	  the	  term	  placenta	  a	  distinct	  positive	  staining	  of	  SALSA	  was	  observed	   intracellularly	   in	   the	   syncytiotrophoblasts	   (III,	  Figure	  2C	  and	  D).	  The	  cytotrophoblasts	  were	  not	  positive	  for	  SALSA.	   The	   syncytium	   of	   some	   villi	   stained	   more	   strongly	  than	   others,	   indicating	   that	   the	   expression	   of	   SALSA	   is	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inducible	   rather	   than	   constitutive.	   So	   far,	   the	   factors	  regulating	   the	   expression	   of	   SALSA	  here	   are	   not	   known.	   In	  addition,	  we	  observed	  abundant	  focal	  and	  distinct	  staining	  of	  SALSA	  in	  fibrinoid	  structures	  at	  various	  locations	  (Figure	  6).	  Fibrinoids	  are	  divided	  into	  matrix-­‐type	  fibrinoids,	  which	  are	  secretion	   products	   of	   extravillous	   trophoblasts,	   and	   fibrin-­‐type	   fibrinoids,	  which	   are	   blood	   coagulation	   products	  with	  large	   amounts	   of	   fibrin	   [86].	   SALSA	   was	   found	   primarily	   in	  fibrin-­‐type	   fibrinoid.	   These	   SALSA-­‐positive	   structures	  were	  found	   at	   the	   edges	   of	   the	   villous	   trees	   facing	   the	  maternal	  side.	  In	  addition,	  SALSA	  was	  found	  within	  individual	  necrotic	  villous	   structures	   and	   also	   in	   larger	   necrotic	   areas	   with	  massive	   fibrin	   formation.	   No	   major	   differences	   were	  observed	   in	   the	   staining	  pattern	  of	   SALSA	  between	  healthy	  and	  PE	  pregnancies.	  	  	  
	  
Figure	  6:	  SALSA	  in	  placental	  fibrinoid	  structures.	  	  
Frozen	  sections	  were	  stained	  with	  anti-SALSA antibody (Hyb 213-06) 
and Alexa 488-conjucated goat anti-mouse IgG.	  A)	  Fibrinoids	  are	  often	  
found	   lining	   the	   maternal	   side	   of	   the	   villi.	   B)	   When	   the	  
syncytiotrophoblast	   layer	   is	   disrupted,	   fibrinoid	   is	   deposited	  
between	  the	  syncytium	  and	  basement	  membrane	  (white	  arrow).	  In	  
conjunction	   with	   this	   fibrin-­‐formations	   are	   often	   seen	   protruding	  
into	  the	  intervillous	  space.	  Magnification:	  400×.	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To	   our	   knowledge,	   the	   SALSA	   protein	   has	   not	   previously	  been	   described	   in	   the	   placenta.	   However,	   SALSA	   has	   been	  found	   expressed	   on	   cervical	   and	   vaginal	   epithelial	   cells	   in	  humans	   [185].	   Furthermore,	   in	   rodents	   SALSA	  was	   observed	  directly	   in	   the	   uterine	   epithelium	   and	   in	   both	   rodents	   and	  primates	   SALSA	  mRNA	  expression	  was	  markedly	   increased	  after	   estrogen	   stimulation	   [198].	   A	   specific	   sugar	   structure	  expressed	   on	   SALSA	   has	   been	   implicated	   in	   the	   actual	  implantation.	   It	   was	   found	   that	   the	   actual	   implantation	   is	  mediated	  through	  the	  interaction	  of	  L-­‐selectin	  expressed	  on	  the	   surface	   of	   trophoblast	   cells	   and	   the	   MECA-­‐79	  carbohydrate	   epitope	   expressed	   on	   the	   uterine	   epithelium	  [50].	  	  
 Ligands	   of	   SALSA,	   C1q,	   MBL,	   SpA	   and	   SpD,	   were	   recently	  described	   to	   be	   expressed	   in	   the	   decidua	   and	   placenta	   of	  early	  and	  term	  pregnancy	   [2,	  109,	  215].	  C1q,	  SpD	  and	  SpA	  were	  found	   expressed	   by	   decidual	   stromal	   cells	   and	   invading	  trophoblasts	   of	   1st	   trimester	   pregnancy	   [2,	   109].	   In	   term	  placenta	   MBL,	   SpA	   and	   SpD	   were	   also	   found	   in	   the	  syncytiotrophoblast	  layer	  [215].	  These	  SALSA	  ligands	  have	  all	  been	  suggested	  to	  be	  involved	  in	  the	  process	  of	  trophoblast	  invasion,	  embryo	  implantation	  and	  placental	  development	  [2,	  109,	  215].	  	  	  	  
SALSA in fibrinoids (III) The	   function	  of	   fibrinoid	  has	  so	   far	  been	   linked	  to	  adapting	  the	   intervillous	   space	   to	   the	   altering	   flow	   conditions,	   to	  control	   the	   growth	   of	   the	   sprouting	   villous	   trees	   and	   to	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function	   as	   a	   substitute	   barrier	  wherever	   the	   continuity	   of	  the	   syncytiotrophoblast	   layer	  at	   the	   feto-­‐maternal	   interface	  has	   broken	  down	   [86].	   Furthermore,	   it	   has	   been	   shown	   that	  the	   formation	   of	   fibrinoid	   is	   utilized	   by	   trophoblasts	   to	   re-­‐epithelialize	  the	  villi	  [136].	  In	  the	  early	  stages	  of	  pregnancy	  the	  oxygen	   pressure	   in	   the	   placenta	   is	   very	   low.	   After	   10-­‐12	  weeks	   of	   gestation,	   the	   intervillous	   space	   is	   flooded	   by	  maternal	   blood.	   This	   may	   cause	   oxidative	   stress	   with	  subsequent	  injury	  to	  the	  syncytium	  [73,	  74].	  After	  a	  local	  injury	  or	  damage	  the	  syncytiotrophoblast	  layer	  may	  be	  interrupted.	  We	   often	   found	   strong	   fibrinoid	   formation	   with	   SALSA	  deposition	   in	   conjunction	   with	   a	   disrupted	   syncytium.	   We	  also	   observed	   the	   fibrinoids	   separating	   the	  syncytiotrophoblast	   from	   the	   basement	   membrane	   and	  extending	  into	  the	  intervillous	  space.	  It	  appears	  that	  damage	  to	   the	   syncytium	   allows	   SALSA	   to	   enter	   the	   intervillous	  space	   and	   deposit	   into	   the	   formed	   fibrinoid.	   In	   some	   cases	  maternal	  blood	  will	  flow	  into	  the	  villus	  after	  a	  breach	  of	  the	  syncytium.	  When	  this	  had	  occurred	  we	  saw	  SALSA	  deposited	  in	   ring-­‐like	   fibrinoid	   structures	   separating	   the	  syncytiotrophoblasts	   from	  the	  basement	  membrane	  (Figure	  6B,	  white	  arrow).	  	  	  Previous	   studies	  have	   indicated	   that	  SALSA	  and	   fibronectin	  are	   both	   involved	   in	   epithelial	   differentiation	   [169,	   179,	   200].	  SALSA	  and	  fibronectin	  may	  be	  involved	  in	  this	  process	  in	  the	  developing	   placenta,	   as	  well.	   Thus,	   SALSA	   secretion	   by	   the	  endothelial	  cells	  or	  by	  the	  damaged	  syncytium	  would	  result	  in	   the	   deposition	   of	   SALSA	   into	   the	   ECM,	   e.g.	   through	  interaction	  with	  fibronectin.	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The	   analysis	   of	   SALSA	   expression	   in	   the	   placenta	   showed	  that	  SALSA	  was	  deposited	   in	   fibrin-­‐type	   fibrinoids,	  necrotic	  villi	  and	  irregularly	  on	  vascular	  endothelial	  cells.	  To	  identify	  further	   potential	   targets	   for	   SALSA	   an	   overlay	   of	   frozen	  placental	   sections	  with	   SALSA-­‐containing	  AF	  was	   done	   (III,	  Figure	   5).	   In	   addition	   to	   the	   previously	   described	   staining	  patterns,	  we	  observed	  binding	  of	  SALSA	  to	  a	  large	  part	  of	  the	  syncytial	  basement	  membranes	  and	  the	  endothelium	  of	  most	  capillaries	   and	   large	   vessels.	   This	   indicated	   that	   targets	   for	  SALSA	  are	  present	  in	  the	  endothelium	  either	  directly	  on	  the	  surface	  of	  the	  endothelial	  cells	  or	  in	  the	  extracellular	  matrix.	  We	  suspect	  that	  the	  deposition	  of	  SALSA	  in	  the	  tissue	  is	  more	  related	   to	   the	   availability	   of	   SALSA	   rather	   than	   the	  expression	  of	  specific	  targets	  because	  of	  e.g.	  tissue	  injury.	  	  
 
SALSA in 1st trimester placenta In	   the	   sections	   from	   1st	   trimester	   placenta	   fibrinoids	   were	  almost	   absent.	   Instead,	  we	   observed	   SALSA	   in	   the	   decidual	  endothelium	   of	   both	   small	   capillaries	   and	   larger	   blood	  vessels.	   The	   staining	   pattern	   was	   irregular	   suggesting	   that	  the	  expression	  of	  SALSA	  is	  induced	  under	  certain	  conditions.	  A	   recent	   study	   described	   for	   the	   first	   time	   that	   endothelial	  cells	   secrete	   SALSA	   into	   the	   ECM	   [130].	   It	   was	   found	   that	  endothelium-­‐derived	   SALSA	   bound	   galectin-­‐3,	   affected	  Notch	   signalling	   and	   promoted	   proliferation,	   angiogenesis	  and	   vascular	   repair	   [130].	   Our	   findings	   in	   the	   early	   human	  placenta	  and	  decidua	  provide	  further	  evidence	  that	  SALSA	  is	  expressed	   in	   blood	   vessels	   and	   is	   deposited	   into	   the	   ECM	  under	  physiological	  conditions.	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At	   the	   1st	   trimester	   stage	   of	   a	   normal	   healthy	   placentation,	  angiogenesis	   is	   an	   ongoing	   process.	   As	   the	   pregnancy	  continues,	   various	   areas	   of	   the	   placenta	   may	   experience	  either	   local	   hypoxia	   or	   oxidative	   stress.	   The	  syncytiotrophoblast	   may	   be	   damaged	   by	   oxidative	   stress	  when	   the	   maternal	   blood	   flow	   into	   the	   placenta	   is	   first	  established	  [73,	  74].	   In	  cases	  of	  failing	  blood	  flow	  the	  placenta	  will	   experience	   hypoxia.	   In	   both	   cases	   this	   may	   present	   a	  “danger	   signal”	   and	   one	   of	   the	   responses	   could	   be	   the	  expression	   of	   SALSA.	   Indeed,	   recent	   work	   with	   a	   SALSA	  knock-­‐out	  mouse	  model	  suggested	  that	  SALSA	  is	  part	  of	  the	  endothelial	  cell	  response	  to	  hypoxia,	  as	  the	  mice	  showed	  an	  impaired	   recovery	   from	   ischemic	   hindlimb	   injury	   [130].	  Although	  we	  have	  not	  yet	  been	  able	  to	  address	  the	  inducing	  factors	  of	  SALSA	  expression,	  together	  the	  described	  findings	  support	   a	   physiologically	   relevant	   function	   of	   SALSA	   in	  endothelial	   remodelling	   during	   placentation.	   Whether	   the	  role	   of	   SALSA	   in	   fibrinoid	   formation	   and	   the	   ECM	   of	  syncytiotrophoblast	   is	   linked	   to	   its	   function	   in	   the	   ECM	   of	  endothelial	   cells	   remains	   to	   be	   investigated.	   Indeed	   SALSA	  may	   be	   interacting	   with	   different	   ligands	   at	   the	   two	  locations.	   It	   is	   evident	   that	   both	   vascular	   development	   and	  syncytium	   regeneration	   require	   cell	   proliferation	   and	  migration.	  This	  happens	  in	  interactions	  with	  the	  underlying	  ECM,	  where	  SALSA	  could	  have	  an	  important	  function.	  	  	  
Effect of SALSA on blood clotting (III) The	   complement	   and	   the	   coagulation	   systems	   are	   closely	  linked.	   It	   has	   been	   shown	   that	   several	   proteins	   of	   the	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coagulation	   system	   can	   activate	   C,	   e.g.	   proteases	   such	   as	  plasmin	   and	   thrombin	   can	   cleave	   C3	   [114].	   SALSA	   has	  previously	  been	  suggested	  to	  interact	  with	  fibrin/fibrinogen,	  platelets	   and	   erythrocytes	   [129].	   Our	   finding	   of	   SALSA	   in	  fibrin-­‐type	  fibrinoids	  led	  us	  to	  investigate	  the	  role	  of	  SALSA	  in	   the	   formation	   of	   blood	   clots.	   We	   performed	   basic	  coagulation	   assays	   such	   as	   Thrombin	   Time	   and	   Activated	  Prothrombin	  Time	  measurements	  with	  SALSA	  present	  in	  the	  fluid	   phase.	   In	   addition	   we	   analyzed	   clot	   formation	   on	   a	  surface	  coated	  with	  SALSA	  by	  measuring	  absorbance	  at	  405	  nm	   of	   citrated	   blood	   plasma	   after	   initiation	   of	   coagulation	  (III,	   Figure	   6).	   In	   these	   experiments	   the	   increase	   in	  absorbance	  correlates	  to	  the	  formation	  of	   the	  clot,	  however	  we	   did	   not	   observe	   any	   effect	   of	   SALSA	   on	   the	   extent	   or	  speed	   of	   clot	   formation.	   Our	   assays	   were	   performed	   in	  plasma	   without	   platelets.	   Thus,	   our	   results	   are	   not	  contradictory	   to	   the	   finding	   that	   SALSA	   aggregates	   and	  activates	  platelets	  [129].	  Müller	  et	  al.	  gave	  indications	  that	  the	  interaction	  of	  SALSA	  with	  fibrinogen	  was	  stronger	  than	  with	  fibrin.	   Under	   physiological	   conditions,	   this	   would	   suggest	  that	  SALSA	  exerts	  its	  function	  before	  fibrinogen	  is	  activated	  into	  fibrin.	  In	  light	  of	  this,	  it	  is	  somewhat	  surprising	  that	  we	  did	  not	  see	  any	  effect	  on	  the	  formation	  of	  the	  fibrin	  clot.	  For	  coagulation	  assays	  citrated	  plasma	  is	  used,	  in	  order	  to	  inhibit	  the	  untimely	  activation	  of	  clotting.	  Many	  functions	  of	  SALSA	  are	   known	   to	   depend	   on	   the	   presence	   of	   calcium,	   and	   this	  could	   be	   an	   explanation	   for	   the	   apparent	   lack	   of	   effect	   on	  clotting	   [154].	   We	   performed	   our	   assays	   with	   addition	   of	  calcium,	  enough	   to	   initiate	   coagulation.	  However,	   it	  may	  be	  that	  SALSA	  requires	  even	  higher	   concentrations	  of	   calcium.	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Still,	  based	  on	  the	  data	  from	  our	  assays	  it	  appears	  that	  SALSA	  is	  not	  involved	  in	  the	  process	  of	  fibrinoid	  formation.	  Instead	  it	  seems	  SALSA	   is	  deposited	  after	   fibrin	  deposits	  have	  been	  formed.	  	  
 
Co-localization of SALSA with complement and 
fibronectin (III) We	   have	   described	   fibronectin	   and	   confirmed	   C1q	   as	  endogenous	   binding	   partners	   of	   SALSA	   (III	   Figure	   7	   and	   I	  Figure	   2).	   Both	   proteins	   have	   been	   linked	   to	   fibrinoids	   [86,	  105].	  To	   investigate	   if	  SALSA	   interacts	  with	   these	  proteins	   in	  
vivo,	   co-­‐localization	   of	   the	   two	   proteins	   with	   SALSA	   in	  human	  placenta	  was	  studied.	  Both	  fibronectin	  and	  C1q	  were	  found	  associated	   to	   the	   same	   fibrinoid	   structures	  as	   SALSA	  (III,	   Figure	   8).	   Although	   some	   co-­‐localization	  was	   observed	  in	   the	   fibrinoids,	   in	   particular	   for	   fibronectin,	   most	   SALSA	  staining	   was	   seen	   in	   the	   inner	   part	   of	   the	   fibrinoid	  structures,	   while	   fibronectin	   and	   C1q	   were	   located	   at	   the	  edges	  of	  the	  structures	  (Figure	  7).	  It	  thus	  appears	  that	  SALSA	  is	   directly	   incorporated	   into	   the	   fibrinoid	   matrix,	   and	   to	  some	   extent	   the	   same	   applies	   for	   fibronectin	   (Figure	   7A).	  However,	   the	   staining	   of	   C1q	   shows	   that	   the	   protein	  encapsulates	  the	  SALSA	  positive	  areas,	  especially	  in	  necrotic	  villi	  (Figure	  7B).	  Our	  findings	  are	  supported	  by	  other	  studies	  where	   it	   was	   found	   that	   C	   components	   and	   SALSA	   were	  deposited	   in	   the	   same	   necrotic	   amyloid	   depositions	   in	   the	  heart	   tissue.	   However,	   no	   direct	   co-­‐localization	   was	  observed	  [131].	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Figure	  7:	  Fibronectin,	  C1q	  and	  SALSA	  in	  placental	  fibrinoids.  
Paraffin embedded placental tissue sections of healthy term placentas 
were stained with anti-fibronectin antibody and anti-C1q antibody (both 
green). SALSA was stained using anti-SALSA antibody (Hyb 213-06, 
red).	   A)	   SALSA	   and	   fibronectin	   are	   found	   in	   the	   same	   structures,	  
with	   some	   degree	   of	   co-­‐localization	   (white	   arrow).	   B)	   SALSA	   is	  
observed	   staining	   a	   fibrinoid	   ghost-­‐like	   structure	   of	   a	   necrotic	  
villus.	   C1q	   is	   deposited	   as	   a	   coating	   on	   the	   edge	   of	   the	   SALSA-­‐
positive	  fibrinoid	  (white	  arrow).	  Magnification:	  200×.	  	  In	   pre-­‐eclampsia	   and	   other	   complicated	   pregnancies,	  excessive	   placental	   hypoxia	   and	   damage	   of	   the	   syncytium	  commonly	   occurs.	   In	   these	   situations	   the	   expression	   of	  SALSA	  could	  be	  induced	  locally	  at	  the	  same	  time	  as	  the	  clot	  formation	  takes	  place.	  C1q	  is	  known	  to	  target	  apoptotic	  cells,	  cellular	  debris	  and	  the	  ECM.	  Complement	  activation	  thus	  has	  important	   housekeeping	   functions	   [135].	   Interestingly,	   MBL	  and	   the	   SALSA	   ligands	   SpA	   and	   SpD	   have	   been	   linked	   to	  similar	   processes	   [90,	   134,	   143].	   A	   recent	   study	   described	  differences	   in	   the	   deposition	   of	   C1q	   and	   the	   complement	  inhibitor	   C4bp	   in	   fibrinoid	   structures	   between	   healthy	   and	  PE	   placentas	   [105].	   We	   suggest	   that	   in	   the	   case	   of	   local	  placental	  ischemia	  and	  tissue	  damage,	  the	  function	  of	  SALSA	  is	   to	   help	   contain	   the	   necrotic	   process	   and	   the	   excessive	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formation	   of	   fibrinoid	   through	   interactions	  with	   fibrin	   and	  fibronectin	   and	   thereafter	  participate	   in	   the	   removal	  of	   the	  debris	  through	  interactions	  with	  C1q	  and	  C.	  Dysregulation	  of	  C	  at	   the	   feto-­‐maternal	   interface	  has	   long	  been	  suspected	   to	  be	   part	   of	   the	   etiology	   of	   PE	   [107,	  108].	   A	   recent	   study	   found	  deposition	   of	   C4d	   on	   the	   syncytiotrophoblast	   layer	   in	   PE	  placentas,	  but	  not	  in	  healthy	  controls	  [27].	  We	  did	  not	  observe	  a	  difference	  in	  the	  pattern	  of	  SALSA	  staining	  in	  PE	  placentas	  compared	   to	  placentas	   from	  healthy	  pregnancies.	  However,	  as	   there	   is	   more	   syncytial	   damage	   in	   PE	   than	   normal	  placentas,	  a	  greater	  activation	  of	  C	  and	  deposition	  of	  SALSA	  is	   likely	   to	   occur	   in	   PE.	   Secretor	   status	   and	   Leb	   expression	  was	   shown	   to	   affect	   the	   C	   activation	   mediated	   by	   SALSA.	  These	   specific	   carbohydrate-­‐structures	   have	   also	   been	  linked	   to	   pregnancy	   disorders	   such	   as	   IUGR	   and	   recurrent	  spontaneous	   abortion	   [31,	   51].	   In	   the	   future	   it	   will	   be	   of	  interest	   to	   understand	   more	   thoroughly	   the	   interaction	  between	  SALSA	  and	   individual	  C	  components	   in	   the	  human	  placenta.	   Furthermore	   a	   better	   knowledge	   of	   variations	   in	  the	   SALSA	   genotypes	   and	   phenotypes	   and	   how	   they	   could	  lead	  to	  altered	  C	  interactions	  could	  help	  us	  to	  understand	  the	  effect	  of	  SALSA	  on	  the	  placental	  development	  in	  both	  healthy	  and	  complicated	  pregnancies.	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Conclusion 	  The	   early	   work	   on	   the	   function	   of	   the	   SALSA	   protein	   has	  primarily	   focused	   on	   understanding	   the	   interplay	   between	  control	   of	   epithelial	   re-­‐generation	   and	   immune	   defense	   at	  the	   mucosal	   surface.	   However,	   the	   results	   obtained	   in	   this	  work,	   together	   with	   observations	   made	   elsewhere	   during	  recent	   years	  point	   to	   a	  much	  broader	   field	  of	   action.	   It	   has	  long	  been	  known	  that	  SALSA	  is	  a	  molecule	  with	  the	  ability	  to	  bind	  many	  different	  endogenous	  protein	   ligands,	   as	  well	   as	  microbes.	   Lately	   even	   gametes	   and	   stem	   cells	   have	   been	  suggested	  as	  targets	  for	  SALSA	  [5,	  111,	  188,	  192].	  	  Table	   1	   lists	   sites	   of	   SALSA	   expression	   in	   human	   known	  prior	   to	   this	   study.	   In	   this	   thesis	   work	   we	   have	   described	  novel	  sites,	  tissues	  and	  secretions,	  of	  SALSA	  expression.	  We	  have	   shown	   e.g.	   that	   the	   SALSA	   protein	   is	   present	   in	  amniotic	   fluid,	   and	   very	   abundantly	   in	   meconium	   and	   in	  infant	   feces.	   In	   addition,	   we	   have	   described	   SALSA	   in	   the	  placenta	  and	  in	  the	  decidua.	   	  When	  combined,	  the	  different	  studies	  show	  a	  clear	  profile	  of	  constitutive	   SALSA	   expression	   at	   the	   mucosal	   surfaces.	  However,	   the	   protein	   production	   or	   secretion	   is	   clearly	  inducible	   in	   several	   other	   tissues.	   Therefore,	   a	   key	   to	  understanding	   the	   multi-­‐faceted	   role	   of	   SALSA	   is	   to	  understand	  site-­‐	  and	  time-­‐patterns	  of	  its	  expression.	  It	  is	  not	  only	   interesting,	  where	   the	  protein	   is	   found,	  but	  also	  under	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which	  circumstances.	  Both	  inflammatory	  inducers	  as	  well	  as	  other	   stimuli	   are	   most	   likely	   involved	   in	   activating	   the	  expression	  of	  SALSA.	  In	  these	  situations,	  SALSA	  exerts	  other	  functions	   than	   simple	   scavenging	   for	   bacteria	   or	   tissue	  debris.	  In	  the	  future,	  a	  better	  understanding	  of	  the	  inducing	  factors	  of	  SALSA,	  e.g.	  in	  the	  placenta,	  is	  needed.	  	  	  Previously,	   it	   has	   been	   shown	   that	   different	   forms	   of	   the	  SALSA	  protein	  exist	  in	  both	  saliva	  and	  tear	  fluid.	  In	  this	  study	  we	   further	   describe	   individual	   variations	   of	   the	   protein	   in	  amniotic	  fluids	  and	  in	  intestinal	  secretions.	  We	  found,	  for	  the	  first	  time,	  that	  for	  a	  given	  individual,	  the	  protein	  may	  exist	  in	  several	   forms	   in	   different	   tissues.	   By	   comparing	   the	  descriptions	   of	   the	   types	   of	   variations	   in	   other	   tissue	  compartments,	   the	  differences	  between	   the	  SALSA	  proteins	  that	   we	   have	   described,	   are	   most	   likely	   due	   to	   alternative	  splicing	   and	   posttranslational	   modifications	   such	   as	  proteolysis	  and	  differential	  glycosylations	  [46,	  153,	  180].	  	  	  The	   different	   forms	   of	   the	   SALSA	   protein	   were	   linked	   to	  varying	   functional	   abilities.	   Lately,	   certain	   isoforms	   have	  even	   been	   associated	   with	   the	   development	   of	   chronic	  inflammatory	  conditions	  such	  as	  Crohn’s	  disease	  [37].	  To	  fully	  understand	   the	   role	   of	   SALSA,	   a	   better	   knowledge	   of	   these	  differences	   becomes	   essential.	   We	   have	   shown	   that	   SALSA	  may	  regulate	  the	  complement	  system	  to	  different	  outcomes,	  depending	   on	  whether	   it	   is	   found	   in	   the	   solution	   or	   in	   the	  solid	   phase.	   To	   further	   complicate	   things,	   a	   recent	   study	  found	   that	   individual	   expression	   of	   the	   carbohydrate	  structures	  attached	  to	  Se(+)	  and	  Se(-­‐)	  status	  had	  an	  effect	  on	  
Conclusion	  
	   	  118	  
the	   ability	   of	   SALSA	   to	   regulate	   the	   C	   system	   [55].	   The	  activation	   of	   the	   C	   system	   by	   SALSA	   has	   already	   been	  suggested	   to	  be	  mediated	  by	  an	   interaction	  with	   the	  sugar-­‐binding	   globular	   domain	   of	   C1q,	   and	   it	   is	   therefore	   not	  surprising,	  that	  these	  interactions	  are	  altered	  by	  differences	  in	  the	  secretor	  status	  –	  and	  possibly	  also	  other	  variations	  in	  glycosylations.	  As	  such,	  we	  described	  a	  binding	  of	  AF-­‐SALSA	  to	   both	   C1q	   and	   MBL,	   but	   no	   binding	   was	   observed	   for	  SALSA	   obtained	   from	   meconium.	   In	   the	   future,	   it	   is	  important	   to	   understand	   how	   the	   phenotype	   of	   SALSA,	  glycoforms	  as	  well	  as	  protein	  isoforms,	  relate	  to	  the	  function	  of	  the	  protein.	  And	  furthermore,	  knowledge	  is	  needed	  on	  the	  possible	   individual	   regulation	   of	   the	   expression	   of	   specific	  SALSA	   phenotypes.	   Can	   there	   be	   temporal,	   e.g.	   hormonally	  induced,	  alterations	  in	  the	  function	  of	  the	  SALSA	  protein,	  as	  has	   been	   suggested	   previously	   [1,	   153,	   198]?	   Or	   is	   it	   simply	   a	  question	   of	   individual	   genetic	   variation	   leading	   to	   the	  expression	   of	   SALSA	   molecules	   with	   a	   certain	   palette	   of	  functions?	   At	   the	   mucosal	   surfaces	   this	   could	   indicate	   the	  existence	   of	   particular	   phenotypes	   of	   SALSA.	   These	   would	  inhibit	   colonization	   by	   certain	   bacterial	   species,	   but	   not	   by	  others.	   Depending	   on	   the	   phenotype,	   this	   would	   have	  different	   outcomes	   on	   the	   colonizing	   microbiota	   of	   an	  individual.	  Supporting	  this	  hypothesis	  a	  recent	  study	  showed	  a	   link	   between	   the	   evolution	   of	   the	   SALSA	   gene	   and	   S.	  
mutans,	   a	   known	   target	   of	   SALSA	   found	   on	   the	   mucosal	  surfaces	   [151].	   Most	   likely,	   both	   genetic	   and	   environment-­‐induced	   variations	   affect	   the	   final	   expression	   of	   the	   SALSA	  protein.	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The	   current	   study	   suggests	   that	   the	   function	   of	   SALSA	   is	  linked	   to	   an	   innate	   immune	   response	   to	   very	   adverse	  challenges	  such	  as	  microbial	   infection	  and	  tissue	  injury,	  e.g.	  in	   the	   placenta.	   SALSA	   may	   thus	   have	   a	   dual	   role:	   pro-­‐inflammatory	  implied	  by	  the	  C	  activating	  properties,	  or	  anti-­‐inflammatory	  in	  situations,	  where	  injured	  structures	  need	  to	  be	  contained,	  as	   in	   the	  placental	   fibrinoids.	   In	   the	   intestine,	  bacterial	   infections	   as	   well	   as	   chronic	   inflammatory	  conditions	  are	  associated	  with	   increased	  SALSA	  expression.	  The	   future	   hope	   is	   to	   understand	   how	   addition	   of	   SALSA	  would	   either	   aid	   the	   immune	   defense	   in	   the	   battle	   against	  invading	   pathogens	   or	   alleviate	   chronic	   mucosal	  inflammatory	   conditions.	   Perhaps	   one	   day	   restoring	   tissue	  homeostasis	   could	   be	   achieved	   with	   a	   pill	   of	   SALSA?!
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